{"generated_at":"2026-10-28T18:41:35Z","window":["2026-10-28","2027-01-26"],"query":{"sponsor":null,"condition":null,"intervention":null,"phases":["PHASE2","PHASE3"],"industry_only":true,"max_records":1000},"count":934,"events":[{"nct_id":"NCT05115110","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","readout_date":"2026-10-28","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Spinal Muscular Atrophy (SMA)","enrollment":97,"url":"https://clinicaltrials.gov/study/NCT05115110","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05115110","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ffbb59e38c2c5ff07388a8a529cd7722104c71c12b5fa06df1599a19483d4dae"},{"nct_id":"NCT05239728","title":"A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)","readout_date":"2026-10-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","ticker":"MRK","ticker_confidence":0.6,"conditions":"Carcinoma, Renal Cell","enrollment":1800,"url":"https://clinicaltrials.gov/study/NCT05239728","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05239728","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e56c2e883ff2a05cbdc5f1071473d77c05a2ad219c7ee185becb3f94f8d29ea5"},{"nct_id":"NCT05426733","title":"An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia","readout_date":"2026-10-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albireo, an Ipsen Company","ticker":null,"ticker_confidence":0.0,"conditions":"Biliary Atresia","enrollment":180,"url":"https://clinicaltrials.gov/study/NCT05426733","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05426733","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a25e5ccf95df838c508b8c326fd7d8ea65159b99ffec7791b7fc0f3c364027b6"},{"nct_id":"NCT06617416","title":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","readout_date":"2026-10-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":560,"url":"https://clinicaltrials.gov/study/NCT06617416","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06617416","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:41c291f988c30dcbcfc7d96119efb147100dbd23cfd76db22e154112cb997473"},{"nct_id":"NCT06722157","title":"A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy","readout_date":"2026-10-28","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","ticker":null,"ticker_confidence":0.0,"conditions":"Macular Degeneration, Age-related; Geographic Atrophy","enrollment":202,"url":"https://clinicaltrials.gov/study/NCT06722157","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06722157","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7df925ecde428ef080e1e854d6311bdfbe2238a30612506ec4fa554e2bc3b37d"},{"nct_id":"NCT05653349","title":"Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)","readout_date":"2026-10-29","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":226,"url":"https://clinicaltrials.gov/study/NCT05653349","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05653349","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1cb784ca2aa540c7662304f7ca63f00db94b886f81334d5b0126fef89823cd54"},{"nct_id":"NCT05928390","title":"Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia","readout_date":"2026-10-29","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"RECORDATI GROUP","ticker":null,"ticker_confidence":0.0,"conditions":"Post-Bariatric Hypoglycemia","enrollment":93,"url":"https://clinicaltrials.gov/study/NCT05928390","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05928390","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e394f8f6b409711e84085408d00520fd47158e247864205771cddc525c557434"},{"nct_id":"NCT06588855","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis","readout_date":"2026-10-29","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":350,"url":"https://clinicaltrials.gov/study/NCT06588855","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06588855","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6f1aa61cc34010e0ba3c113253e10529f7362911d40fe6814d81eb7d6c485242"},{"nct_id":"NCT06721494","title":"A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine","readout_date":"2026-10-29","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Clear Scientific, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Methamphetamine Intoxication; Methamphetamine Disorders; Methamphetamine Abuse","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT06721494","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06721494","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8772afe6f173dca3b2cfec13bbefc86461ba5581aa9b1915d7445d0db068cedd"},{"nct_id":"NCT02843035","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","ticker":null,"ticker_confidence":0.0,"conditions":"Gaucher Disease Type 1; Gaucher Disease Type 3","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT02843035","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02843035","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c29cfc95fece3dd77a93b9fc4d860794bfa0abb17395c89b1bf519fcafc9d1d4"},{"nct_id":"NCT04041310","title":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nouscom SRL","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult","enrollment":115,"url":"https://clinicaltrials.gov/study/NCT04041310","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04041310","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e7bfd33c13c466687858e0a71ecdd04bea202167f547975ff793c6b351d0697d"},{"nct_id":"NCT04657991","title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Melanoma","enrollment":257,"url":"https://clinicaltrials.gov/study/NCT04657991","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04657991","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:424085f7fbc2114a889a848c0929ed272a5d99ca04bac4cb2d780eaf2936358b"},{"nct_id":"NCT04851613","title":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laekna Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":256,"url":"https://clinicaltrials.gov/study/NCT04851613","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04851613","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:165e656a0bb24e078cf7cce566fcd3c14bf1fb4f6299636433e7b6d4a501d455"},{"nct_id":"NCT05444257","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","ticker":"VERX","ticker_confidence":0.9,"conditions":"Cystic Fibrosis","enrollment":822,"url":"https://clinicaltrials.gov/study/NCT05444257","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05444257","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:aafceb1298eb3f1446a80777023057bffa755c2eedbdeb9c6d4a2fda7e3fac48"},{"nct_id":"NCT05853575","title":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT05853575","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05853575","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:04a676515a62d56dc275ef0a9b83cc75bd97c4c2e3f760ec447bdc4c684f75fd"},{"nct_id":"NCT05918133","title":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"TNBC","enrollment":42,"url":"https://clinicaltrials.gov/study/NCT05918133","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05918133","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f1900519b43615087e59c2a3ce5f344fb2dfbf9d96adf3670fc15028a00b11e2"},{"nct_id":"NCT06186804","title":"A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Abbisko Therapeutics Co, Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"cGvHD","enrollment":64,"url":"https://clinicaltrials.gov/study/NCT06186804","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06186804","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b99bb12bacb2b3351b0b22b565366ae996ef0d9727ad89494c781c9b193614eb"},{"nct_id":"NCT06385925","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Malignant Neoplasm","enrollment":440,"url":"https://clinicaltrials.gov/study/NCT06385925","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06385925","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:40455996d258fa9e70129b779a4b064f100ee8b76eec9c26cef475bebc496898"},{"nct_id":"NCT06679036","title":"A Trial of HRS-2189 in Combination With Fluvastatin\u00b1HRS-6209, or HRS-8080\u00b1HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Unresectable or Metastatic Breast Cancer","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT06679036","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06679036","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c3cbd54e437f34c627c8f1f29ce921a13cf20148ae0e79942ab9a7f81f52689e"},{"nct_id":"NCT06848699","title":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor Cancer; Non Small Cell Lung Cancer","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT06848699","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06848699","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:103188c332ce3e9c32a2aac4989b42e8f5be0a928a3373647a6b3b722be1fe89"},{"nct_id":"NCT06906471","title":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Antelope Surgical Solutions, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT06906471","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06906471","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5c565340da95826f82a7b44002ce402f107ad321ce6dc51fb10de2b4ebf90464"},{"nct_id":"NCT06941350","title":"A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Nuwacell Biotechnologies Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Graft-versus-Host Disease","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT06941350","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06941350","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce300d5234ed44ccd0bd580ce2c737e1cf253c1fdfc2a47666b0b61a171e5e5e"},{"nct_id":"NCT06965621","title":"18F-mFBG Imaging for Myocardial Sympathetic Innervation","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","ticker":null,"ticker_confidence":0.0,"conditions":"Heart Failure; Ischemic Cardiomyopathy; ICD Patients","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT06965621","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06965621","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2ef940a0cb6cb541ae8b79caa614ce2f3da527a44dec2477bd63e4c1e53c6bcb"},{"nct_id":"NCT06968481","title":"Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Insud Pharma","ticker":null,"ticker_confidence":0.0,"conditions":"Post Partum Hemorrhage","enrollment":330,"url":"https://clinicaltrials.gov/study/NCT06968481","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06968481","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:151ebbae3acfea107c992fe09f268f2c5f0af29b7ba6b4159a2876f3cd9db376"},{"nct_id":"NCT07026968","title":"A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 2 Diabetes","enrollment":815,"url":"https://clinicaltrials.gov/study/NCT07026968","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07026968","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce8d4caf3ad2653367f8f95e0cc9bd259173501f288cbf05be2a2d55271be80f"},{"nct_id":"NCT07085507","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Vidya Therapeutics Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Sclerosis","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07085507","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07085507","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:55224920d196133ec8e3c9e4c3bfc87b2901aaea999a476f2eb5e9c65053a530"},{"nct_id":"NCT07176286","title":"18F-mFBG Cardiac Uptake With Lewy Body Dementia","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","ticker":null,"ticker_confidence":0.0,"conditions":"Parkinson Disease (PD); Lewy Body Dementia (LBD)","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT07176286","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07176286","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:73b2d38c195e68138753ee1cc0ef692786fcfa16132278191a2aa1c1194677e5"},{"nct_id":"NCT07345390","title":"Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Acne Vulgaris","enrollment":180,"url":"https://clinicaltrials.gov/study/NCT07345390","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07345390","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7116fef5b8f14cc9d06b340dd9f779e2e6f9d92cbe4113f840665a8cfe19187c"},{"nct_id":"NCT07360275","title":"A Study of VCT220 in Participants With Hypertension and Obesity or Overweight","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Hypertension","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07360275","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07360275","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3d558ba09a3144596ac9091dd7b6c60b424ab4b8b0fb4d804db6c07f4123772e"},{"nct_id":"NCT07494409","title":"A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Anemia Due to Chronic Kidney Disease","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT07494409","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07494409","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e338d10278244bde345e67d4c2aa688818e2d97ce1a5e919a5aee9abd4363f7c"},{"nct_id":"NCT07669467","title":"Nuvastatic\u00ae Phase III Trial for Fatigue in Triple-Negative Breast Cancer","readout_date":"2026-10-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Natureceuticals Sdn Bhd","ticker":null,"ticker_confidence":0.0,"conditions":"Fatigue Related to Cancer Treatment; Breast Cancer","enrollment":250,"url":"https://clinicaltrials.gov/study/NCT07669467","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07669467","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d75f6930b00d17cc5180b02e8f74bc179abf680cb76dc8e61f6d21c896b2d991"},{"nct_id":"NCT03436485","title":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orion Corporation, Orion Pharma","ticker":"ORN","ticker_confidence":0.6,"conditions":"Prostate Cancer Metastatic","enrollment":204,"url":"https://clinicaltrials.gov/study/NCT03436485","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03436485","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a7d19ed78d2fcfe39826e2d702544c5027f5a4091dd7856e4a2b10900c8d7929"},{"nct_id":"NCT03816163","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma","enrollment":393,"url":"https://clinicaltrials.gov/study/NCT03816163","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03816163","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:83afaa6e814534f3840bb5a1f04b365a7dbe461e94ef72c182876c2b51bab4fb"},{"nct_id":"NCT03992430","title":"A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","ticker":"SRPT","ticker_confidence":0.9,"conditions":"Muscular Dystrophy, Duchenne","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT03992430","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03992430","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1b65642534d936a1bbb8cb01388f1a2b1b5a2bbff9adb7a289fa4b6d2b393409"},{"nct_id":"NCT04842617","title":"Phase III Study \uff1aSHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage\uff0cFemale Breast Cancer","enrollment":5274,"url":"https://clinicaltrials.gov/study/NCT04842617","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04842617","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a970387bf8a0b0a8df5aea9e4eaad1d292f1ed7cc1caa160490dd2aec5d731e8"},{"nct_id":"NCT05405595","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Adagene Inc","ticker":"ADAG","ticker_confidence":0.9,"conditions":"Advanced/Metastatic Solid Tumors","enrollment":186,"url":"https://clinicaltrials.gov/study/NCT05405595","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05405595","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ffbc20e4ac98b3bef887ec54a363fada25157d984b0500942e7880ae6dbb26ca"},{"nct_id":"NCT05518045","title":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":392,"url":"https://clinicaltrials.gov/study/NCT05518045","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05518045","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:47628d55ca4e910d5e67f2e0a7888805f5b154b0aa1add67b4b3c1abdefa2a1b"},{"nct_id":"NCT05598333","title":"Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskBio Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Congestive Heart Failure","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT05598333","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05598333","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:21a9501b0d8e84fb1fdb82d589bea99860eccfb4d0b29d5e6e6f68aa3d5e1711"},{"nct_id":"NCT05762211","title":"Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"MaaT Pharma","ticker":null,"ticker_confidence":0.0,"conditions":"Transplant Complication","enrollment":387,"url":"https://clinicaltrials.gov/study/NCT05762211","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05762211","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:85bbdef66e1f5ef096d1e92e2672870e4ea0d3e2c6a9250c606b59754d4f91f5"},{"nct_id":"NCT05890729","title":"Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xentria, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Pulmonary Sarcoidosis","enrollment":32,"url":"https://clinicaltrials.gov/study/NCT05890729","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05890729","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9d55a7869416d0a657b847504e646069c8cf3824c527deb4e86a50066ec33fc0"},{"nct_id":"NCT06016738","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","ticker_confidence":0.9,"conditions":"Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma","enrollment":510,"url":"https://clinicaltrials.gov/study/NCT06016738","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06016738","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a9447a81c8efef8dc91347e060ce13eb32383ec61bb82367d8bb18d6bf9b47f8"},{"nct_id":"NCT06052267","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Asthma","enrollment":2772,"url":"https://clinicaltrials.gov/study/NCT06052267","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06052267","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1a60f839e05fd226d42bb81b72c021914ec3e689ed18b24d3d9a535a6b4e339e"},{"nct_id":"NCT06083207","title":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma","enrollment":116,"url":"https://clinicaltrials.gov/study/NCT06083207","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06083207","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:96bdac564cdd7322f8515aceef5bac6478fd90e8be4501f6394dd8a93f56c7c6"},{"nct_id":"NCT06104839","title":"Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"NEXTGEN Bioscience","ticker":null,"ticker_confidence":0.0,"conditions":"Alopecia Areata","enrollment":73,"url":"https://clinicaltrials.gov/study/NCT06104839","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06104839","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a1f37907f40a01028f1d02e238b02b471061836d4862d6b2e440bf7d1efe8442"},{"nct_id":"NCT06116916","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Diabetic Macular Edema (DME)","enrollment":185,"url":"https://clinicaltrials.gov/study/NCT06116916","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06116916","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dd5511446f550d9fe7688cb0ac8e768cd00ab3c9c56ac979e3fb0e98e720f3db"},{"nct_id":"NCT06222879","title":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":350,"url":"https://clinicaltrials.gov/study/NCT06222879","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06222879","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:376677fb44d29e192d357ea0f58bf0d5217c772e4f389df93c983425de9950f6"},{"nct_id":"NCT06369298","title":"Study of JK07 in Patients With Chronic Heart Failure","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Salubris Biotherapeutics Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction","enrollment":282,"url":"https://clinicaltrials.gov/study/NCT06369298","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06369298","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:232e0ee889cc16210ecc1e57cdf04969403b87a200308e9ccb72320f31380cab"},{"nct_id":"NCT06524375","title":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Lymphocytic Leukemia","enrollment":118,"url":"https://clinicaltrials.gov/study/NCT06524375","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06524375","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b9a96300374564f07e3c55b75b11936d059112567fcc36e208f95dce0e0542dc"},{"nct_id":"NCT06574347","title":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Small-Cell Lung Cancer","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06574347","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06574347","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:51704b45bf797f87fd14125df70363998e8de4d7e6913c58211cdd3f099d17fb"},{"nct_id":"NCT06593522","title":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","ticker":"AMGN","ticker_confidence":0.9,"conditions":"MTAP-deleted NSCLC","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT06593522","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06593522","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9305f7215d842c921129fb3db0a557e8213fb1706fb5e0cdb8beb3cdaadf1ca6"},{"nct_id":"NCT06635447","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Breast Cancer","enrollment":293,"url":"https://clinicaltrials.gov/study/NCT06635447","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06635447","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7e523e628392254ebfb9a99ab15a17f9b4adde56e08e9c923ad9a903b167cfcf"},{"nct_id":"NCT06719141","title":"A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Longboard Pharmaceuticals","ticker":null,"ticker_confidence":0.0,"conditions":"Developmental and Epileptic Encephalopathy","enrollment":367,"url":"https://clinicaltrials.gov/study/NCT06719141","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06719141","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:40eb0390405e4c78a813fd1930c98bdd6e4d5438518abf3b28f8e48f401f8dad"},{"nct_id":"NCT06742892","title":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Carcinoma, Hepatocellular","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06742892","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06742892","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:664434933fea4b07fa7424c60e5f09147d34b855abfc297317bce0b10cae7fd8"},{"nct_id":"NCT06769113","title":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Esophageal Cancer","enrollment":102,"url":"https://clinicaltrials.gov/study/NCT06769113","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06769113","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f23158f9048b5066546480ec7547381633f42cf013d814bcba249326494fee08"},{"nct_id":"NCT06772597","title":"A Study of Setmelanotide in Patients With Prader-Willi Syndrome","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rhythm Pharmaceuticals, Inc.","ticker":"RYTM","ticker_confidence":0.9,"conditions":"Prader-Willi Syndrome; Obesity; Hyperphagia","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT06772597","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06772597","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d738171add9107cf09771a6152ef252adbc278edf6bb87d3c70b9addc80521cc"},{"nct_id":"NCT06954597","title":"Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Topadur Pharma AG","ticker":null,"ticker_confidence":0.0,"conditions":"Digital Ulcers in Systemic Sclerosis","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT06954597","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06954597","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d7c5ebfd822387155eabde217e7ab4909fbb8693b8aecc3aa3757b10718840e5"},{"nct_id":"NCT07019090","title":"Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07019090","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07019090","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c21bb200c23b3215742f51e500dceb238a79342afd29a020424ad2d3ecdeafdc"},{"nct_id":"NCT07072195","title":"A Study of AMC6156 in People With Sarcopenia","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Animuscure Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Sarcopenia in Elderly; Sarcopenia","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT07072195","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07072195","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5733af3bf8fb1dcd1e87f58268991f75b36068ed090a708cabc0fdc12485103d"},{"nct_id":"NCT07148414","title":"A Study of SPY072 in Rheumatic Disease","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spyre Therapeutics, Inc.","ticker":"SYRE","ticker_confidence":0.9,"conditions":"Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joint Disease; PsA (Psoriatic Arthritis); AxSpA; Rheumatologic Disease","enrollment":285,"url":"https://clinicaltrials.gov/study/NCT07148414","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07148414","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e4a8c80810715bf3148232db0a85fbc02d0268b70727dbb9061622eb4fbc8a74"},{"nct_id":"NCT07185880","title":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Myosin Therapeutics Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Glioblastoma (GBM)","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT07185880","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07185880","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:471cf3cf93ceb0805ba41063e911e75b59cc0fcf9714b6e5c36a1c4da2703ef6"},{"nct_id":"NCT07211633","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"TG Therapeutics, Inc.","ticker":"TGTX","ticker_confidence":0.9,"conditions":"Relapsing Multiple Sclerosis","enrollment":360,"url":"https://clinicaltrials.gov/study/NCT07211633","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07211633","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3b743e68c9f3d3cb3fee7b2f63a0ea3b95ffaeafc473ece4a5e048ea8d70568c"},{"nct_id":"NCT07213583","title":"Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Neurimmune AG","ticker":null,"ticker_confidence":0.0,"conditions":"Amyloid Transthyretin Cardiomyopathy","enrollment":35,"url":"https://clinicaltrials.gov/study/NCT07213583","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07213583","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ca6dec9034e2281edce9b728ecfe1129510a94245e23af2c45fd3329cfbbf9d5"},{"nct_id":"NCT07396337","title":"Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Changzhou Qianhong Bio-pharma Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Ischemic Stroke","enrollment":320,"url":"https://clinicaltrials.gov/study/NCT07396337","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07396337","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:03487accbc09fabe335b2d8b158ed4fef346461d82c6b1eea8f1ceeb7af0d057"},{"nct_id":"NCT07434271","title":"Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Kadence Bio","ticker":null,"ticker_confidence":0.0,"conditions":"Premature Ejaculation","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07434271","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07434271","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dff58db5db7e01493adc9a365f202edf69b448e2a57bb768a6bfa2f824e10dd7"},{"nct_id":"NCT07453069","title":"Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Freya Biosciences ApS","ticker":null,"ticker_confidence":0.0,"conditions":"Vaginal Dysbiosis","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT07453069","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07453069","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bc76996ca9a2b7c86f7ea2bee1cbdeaf6f93742e422ad1772016aad0c6b547f7"},{"nct_id":"NCT07669454","title":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic\u00ae 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","readout_date":"2026-10-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Natureceuticals Sdn Bhd","ticker":null,"ticker_confidence":0.0,"conditions":"Fatigue Related to Cancer Treatment; Colon Cancer","enrollment":250,"url":"https://clinicaltrials.gov/study/NCT07669454","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07669454","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:538f295f1efbd1985c7d82eb1a1be28ca642ffb5736d6758ed63ff0930fa9397"},{"nct_id":"NCT03736889","title":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"BeiGene","ticker":null,"ticker_confidence":0.0,"conditions":"MSI-H/dMMR Solid Tumors","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT03736889","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03736889","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5a6b50b29e0008993b449e25ad66c2ea4a1755b61dfc6428a26cf1b42a660b98"},{"nct_id":"NCT03850574","title":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Aptose Biosciences Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess Blasts-2; Chronic Myelomonocytic Leukemia","enrollment":240,"url":"https://clinicaltrials.gov/study/NCT03850574","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03850574","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0480be79a59d2dbb1a2f5286a749d22278c56ec542d6370affb9618ba7bf7419"},{"nct_id":"NCT04486378","title":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","ticker":"BNTX","ticker_confidence":0.9,"conditions":"Colorectal Cancer Stage II; Colorectal Cancer Stage III","enrollment":327,"url":"https://clinicaltrials.gov/study/NCT04486378","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04486378","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c7dd81bdfe9b00b2fab01219327d28dcb7f9507ce5f65c7d5739d6d25a76a718"},{"nct_id":"NCT04895436","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT04895436","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04895436","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fb2c61c6d8c0d7d944ab9d9248bec73cd4136bd8e1ea8200b363f8d05cda47b3"},{"nct_id":"NCT04973605","title":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"BeOne Medicines","ticker":"ONC","ticker_confidence":0.9,"conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":246,"url":"https://clinicaltrials.gov/study/NCT04973605","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04973605","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c2b9b7bc2cb8c23a8d3adecb9424f6a4c4d39ae5984e888eb25dfa7ac779d599"},{"nct_id":"NCT05050942","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","ticker":null,"ticker_confidence":0.0,"conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332,"url":"https://clinicaltrials.gov/study/NCT05050942","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05050942","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2a3fc0cf9d2b557c9a5809e174082dcff95068921a0ad96f3ef5c99c0570e10f"},{"nct_id":"NCT05134441","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunic AG","ticker":"IMUX","ticker_confidence":0.9,"conditions":"Multiple Sclerosis","enrollment":1121,"url":"https://clinicaltrials.gov/study/NCT05134441","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05134441","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dee0c63613a3daa5a65d5268a343104ec965f5001dde2a68eb170183502441f5"},{"nct_id":"NCT05201638","title":"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunic AG","ticker":"IMUX","ticker_confidence":0.9,"conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1100,"url":"https://clinicaltrials.gov/study/NCT05201638","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05201638","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8d323bcfaabb68cd1ec0f60b5475c1c98d54a2a3c7cb52057057090bd0d0c8d9"},{"nct_id":"NCT05202509","title":"Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"NewAmsterdam Pharma","ticker":"NAMS","ticker_confidence":0.9,"conditions":"Atherosclerotic Cardiovascular Disease","enrollment":9541,"url":"https://clinicaltrials.gov/study/NCT05202509","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05202509","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3cbbe3e5b2b887a6291d3cbf81b6b5f158b612d71f8a6f9e420c092433b7f880"},{"nct_id":"NCT05322590","title":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bexion Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Colorectal Carcinoma; Neuropathy","enrollment":195,"url":"https://clinicaltrials.gov/study/NCT05322590","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05322590","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:66afa245b150542470386e87242b81973059afb2dc7de3ad845cb013701ff758"},{"nct_id":"NCT05456685","title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR\u03b1) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer","enrollment":125,"url":"https://clinicaltrials.gov/study/NCT05456685","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05456685","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ca145aacfa9cd5dc249bb802393be8438d8364dd89bfda62bf1a474d5dde013a"},{"nct_id":"NCT05514340","title":"Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Pharmazz, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Hypoxic-Ischemic Encephalopathy; Neonatal Asphyxia; Neonatal Encephalopathy","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT05514340","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05514340","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:786fc8edce8efe41c1ba4107ed415944fa8d44923c468973e1e367ff388eb8a2"},{"nct_id":"NCT05532696","title":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Anbogen Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutations","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT05532696","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05532696","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:28ff15e03dc56c3f021d2dc3a02882ca92a75c20ebcb722819d1397c18051d6c"},{"nct_id":"NCT05543681","title":"Clinical Trial on Agitation in Alzheimer's Dementia","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"IGC Pharma, LLC","ticker":"IGC","ticker_confidence":0.9,"conditions":"Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden; NPS; Aggression","enrollment":164,"url":"https://clinicaltrials.gov/study/NCT05543681","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05543681","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce883c4d858e52a5e4d08a9982bef3d19706b2a44f7078f15601d0467c9a6066"},{"nct_id":"NCT05544552","title":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tyra Biosciences, Inc","ticker":"TYRA","ticker_confidence":0.9,"conditions":"Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcinoma; Solid Tumor, Adult; Bladder Cancer; Non-muscle-invasive Bladder Cancer; FGFR3 Gene Mutation; FGFR3 Gene Alteration; Advanced Solid Tumor; Advanced Urothelial Carcinoma; Urinary Tract Cancer; Urinary Tract Tumor; Urinary Tract Carcinoma","enrollment":310,"url":"https://clinicaltrials.gov/study/NCT05544552","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05544552","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:be177abea3c1c196ba5a0aa4e48f14b5b6abe7574d03837b315fb1be2aa6bf7e"},{"nct_id":"NCT05596409","title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stemline Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Breast Cancer","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT05596409","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05596409","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ea398bf12263acb532bf52e273661220560704403e8f2b1567ec7bc65705a2bd"},{"nct_id":"NCT05607004","title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atossa Therapeutics, Inc.","ticker":"ATOS","ticker_confidence":0.9,"conditions":"Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Breast Cancer","enrollment":87,"url":"https://clinicaltrials.gov/study/NCT05607004","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05607004","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3e97f004110f6da363d8c24d90360c5ee08ae94449722636b1cb016133b11e95"},{"nct_id":"NCT05660642","title":"An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Beckley Psytech Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Treatment Resistant Depression","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT05660642","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05660642","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:af42ee5cd565fcde690f10a533dbfe4bc3e5acea4a5299757cf4b5d145297f4b"},{"nct_id":"NCT05739643","title":"Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Forge Biologics, Inc","ticker":"FIGP","ticker_confidence":0.6,"conditions":"Krabbe Disease","enrollment":9,"url":"https://clinicaltrials.gov/study/NCT05739643","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05739643","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7e5ff0befb75d26f9ec6d67fc8bd7ed0bb75a367d2bff567ae2ebfd793cdf9cf"},{"nct_id":"NCT05822752","title":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Hepatocellular Carcinoma","enrollment":130,"url":"https://clinicaltrials.gov/study/NCT05822752","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05822752","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e1a207cad057f887e9a36c98e60532dc4b6a9e7e5e5ba840ddf99e808ae8e7e0"},{"nct_id":"NCT06015048","title":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"HER2-expressing Advanced Solid Tumors","enrollment":364,"url":"https://clinicaltrials.gov/study/NCT06015048","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06015048","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:00257337d77934a0fbf1d1b71e49a24d297a9ec521ca4b8784ff7bb5d1584fa7"},{"nct_id":"NCT06038331","title":"Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"TBF Genie Tissulaire","ticker":null,"ticker_confidence":0.0,"conditions":"Osteoarthritis Hand","enrollment":14,"url":"https://clinicaltrials.gov/study/NCT06038331","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06038331","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e40bd39de7cc2344da4e391ca28f2e1074d6dfa96b4075bec7cfc63d527761a7"},{"nct_id":"NCT06106308","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff Oncology","ticker":"CRDF","ticker_confidence":0.9,"conditions":"Metastatic Colorectal Cancer; CRC; KRAS/NRAS Mutation","enrollment":110,"url":"https://clinicaltrials.gov/study/NCT06106308","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06106308","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7f20867022e45e6d3e36acfee64ae8ec0723a0c88ae7597a0065ae6674cbfb50"},{"nct_id":"NCT06107686","title":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT06107686","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06107686","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:be7c850c7b9e62422e7d90d1b4f64bee05e6f7eb79bbae0236cb96cbf37db025"},{"nct_id":"NCT06111235","title":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Oncology, Inc.","ticker":"CGON","ticker_confidence":0.9,"conditions":"Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma","enrollment":367,"url":"https://clinicaltrials.gov/study/NCT06111235","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06111235","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6e6cc595d2b6189bb852d4bf28cbbad5ad36142c8056ea2f7f648100ac6d7371"},{"nct_id":"NCT06118333","title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Nasopharyngeal Carcinoma","enrollment":386,"url":"https://clinicaltrials.gov/study/NCT06118333","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06118333","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:23e0320de49b0b51af96882fca06be96c63c95710e3a976b242642494b8ac311"},{"nct_id":"NCT06237335","title":"A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"ReCode Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Cystic Fibrosis","enrollment":128,"url":"https://clinicaltrials.gov/study/NCT06237335","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06237335","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1581ffcba4ca15d73993b91e19ace6b226cca26fd18910c3ed11fd666fc1d814"},{"nct_id":"NCT06239311","title":"Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"medac GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Moderate to Severe Atopic Dermatitis","enrollment":277,"url":"https://clinicaltrials.gov/study/NCT06239311","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06239311","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:21924711ed7ae8bf5b5d824b1071ecb94e8c0af0e167a9a62142f8a4298c51a0"},{"nct_id":"NCT06284954","title":"A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","ticker":"ARGX","ticker_confidence":0.6,"conditions":"Dermatomyositis; Myositis","enrollment":3,"url":"https://clinicaltrials.gov/study/NCT06284954","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06284954","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e01bef563d17179b1237d8a0efd9979424e3ce171df850314398e1e0130df61f"},{"nct_id":"NCT06341335","title":"A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Gastric and Gastroesophageal Junction Adenocarcinoma","enrollment":506,"url":"https://clinicaltrials.gov/study/NCT06341335","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06341335","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:542bd8508091e0c57186639017549de3d65b26cf19f47629623eee8ed368aa51"},{"nct_id":"NCT06355531","title":"A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ferrer Internacional S.A.","ticker":null,"ticker_confidence":0.0,"conditions":"Progressive Supranuclear Palsy","enrollment":241,"url":"https://clinicaltrials.gov/study/NCT06355531","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06355531","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6e50ee07cd30167bd70da52a93ee4b1c52f4b2592b80ff527f5fe5bb81cfce9e"},{"nct_id":"NCT06389136","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Atopic Dermatitis","enrollment":184,"url":"https://clinicaltrials.gov/study/NCT06389136","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06389136","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49f03f5804279646ba8b34c3f3c53aab227115c717ac2aea75fb68abb4390961"},{"nct_id":"NCT06395948","title":"A Study Evaluating APG777 in Atopic Dermatitis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Apogee Therapeutics, Inc.","ticker":"APOG","ticker_confidence":0.6,"conditions":"Atopic Dermatitis","enrollment":470,"url":"https://clinicaltrials.gov/study/NCT06395948","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06395948","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:24098c071e86529d0d16e2e5e7e79826b6fe94a4b696e64f08b2c7176947c339"},{"nct_id":"NCT06448312","title":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"SKBBY","ticker_confidence":0.6,"conditions":"Non-Small Cell Lung Cancer","enrollment":406,"url":"https://clinicaltrials.gov/study/NCT06448312","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06448312","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e718b879ab70cb28b831458931a0ebd593f3f42d0da6cd6eb70b28d7b0b24134"},{"nct_id":"NCT06496243","title":"Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"NewAmsterdam Pharma","ticker":"NAMS","ticker_confidence":0.9,"conditions":"Dyslipidemias","enrollment":69,"url":"https://clinicaltrials.gov/study/NCT06496243","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06496243","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:866fe118bece2da797a05c6c7dc6123c80e03397057a43763f5cef17ca2a7308"},{"nct_id":"NCT06529432","title":"A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Local Analgesia Via Nerve Block","enrollment":96,"url":"https://clinicaltrials.gov/study/NCT06529432","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06529432","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1d94767171a4557947a4019890f07f058d1715e89189ccb64246690f5e3bbee3"},{"nct_id":"NCT06637501","title":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","ticker":"ONC","ticker_confidence":0.9,"conditions":"Chronic Lymphocytic Leukemia","enrollment":94,"url":"https://clinicaltrials.gov/study/NCT06637501","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06637501","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f546e222ac4bb08acf06d5b51a581c413fdbaf8eb0e37c1a94eeb5e2f2dd9e6e"},{"nct_id":"NCT06662383","title":"A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","ticker":"LLY","ticker_confidence":0.95,"conditions":"Obesity","enrollment":800,"url":"https://clinicaltrials.gov/study/NCT06662383","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06662383","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3402b223a32d2032e729e625757bbad1e9c20eb62f419bfd0bedcd803f5b0a0b"},{"nct_id":"NCT06668961","title":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT06668961","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06668961","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:03ba437c5c939dd908f04facc209af2bb1237ab552d34169f90aa547d767660a"},{"nct_id":"NCT06736990","title":"A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calluna Pharma AS","ticker":null,"ticker_confidence":0.0,"conditions":"Idiopathic Pulmonary Fibrosis","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT06736990","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06736990","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:42cba45d3f36bb6ded694caf1f438b0be8f6dfd4f24138c38aa70edb5571bc15"},{"nct_id":"NCT06737731","title":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Malignant Solid Tumors","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT06737731","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06737731","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:67cd4fc417a56d8248a3df916c368e970a5eaae666574bef961058b173662ec2"},{"nct_id":"NCT06767813","title":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Pancreatic Neoplasms","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT06767813","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06767813","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4a30d765cb8077bc25d0b3bb85d37cfbc68e621f2952e93208c0aee0fff2d6a6"},{"nct_id":"NCT06825702","title":"Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Kiora Pharmaceuticals, Inc.","ticker":"KPRX","ticker_confidence":0.9,"conditions":"Macular Edema","enrollment":28,"url":"https://clinicaltrials.gov/study/NCT06825702","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06825702","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:301b30bcaae5c4699819bcabe5608fa0bc966b4080b84fdec9b073ca2192553e"},{"nct_id":"NCT06829823","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","ticker":"IBRX","ticker_confidence":0.9,"conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT06829823","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06829823","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:acc3f2e3c682779c2fb9e86c46c795ab210c100a31451324b6555e0db775566f"},{"nct_id":"NCT06833749","title":"Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"KeyBioscience AG","ticker":null,"ticker_confidence":0.0,"conditions":"Osteoarthritis in the Knee; Obesity","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06833749","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06833749","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c94e75aa88e1a4a63c0b8ddfc881ffa76c2aaf62d9aadd73b09b467cd6f639af"},{"nct_id":"NCT06843590","title":"A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alkermes, Inc.","ticker":"ALKS","ticker_confidence":0.9,"conditions":"Idiopathic Hypersomnia","enrollment":126,"url":"https://clinicaltrials.gov/study/NCT06843590","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06843590","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b05093e80a6e41edbbe2f5f04e225d7b014f266ffda29e1acba34474cbd75d09"},{"nct_id":"NCT06846320","title":"Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Generalized Anxiety Disorder (GAD)","enrollment":315,"url":"https://clinicaltrials.gov/study/NCT06846320","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06846320","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:acb687f99de19b1696cd9fe240b078d335eefb037a509aaadd24049f3e6cd16b"},{"nct_id":"NCT06847724","title":"Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sandoz","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsing Multiple Sclerosis","enrollment":183,"url":"https://clinicaltrials.gov/study/NCT06847724","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06847724","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0591a113fa153d437cd3c8cff18c67ba2a423140b1c3e9234f398135177277a6"},{"nct_id":"NCT06884865","title":"A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Pacira Pharmaceuticals, Inc","ticker":"PCRX","ticker_confidence":0.9,"conditions":"Osteoarthritis (OA) of the Knee","enrollment":135,"url":"https://clinicaltrials.gov/study/NCT06884865","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06884865","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6f2bb5f3fd06bfcd83cda74ce1c18d79449045071dee8bc110dd8ba3a86105e5"},{"nct_id":"NCT06914895","title":"A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","ticker":"LLY","ticker_confidence":0.95,"conditions":"Type 1 Diabetes; Obesity; Overweight","enrollment":905,"url":"https://clinicaltrials.gov/study/NCT06914895","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06914895","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e94ae08bab18d8a5eb4c1e072069dade9df2419f7a4caa3deea2fdbd41579e2b"},{"nct_id":"NCT06962280","title":"A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","ticker":"LLY","ticker_confidence":0.95,"conditions":"Type 1 Diabetes; Obesity; Overweight","enrollment":465,"url":"https://clinicaltrials.gov/study/NCT06962280","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06962280","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b15dbb388a60d4829ed7096b3371e18335fdd37c46938875ca3e01f048dc762b"},{"nct_id":"NCT07002034","title":"RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Reunion Neuroscience Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Adjustment Disorder","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07002034","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07002034","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:13de9d04f5b89b2ca83d710220471df5e922bf17ad3f1d8247a34f9c5192b2fd"},{"nct_id":"NCT07003919","title":"Safety Study of Viaskin\u00ae Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"DBV Technologies","ticker":"DBVT","ticker_confidence":0.9,"conditions":"Allergy; Peanut Allergy","enrollment":480,"url":"https://clinicaltrials.gov/study/NCT07003919","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07003919","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4657448fa03b1910ec3cbbd65cfd7baf389206a02c50f40307b40b9113443f2a"},{"nct_id":"NCT07029516","title":"Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Wooshin Labottach Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Nail Psoriasis; Nail Damage; Mycosis","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT07029516","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07029516","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:51013c87560db94a20370baedc1c99bacbdc97548865a4e97cfd76a261b74e44"},{"nct_id":"NCT07078955","title":"A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"BRIM Biotechnology Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Dry Eye Disease (DED); Keratoconjunctivitis Sicca","enrollment":99,"url":"https://clinicaltrials.gov/study/NCT07078955","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07078955","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0116752a3c7667de1dce12a265bf96005166a5da6735551f1dbaa2340ff092ac"},{"nct_id":"NCT07104643","title":"Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer\uff08mCRPC\uff09","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"TYK Medicines, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"mCRPC","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT07104643","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07104643","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2bde97f6139b12be5c532b94293871fd1987a90ebb7cd30789949990c40b0698"},{"nct_id":"NCT07116746","title":"Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arthrosi Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Gout; Gouty Arthritis; Hyperuricemia; Gout Chronic; Refractory Gout; Uncontrolled Gout; Tophaceous Gout","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT07116746","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07116746","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:123af688843a19df720137559248ded5494d286afa56779496fe22f14376aa76"},{"nct_id":"NCT07142811","title":"A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","ticker":"VIR","ticker_confidence":0.9,"conditions":"Viral Hepatitis","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07142811","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07142811","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:497740a422b52f71c70358ece87c539ae6004df8fcdb38dd48824e3049514f7b"},{"nct_id":"NCT07177859","title":"A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","ticker":null,"ticker_confidence":0.0,"conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":78,"url":"https://clinicaltrials.gov/study/NCT07177859","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07177859","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:45c6f08410695f818ec3d3fa3271ab9157f1442188083952933fb1dca3c064cc"},{"nct_id":"NCT07199777","title":"A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"SciNeuro","ticker":null,"ticker_confidence":0.0,"conditions":"Diabetic Macular Edema; DME","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07199777","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07199777","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9954cbf53391e750985fa844007685c6fed5534be228a46c213b14d24bb08649"},{"nct_id":"NCT07215312","title":"A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","ticker":"LLY","ticker_confidence":0.95,"conditions":"Diabetes Mellitus, Type 2","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07215312","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07215312","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b676231ca64de8baac44b5c97b6c06bf04117a8156d4bf541862996a034796dc"},{"nct_id":"NCT07237568","title":"A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Lynk Pharmaceuticals Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Ankylosing Spondylitis","enrollment":352,"url":"https://clinicaltrials.gov/study/NCT07237568","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07237568","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fdc8e31763a6cc80616575c5851276119226f0b2679bf67eeed368c3d4211dee"},{"nct_id":"NCT07246590","title":"Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","ticker_confidence":0.9,"conditions":"Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts","enrollment":302,"url":"https://clinicaltrials.gov/study/NCT07246590","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07246590","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ee5712ea9b14297e6b5612721256e09dff4054083c7a2359ff7a11be3892df51"},{"nct_id":"NCT07251309","title":"A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Waterstone Pharmaceutical (Wuhan) Co., LTD.","ticker":null,"ticker_confidence":0.0,"conditions":"Hyperkalemia","enrollment":420,"url":"https://clinicaltrials.gov/study/NCT07251309","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07251309","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ab996b2e772336baae8c026dcba4cfae6d762a016540069fca60b97d0401458b"},{"nct_id":"NCT07266324","title":"A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Bright Minds Biosciences Pty Ltd","ticker":"DRUG","ticker_confidence":0.6,"conditions":"Prader-Willi Syndrome","enrollment":16,"url":"https://clinicaltrials.gov/study/NCT07266324","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07266324","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:87de9affdf180d25f5886d36698275a402b06969f0f281fbd85e0842517f127f"},{"nct_id":"NCT07282028","title":"A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Nuance Hearing","ticker":null,"ticker_confidence":0.0,"conditions":"Hearing Loss Mixed","enrollment":89,"url":"https://clinicaltrials.gov/study/NCT07282028","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07282028","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8e0e61751a8a081e8b988ebbc1779c5136b84a647d666d3de8e5fd46edd69713"},{"nct_id":"NCT07336732","title":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Small-Cell Lung Cancer","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07336732","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07336732","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e4de052bb3aa94e4a777783f08e96790aa141c85c4ed459c36c5ad4bcb589bbc"},{"nct_id":"NCT07398859","title":"Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Seasonal Allergic Rhinitis","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT07398859","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07398859","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5f4dda6465dec61dd38e682dc04d5d58b0e4111c567a4b2f1de0a0d4e820d13a"},{"nct_id":"NCT07470983","title":"A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Aldosteronism","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT07470983","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07470983","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d7db224f4c99fd090ca0a547caf79e6bd29af9f3668e395fad6605f0a892b7ec"},{"nct_id":"NCT07503405","title":"Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Traws Pharma, Inc.","ticker":"TRAW","ticker_confidence":0.9,"conditions":"Influenza","enrollment":165,"url":"https://clinicaltrials.gov/study/NCT07503405","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07503405","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:93422e102cdcdb3f4eff5dc0e6400640f26eaac963b7ac3fde0b7737c55cffd8"},{"nct_id":"NCT07505888","title":"Phase \u2162 Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","ticker":"SVA","ticker_confidence":0.9,"conditions":"Epidemic Meningitis; Meningococcal Vaccines","enrollment":660,"url":"https://clinicaltrials.gov/study/NCT07505888","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07505888","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:09aa919b7bf895e2a9830d4dbeac396bb7872c7dcc37a33979ce95dd8ea7083f"},{"nct_id":"NCT07511816","title":"A Study of LY4515100 in Participants With Pain Following Third Molar Removal","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Eli Lilly and Company","ticker":"LLY","ticker_confidence":0.95,"conditions":"Acute Pain; Molar; Molar, Third; Surgery, Oral","enrollment":212,"url":"https://clinicaltrials.gov/study/NCT07511816","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07511816","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:35090081154d23ea618d2fe7d3b374eebc3bc4ae1288f53625e3963179f2c23c"},{"nct_id":"NCT07521683","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"NeuShen Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Schizophrenia(Acute)","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT07521683","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07521683","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0605090881f4bbcc8a021faf366592ab53d0e3c61fdd4b35a5998e90fa9a7e53"},{"nct_id":"NCT07551739","title":"A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Pain After Surgery","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT07551739","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07551739","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:238d0a6757b9d5da600acd1683dda14d416a1f8f7e9835edd9fcedb5fe84ac2a"},{"nct_id":"NCT07605338","title":"To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.","readout_date":"2026-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Colgate Palmolive","ticker":"CL","ticker_confidence":0.9,"conditions":"Plaque, Dental; Gingivitis","enrollment":85,"url":"https://clinicaltrials.gov/study/NCT07605338","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07605338","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:634f8c339b40d746eeaeee127e47a44455471d6bbe34e76892143be95434a0d6"},{"nct_id":"NCT04800874","title":"Study of BBP-418 in Patients With LGMD2I","readout_date":"2026-11-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"ML Bio Solutions, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"LGMD2I","enrollment":14,"url":"https://clinicaltrials.gov/study/NCT04800874","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04800874","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:96055f63b9ce5533be4cc3f25326a1dcea8c2b0d8199247b3b735eeaecd2f902"},{"nct_id":"NCT05066217","title":"An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome","readout_date":"2026-11-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Epygenix","ticker":null,"ticker_confidence":0.0,"conditions":"Lennox Gastaut Syndrome","enrollment":260,"url":"https://clinicaltrials.gov/study/NCT05066217","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05066217","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:365f04ccb057fce550c54d1f37eb9eaee9a6a272aaf3262f82263f84da314c26"},{"nct_id":"NCT05584800","title":"Study of ZGGS18 in Patients With Advanced Solid Tumors","readout_date":"2026-11-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":222,"url":"https://clinicaltrials.gov/study/NCT05584800","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05584800","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5ee6aac6bf73b19299f96e919a8ec7d250e8b7f9a0133145a239707e4dcddd2e"},{"nct_id":"NCT05626855","title":"Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab","readout_date":"2026-11-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Scholar Rock, Inc.","ticker":"SRRK","ticker_confidence":0.6,"conditions":"Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations; Anti-myostatin","enrollment":238,"url":"https://clinicaltrials.gov/study/NCT05626855","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05626855","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b9bbc239b169ad23f835ee3a1f9940581c98bd40d3411c8d8cea8ed5f29caf59"},{"nct_id":"NCT06603844","title":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","readout_date":"2026-11-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Corbus Pharmaceuticals Inc.","ticker":"CRBP","ticker_confidence":0.9,"conditions":"Solid Tumor","enrollment":156,"url":"https://clinicaltrials.gov/study/NCT06603844","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06603844","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dec09bd5aaedb50d73ab6a93086ac368b3632ee49e17b3d866d480ffe1f29b11"},{"nct_id":"NCT06951698","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder","readout_date":"2026-11-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","ticker":"BMY","ticker_confidence":0.9,"conditions":"Bipolar-I Disorder With Mania or Mania With Mixed Features","enrollment":274,"url":"https://clinicaltrials.gov/study/NCT06951698","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06951698","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:15ae0461bd81e82971fc464bea5ec0cd3ba002cac07aa4ec42159dc318f6e13d"},{"nct_id":"NCT05723562","title":"A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer","readout_date":"2026-11-02","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Neoplasms, Rectal","enrollment":154,"url":"https://clinicaltrials.gov/study/NCT05723562","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05723562","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7bbb78d1074119a219e1c3cd779a7a283ba82147c656847bf9def894aeeb6fd6"},{"nct_id":"NCT06015737","title":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","readout_date":"2026-11-02","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Cutaneous Lupus Erythematosus","enrollment":339,"url":"https://clinicaltrials.gov/study/NCT06015737","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06015737","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1d044325d13646d1f2e6e0eeb53e0dbb4797ab8a4fedce4e1d6bfd7211a30e97"},{"nct_id":"NCT06190951","title":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","readout_date":"2026-11-02","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","ticker":"REGN","ticker_confidence":0.9,"conditions":"Melanoma","enrollment":151,"url":"https://clinicaltrials.gov/study/NCT06190951","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06190951","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5a66c5d7fafbc498eb37f5968f13b434e9e36beca6710e6a2563471bbad64ea3"},{"nct_id":"NCT06664619","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","readout_date":"2026-11-02","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Asthma","enrollment":649,"url":"https://clinicaltrials.gov/study/NCT06664619","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06664619","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4b845f25a066f2ebfd76a67d1b96c49133415409d0fd7c61e245c07d003046eb"},{"nct_id":"NCT06951711","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)","readout_date":"2026-11-02","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","ticker":"BMY","ticker_confidence":0.9,"conditions":"Bipolar Disorder Type I With Mania or Mania With Mixed Features","enrollment":274,"url":"https://clinicaltrials.gov/study/NCT06951711","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06951711","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c7465633561ca2007601b04ef61e718c8348e706c3a6f8099b8fb47565ba133e"},{"nct_id":"NCT07166211","title":"Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)","readout_date":"2026-11-02","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT07166211","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07166211","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a7561317ccaa6763dc4a9bada740b21f0a9836ca501da14043925a9296a504a1"},{"nct_id":"NCT05677451","title":"24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","readout_date":"2026-11-03","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"Chronic Spontaneous Urticaria","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT05677451","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05677451","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:99dfeba548e90d25a2bc823dce30b2f93b15a480761e91fa36e6ed4b34c3f648"},{"nct_id":"NCT06772168","title":"Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia","readout_date":"2026-11-04","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"CMG Pharmaceutical Co. Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Dyslipidemia; Type 2 Diabetes","enrollment":240,"url":"https://clinicaltrials.gov/study/NCT06772168","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06772168","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c31baeefd1c1c669bc67f19887435e51accfd65d8e70ab565eee55690aa2fcb3"},{"nct_id":"NCT04509700","title":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","readout_date":"2026-11-05","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","ticker":"INCY","ticker_confidence":0.9,"conditions":"B-Cell Malignancies","enrollment":112,"url":"https://clinicaltrials.gov/study/NCT04509700","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04509700","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c8e0f53db877f2e70cb8fa1801abba4e95c9b73542d5dc62f3d5c8fe85959422"},{"nct_id":"NCT07336446","title":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","readout_date":"2026-11-05","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Prostate Cancer","enrollment":6,"url":"https://clinicaltrials.gov/study/NCT07336446","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07336446","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:600e5fbed22c5dc6a544cb2bfc54370722868792b99c6cb749ac837089881032"},{"nct_id":"NCT07150988","title":"A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis","readout_date":"2026-11-06","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Psoriasis","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT07150988","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07150988","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f99f3fc306bfa995290722d0731a0a88271915f0e567b0af8512ec1635b3b5d7"},{"nct_id":"NCT05565378","title":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","readout_date":"2026-11-09","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Lung Cancer, Non-Small Cell","enrollment":351,"url":"https://clinicaltrials.gov/study/NCT05565378","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05565378","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a01ff340fe581d61fcd0e97fdb6532494946b6d8105db7b064ada8aa0431bef1"},{"nct_id":"NCT06640777","title":"Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome","readout_date":"2026-11-09","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"LEAF4Life, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Respiratory Distress Syndrome","enrollment":310,"url":"https://clinicaltrials.gov/study/NCT06640777","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06640777","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ec86593624eb46517dbec0234875a6cb37ab1b14ca10a24fedd31cc20c0a4927"},{"nct_id":"NCT06340048","title":"Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure","readout_date":"2026-11-10","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"HELP Therapeutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Heart Failure","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT06340048","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06340048","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:162a46cb9ca4926bdb63e2ac9d8e73a7d8cd86b6c2e5ab4be161f747af5ed7ea"},{"nct_id":"NCT06351020","title":"LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.","readout_date":"2026-11-10","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced or Metastatic GC and GCJ Adenocarcinoma","enrollment":387,"url":"https://clinicaltrials.gov/study/NCT06351020","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06351020","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3ddfd8cb66c83a328d5d060234f52684f3782ca7f71d87d581344bd50de91e22"},{"nct_id":"NCT07165223","title":"A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin","readout_date":"2026-11-10","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","ticker":null,"ticker_confidence":0.0,"conditions":"Diabetes","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT07165223","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07165223","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ae56ca417dd3169befb200060c390e480892bfad471fc3dc391f772f578d32d3"},{"nct_id":"NCT06157151","title":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","readout_date":"2026-11-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Precigen, Inc","ticker":"PGEN","ticker_confidence":0.9,"conditions":"Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metastatic Cervical Cancer","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT06157151","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06157151","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b27b59450e89ecaa99251609bebce633072fc6f1929bcc0cea291536779fdd64"},{"nct_id":"NCT06753890","title":"Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)","readout_date":"2026-11-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Diarrhea-predominant Irritable Boewl Syndrome","enrollment":520,"url":"https://clinicaltrials.gov/study/NCT06753890","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06753890","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:95e6c903dfa62d7f7e76c7fbc8b68fbe6d6c2b8c54b65419303fd536fd188937"},{"nct_id":"NCT05995964","title":"A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis","readout_date":"2026-11-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Atopic Dermatitis","enrollment":507,"url":"https://clinicaltrials.gov/study/NCT05995964","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05995964","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e92fded3b39b071b754f574420a971bcf2151fd7f25cb35beafb4e49766d8c39"},{"nct_id":"NCT06671548","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","readout_date":"2026-11-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Heavy Menstrual Bleeding; Uterine Fibroids","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06671548","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06671548","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:490ffefdc46a70e88a3a94b0b874757c6395c5d89ad21cbd59685806aa3c5635"},{"nct_id":"NCT07603713","title":"Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis","readout_date":"2026-11-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Longbio Pharma (Suzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Periodontitis","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07603713","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07603713","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:eaa0f893b7accdd94972d23e188bc88c0ab87e675f19af0fcc118c505ff72325"},{"nct_id":"NCT04626635","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","readout_date":"2026-11-13","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","ticker":"REGN","ticker_confidence":0.9,"conditions":"Advanced Solid Tumors","enrollment":548,"url":"https://clinicaltrials.gov/study/NCT04626635","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04626635","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1d77c6ed0be25069d1e1527325c0c151ba52590f7461f2897d9de8b08476e53c"},{"nct_id":"NCT05646862","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","readout_date":"2026-11-13","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":420,"url":"https://clinicaltrials.gov/study/NCT05646862","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05646862","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:775caa1c0b2e3db4980aad623ad06a6ce65324fae686473b700cf5f1729a918c"},{"nct_id":"NCT06682611","title":"Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.","readout_date":"2026-11-13","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Unresectable Locally Advanced or Metastatic Solid Tumors","enrollment":380,"url":"https://clinicaltrials.gov/study/NCT06682611","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06682611","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cbff2e25478fdcff39aa88d04fa6feeb807c82057bb7839b8d730b80b7c2baa6"},{"nct_id":"NCT07431086","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","readout_date":"2026-11-13","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","ticker":"REGN","ticker_confidence":0.9,"conditions":"Overweight or Obesity","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07431086","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07431086","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6bd94c714f837142cc834ecc43b3e54cb25fe748fba5ae679d13f19c6eb20831"},{"nct_id":"NCT06716203","title":"A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise","readout_date":"2026-11-14","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":207,"url":"https://clinicaltrials.gov/study/NCT06716203","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06716203","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:06be893b69c932cdfa0441cd3c9f5e6aa27891b0d245d630df60a8cf92da362c"},{"nct_id":"NCT06716216","title":"A Study of BGM0504 in Participants With Type 2 Diabetes","readout_date":"2026-11-14","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":537,"url":"https://clinicaltrials.gov/study/NCT06716216","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06716216","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fe3ab366381a88083e2d442e02338b0c85450db2fb044335e3e62ccbe7baa9f5"},{"nct_id":"NCT06964191","title":"Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","readout_date":"2026-11-15","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"PolyActiva Pty Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Glaucoma, Open-Angle; Ocular Hypertension","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT06964191","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06964191","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d1c20a7f2f8f02898918437c0270657f9a066e1c277ff5a946730ca8f27ba639"},{"nct_id":"NCT07392125","title":"Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes","readout_date":"2026-11-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Achieve Life Sciences","ticker":"ACHV","ticker_confidence":0.9,"conditions":"Vaping Cessation","enrollment":800,"url":"https://clinicaltrials.gov/study/NCT07392125","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07392125","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:df9c527935a3c5346e982d53c42afd022eaa34c5c8f44e6bcb604fc2f0f7b14f"},{"nct_id":"NCT06055959","title":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","readout_date":"2026-11-16","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"UCB Biopharma SRL","ticker":null,"ticker_confidence":0.0,"conditions":"Generalized Myasthenia Gravis","enrollment":8,"url":"https://clinicaltrials.gov/study/NCT06055959","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06055959","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e54332f77bb5b5c0029a3b4486ed77d1ed0efcde9d6531ff8344804f97e32d9e"},{"nct_id":"NCT06219941","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","readout_date":"2026-11-17","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma","enrollment":226,"url":"https://clinicaltrials.gov/study/NCT06219941","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06219941","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d9a6640a06f7208572bda2a1cee39d5fb6e337741ecbe959a3e7adca5d130471"},{"nct_id":"NCT01064466","title":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","readout_date":"2026-11-18","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair","ticker":null,"ticker_confidence":0.0,"conditions":"Small Cell Lung Cancer","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT01064466","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT01064466","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:115004ab103495d40ffb359effd794e912e24d3e3920b4bb1c05de7350639298"},{"nct_id":"NCT03348670","title":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","readout_date":"2026-11-18","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","ticker":null,"ticker_confidence":0.0,"conditions":"Prostate Cancer","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT03348670","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03348670","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:def94b94b3dcf78ef0c2aa157aaa7cc7232bae8b3f89a8e0b356d57d5501e20b"},{"nct_id":"NCT05946941","title":"A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sj\u00f6gren's Syndrome","readout_date":"2026-11-18","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","ticker":"BMY","ticker_confidence":0.9,"conditions":"Sj\u00f6gren's Syndrome","enrollment":774,"url":"https://clinicaltrials.gov/study/NCT05946941","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05946941","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:03f4431a8c41f12d9a55402380dfc780fb940fa18ea6682d800652c6ba326a29"},{"nct_id":"NCT05987956","title":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","readout_date":"2026-11-18","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medicine Invention Design, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"ALK-Positive Non-Small Cell Lung Cancer (NSCLC)","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT05987956","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05987956","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cace56349de5d978849333aa287934e75194f47c232b14de8d87550311bc4925"},{"nct_id":"NCT06450639","title":"A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)","readout_date":"2026-11-18","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Duchenne Muscular Dystrophy","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT06450639","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06450639","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dadad8e4f85f7b158bba67e007cffbc49ded3cd8159b28fd620633a398071fea"},{"nct_id":"NCT06693336","title":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","readout_date":"2026-11-18","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"ToLymph Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)","enrollment":42,"url":"https://clinicaltrials.gov/study/NCT06693336","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06693336","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8ef68197797b60cbaa56849b891adc837372b35e7db65bc87881e4f8bb97b471"},{"nct_id":"NCT06402838","title":"A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)","readout_date":"2026-11-19","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Alzheimer's Disease","enrollment":256,"url":"https://clinicaltrials.gov/study/NCT06402838","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06402838","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:82c5c903276b498611d8c4c296d916ddd812a1a29d3a1d3e2895f5b01aed440d"},{"nct_id":"NCT07230860","title":"A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis","readout_date":"2026-11-19","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Dermatitis, Atopic","enrollment":189,"url":"https://clinicaltrials.gov/study/NCT07230860","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07230860","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:29ec6f6473042e30bac226b0fef2de26561269cef09f546e15ca4d067b328c8d"},{"nct_id":"NCT04634877","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","readout_date":"2026-11-20","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","ticker":"MRK","ticker_confidence":0.6,"conditions":"Endometrial Neoplasms","enrollment":990,"url":"https://clinicaltrials.gov/study/NCT04634877","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04634877","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f2aae0f788bb4363ed2b859bac58e3f10e0046d4683d2eeae6523300f00e9fbd"},{"nct_id":"NCT05851443","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma","readout_date":"2026-11-20","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","ticker":"INCY","ticker_confidence":0.9,"conditions":"Moderate to Severe Asthma","enrollment":247,"url":"https://clinicaltrials.gov/study/NCT05851443","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05851443","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9837f235a8d8cedcbaad8622d03a03a38de2339c581cafca336f30060eca9a61"},{"nct_id":"NCT06577090","title":"Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo","readout_date":"2026-11-20","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Skye Bioscience, Inc.","ticker":"SKYE","ticker_confidence":0.9,"conditions":"Obesity","enrollment":136,"url":"https://clinicaltrials.gov/study/NCT06577090","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06577090","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2f84ab80d4f91b0c4905ad6a900321713f4d9da173afd61a9af94e98d88376eb"},{"nct_id":"NCT07124221","title":"A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets","readout_date":"2026-11-21","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hyperprolactinemia","enrollment":382,"url":"https://clinicaltrials.gov/study/NCT07124221","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07124221","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:61675d59e6d25bb1674b7526cec173603c5b444553b642055559c8bb99154500"},{"nct_id":"NCT03160430","title":"A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis","readout_date":"2026-11-22","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Resverlogix Corp","ticker":null,"ticker_confidence":0.0,"conditions":"Kidney Failure, Chronic","enrollment":44,"url":"https://clinicaltrials.gov/study/NCT03160430","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03160430","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:644d2c02f45b8b6fcced54e804c3a6dc3b75dd3f8a0ebb6242c9491eca525290"},{"nct_id":"NCT06839066","title":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","readout_date":"2026-11-22","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":70,"url":"https://clinicaltrials.gov/study/NCT06839066","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06839066","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:809b9373a2eab36e3e0be15f8d1aa71dfa55c3ba91c2051292695cde3c57975b"},{"nct_id":"NCT07533786","title":"A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery","readout_date":"2026-11-22","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Pain After Surgery","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT07533786","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07533786","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:794d7af3ecf2ebe1cdb66f9471218036da53812b103ea777c41dad28531a1318"},{"nct_id":"NCT06567782","title":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","readout_date":"2026-11-23","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Neoplasms, Colon","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06567782","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06567782","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:daffecbe39df37e570e2f5c64bf351a3ae1af9750412457a88eef248641256d5"},{"nct_id":"NCT06693895","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","readout_date":"2026-11-23","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Chickenpox","enrollment":750,"url":"https://clinicaltrials.gov/study/NCT06693895","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06693895","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4e641a9f17bd22c0b75b450989755ac1f8181fb2159ca132002c85b8aa00e4fe"},{"nct_id":"NCT07596199","title":"A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women","readout_date":"2026-11-23","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Diphtheria-Tetanus-acellular Pertussis Vaccines","enrollment":102,"url":"https://clinicaltrials.gov/study/NCT07596199","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07596199","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c979c7b697da41a1e1355c54af3557d068b91c062965a9cc39f8ad38f29ca4c1"},{"nct_id":"NCT03815643","title":"Avelumab Program Rollover Study","readout_date":"2026-11-24","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumors","enrollment":205,"url":"https://clinicaltrials.gov/study/NCT03815643","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03815643","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4fa3cc6216cf8ff6d193804e7c1a81dbffef8e69633380d9084e59470d09088a"},{"nct_id":"NCT06267729","title":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","readout_date":"2026-11-24","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Metastatic Prostate Cancer","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06267729","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06267729","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:858dd355cebea3dea127a31bcddbe7361addeb19c376941e5c2462c2ab070c3a"},{"nct_id":"NCT06585787","title":"A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)","readout_date":"2026-11-24","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","ticker":null,"ticker_confidence":0.0,"conditions":"Alzheimer Disease","enrollment":406,"url":"https://clinicaltrials.gov/study/NCT06585787","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06585787","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:001c81896b09cbec0372875ddb38bfbd93337199e28b29ae5770aae8e5f36e2e"},{"nct_id":"NCT06616974","title":"A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)","readout_date":"2026-11-24","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tectonic Therapeutic","ticker":"TECX","ticker_confidence":0.9,"conditions":"Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction","enrollment":191,"url":"https://clinicaltrials.gov/study/NCT06616974","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06616974","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1c8778e16a0ab6f18fd1973b1fc5c3dbd84335397736c3ee0407a6cce487d1de"},{"nct_id":"NCT07057622","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","readout_date":"2026-11-24","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"HTA Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"NETS Ga68 Lu177","enrollment":184,"url":"https://clinicaltrials.gov/study/NCT07057622","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07057622","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7f6cb4c4e1d79360491d1518fbedd53c8158555ddbf2053f0b0f70f812a3f1b6"},{"nct_id":"NCT07600983","title":"Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)","readout_date":"2026-11-24","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Streptococcus Pneumoniae Infection","enrollment":854,"url":"https://clinicaltrials.gov/study/NCT07600983","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07600983","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4afac6f6baa06a59242ff3b973c62c501f21495233966b00387f692504cabca9"},{"nct_id":"NCT06775860","title":"ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis","readout_date":"2026-11-25","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Atopic Dermatitis","enrollment":552,"url":"https://clinicaltrials.gov/study/NCT06775860","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06775860","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f4c0a48b983b69610afbcbfe02fce1ca17d249ea2915d5acd36c4f093217c873"},{"nct_id":"NCT03981796","title":"A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer","readout_date":"2026-11-26","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Neoplasms","enrollment":785,"url":"https://clinicaltrials.gov/study/NCT03981796","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03981796","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3849b2688d8db835fbcf90cbe157a50f412aeb391fbde5c4bbe226c1884e98a9"},{"nct_id":"NCT07122401","title":"Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism","readout_date":"2026-11-26","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":424,"url":"https://clinicaltrials.gov/study/NCT07122401","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07122401","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2eb62d30494ce6ff2b66c2b45cf7c7dfe7cfa09b65bd4554d0de070577d366e9"},{"nct_id":"NCT06660992","title":"A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis","readout_date":"2026-11-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":669,"url":"https://clinicaltrials.gov/study/NCT06660992","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06660992","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cd0d4bbf9fc55b84db43248e8710dec5e00bc291c5737e55eafa77da1e7deda1"},{"nct_id":"NCT06773962","title":"A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease","readout_date":"2026-11-28","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"TrueBinding, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Parkinson's Disease (PD)","enrollment":62,"url":"https://clinicaltrials.gov/study/NCT06773962","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06773962","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1be64a44d4970885257d35ddf6dc2d9e9d82a15de4bb5351cdb6e7ed92adf3b1"},{"nct_id":"NCT07103148","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","readout_date":"2026-11-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Yellow Fever Immunization","enrollment":2440,"url":"https://clinicaltrials.gov/study/NCT07103148","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07103148","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9df42d0c94abfda825985e5387e9c2705306494c3f223e0706058ec79e7b33ac"},{"nct_id":"NCT06641466","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","readout_date":"2026-11-29","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Menstrual Migraine","enrollment":723,"url":"https://clinicaltrials.gov/study/NCT06641466","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06641466","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:80dc9139b463be1630e09ad5c6d37de1e1c3758b58e501446e64585a290143ee"},{"nct_id":"NCT02704858","title":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Neonc Technologies, Inc.","ticker":"NTHI","ticker_confidence":0.9,"conditions":"Glioblastoma Multiforme","enrollment":49,"url":"https://clinicaltrials.gov/study/NCT02704858","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02704858","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:607f6d3f2a4ad7bd430cafa4ed0699113ddf5222b0b5e8b7123d96bbde8a4d45"},{"nct_id":"NCT03148418","title":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Cancer","enrollment":382,"url":"https://clinicaltrials.gov/study/NCT03148418","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03148418","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e85933af92c44963ebcaadcef241da5502239516bcb01df1402ed067685bac8f"},{"nct_id":"NCT03368742","title":"Microdystrophin Gene Transfer Study in Adolescents and Children With DMD","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Solid Biosciences Inc.","ticker":"SLDB","ticker_confidence":0.9,"conditions":"Duchenne Muscular Dystrophy","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT03368742","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03368742","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:793c44557f5fed8036eb94911ff2996b92e9c04bf5a13a5b04e7cd22509ddc73"},{"nct_id":"NCT03579836","title":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"BeyondBio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT03579836","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03579836","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:85bc41317face8849989725f919b8678c8005bb307715b7c2cd6b6b9bd7d7a25"},{"nct_id":"NCT03989414","title":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma","enrollment":424,"url":"https://clinicaltrials.gov/study/NCT03989414","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03989414","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:77592ee955cbb96c2a5fea2bfbdd180ec0defadeb023c88934a3d0392a5fbf7d"},{"nct_id":"NCT04302025","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Genentech, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer","enrollment":99,"url":"https://clinicaltrials.gov/study/NCT04302025","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04302025","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2fa4cb301ff6c691b1b6c938e6dd269aa9fc765d599a4e3366539decaaf41a6a"},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Medicenna Therapeutics, Inc.","ticker":"MDNAF","ticker_confidence":0.9,"conditions":"Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer; Viral Cancer; Cervical Cancers; Endometrial Cancer","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT05086692","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05086692","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:03a0fd9a4098d687f193d1708b015a502281d7aed03601030e8bec726802d983"},{"nct_id":"NCT05093907","title":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"BeyondBio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Colorectal Cancer","enrollment":27,"url":"https://clinicaltrials.gov/study/NCT05093907","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05093907","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:851ee9b4f1a3dd5ead990ffd8492208293e257da30af0239797b8edeedb5ed31"},{"nct_id":"NCT05094336","title":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","ticker":"AMGN","ticker_confidence":0.9,"conditions":"Advanced MTAP-null Solid Tumors","enrollment":329,"url":"https://clinicaltrials.gov/study/NCT05094336","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05094336","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4284f2b07c08805a1b567eb135579d1fbb49f56981f2409fe37ecad956267136"},{"nct_id":"NCT05095727","title":"A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Glycogen Storage Disease","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT05095727","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05095727","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ca3f1289083a1d1794665afd77c3703dbfcde7ce6ab4695b1cf375bad98080d0"},{"nct_id":"NCT05339126","title":"RNS System LGS Feasibility Study","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroPace","ticker":"NPCE","ticker_confidence":0.9,"conditions":"Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable; Seizures; Seizures, Generalized","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT05339126","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05339126","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ab8e7230a931f1011e334a0c54dab526115c2fa09cb038348f3bd10bf9973032"},{"nct_id":"NCT05438407","title":"Pediatric Patients Aged 4 to 11 Years With APDS","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pharming Technologies B.V.","ticker":"PHAR","ticker_confidence":0.6,"conditions":"APDS","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT05438407","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05438407","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:651a9784483c6f7ba8c0439090d78259b6facc0029fd967dbfeed30ee11df9c7"},{"nct_id":"NCT05462587","title":"A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"AUG Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Leukocyte Adhesion Deficiency","enrollment":4,"url":"https://clinicaltrials.gov/study/NCT05462587","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05462587","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a451cb4be299968f52182a5e6025db6b3d6cf31b9c0c342a684c6bc06153515e"},{"nct_id":"NCT05682443","title":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoC4, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":148,"url":"https://clinicaltrials.gov/study/NCT05682443","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05682443","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:040b2bebaf2ab7b359649656d9186878f4fc9ae05493fab9d16a3ea4965789c0"},{"nct_id":"NCT05924776","title":"Plasmodium Immunotherapy for Advanced Ovarian Cancer","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"NOT_YET_RECRUITING","sponsor":"CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Ovarian Cancer","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT05924776","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05924776","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:507e56e5f8c1e23040ff9f56781cebfb705db960218fd6784bbf83f08992e00d"},{"nct_id":"NCT06063850","title":"AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"UniQure Biopharma B.V.","ticker":"QURE","ticker_confidence":0.6,"conditions":"Mesial Temporal Lobe Epilepsy","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT06063850","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06063850","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dd3ad558c85abac9cec79165447a513238d8a296ab2a4acc98153f9c4aae5506"},{"nct_id":"NCT06129175","title":"UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Cytopeutics Sdn. Bhd.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Ischemic Stroke","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT06129175","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06129175","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5a3dc5eff34563a80ac8da16f47fe6b948269b57479b42c6380624462a5524d4"},{"nct_id":"NCT06182696","title":"OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"OriCell Therapeutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":83,"url":"https://clinicaltrials.gov/study/NCT06182696","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06182696","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:21388b195e438f52e241fbc989d5d2b2c4a59ffeaa0e17420c98f73c60a10187"},{"nct_id":"NCT06341114","title":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bio-Thera Solutions","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":112,"url":"https://clinicaltrials.gov/study/NCT06341114","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06341114","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:660f70529392076b20affd29c82705c9fd3b09c9bc5a5c59271129560803ca2e"},{"nct_id":"NCT06643884","title":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Aura Biosciences","ticker":"AURA","ticker_confidence":0.9,"conditions":"Eye Cancer; Primary Cancer","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT06643884","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06643884","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e9acfc66775e1e58e18965b6f7806a20791c61ad09ad3bf6c2e6effc8c3be312"},{"nct_id":"NCT06741098","title":"A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis\uff08 KOA\uff09","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Nuwacell Biotechnologies Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Knee Osteoarthritis","enrollment":162,"url":"https://clinicaltrials.gov/study/NCT06741098","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06741098","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5d345133ea0a13a8391ae731b8bc6b1d4b2ecd72a01ae34fcbe1cc4b4bbd9c5e"},{"nct_id":"NCT06794554","title":"Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Pulmonary Aspergillosis","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06794554","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06794554","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2fa1e427979f7f026c9ff351fe1ba8bac4fc7cab0aec4f3ee11a64c16349a591"},{"nct_id":"NCT06812078","title":"A Study of TAK-360 in Adults With Idiopathic Hypersomnia","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Takeda","ticker":"TAK","ticker_confidence":0.9,"conditions":"Idiopathic Hypersomnia","enrollment":96,"url":"https://clinicaltrials.gov/study/NCT06812078","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06812078","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:754e7f11b52a7859b8e468ea6ce133de53a1159c47f012d568655a2b770ded9b"},{"nct_id":"NCT06833983","title":"To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Gritgen Therapeutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hemophilia A","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT06833983","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06833983","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:25f6015e54ff7e77078f3041d10e76b3fcc45934b96d0c0e22ce7f4cd30795b6"},{"nct_id":"NCT06840119","title":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Immunocore Ltd","ticker":"IMCR","ticker_confidence":0.9,"conditions":"Cancer; HLA-A*02:01-positive","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06840119","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06840119","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b00293245c8b7502c8db844c3f9821a4364427181d17a5e81aa59d55919c96db"},{"nct_id":"NCT06952699","title":"A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Takeda","ticker":"TAK","ticker_confidence":0.9,"conditions":"Narcolepsy Type 2","enrollment":88,"url":"https://clinicaltrials.gov/study/NCT06952699","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06952699","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e4b23ec74a2375f0e7ee4c3eff86e1d0982548a092f59c29a4dbb0f9c07d975f"},{"nct_id":"NCT06954961","title":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"InventisBio Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":640,"url":"https://clinicaltrials.gov/study/NCT06954961","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06954961","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bae981b2e82d9a1caa6e0b0e51849201dafa5d73389bfc164ffe9873c3a80fb5"},{"nct_id":"NCT06968585","title":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"SKBBY","ticker_confidence":0.6,"conditions":"HER2-positive Breast Cancer","enrollment":365,"url":"https://clinicaltrials.gov/study/NCT06968585","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06968585","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f3c0e9e5aad9ecb1092b5eb9bf26c6262f2b09c4c0bd83a8b56c007a356e3e26"},{"nct_id":"NCT06984718","title":"A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"HCC; Hepatocellular Carcinoma","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06984718","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06984718","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d88dda9714d8ed240f6bf6ecf0b9993ea79ac8877fca89ec2d441dbf1afd1edd"},{"nct_id":"NCT07023731","title":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arvinas Inc.","ticker":"ARVN","ticker_confidence":0.9,"conditions":"KRAS G12D Mutation; Advanced Solid Cancer","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT07023731","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07023731","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:14bd1fe14a86db077737eab2a68ac008db37c62f2ac7dfa91599975e391d8d46"},{"nct_id":"NCT07081633","title":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Hepatocellular Carcinoma","enrollment":114,"url":"https://clinicaltrials.gov/study/NCT07081633","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07081633","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:31e3a31532f113f38cd8a2a2045172abd8800568bbdf9021c096aaa2780c7bfb"},{"nct_id":"NCT07122687","title":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer","enrollment":170,"url":"https://clinicaltrials.gov/study/NCT07122687","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07122687","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7ced8d4d7dfe61cc80d6dc88bef240080851a92df8185fbfe4ab7b3437bc320d"},{"nct_id":"NCT07199569","title":"Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","ticker":null,"ticker_confidence":0.0,"conditions":"Monkeypox (Mpox)","enrollment":970,"url":"https://clinicaltrials.gov/study/NCT07199569","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07199569","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:25b0fff05162a7affce236e756d75c9387f1156aceafc206d7b3ac15266359a9"},{"nct_id":"NCT07216079","title":"Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Immune Thrombocytopenia","enrollment":4,"url":"https://clinicaltrials.gov/study/NCT07216079","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07216079","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:15f2f695f4731dec79d92bbc9e200a1830fbafa3ac875c419d5561a3a6539a28"},{"nct_id":"NCT07226258","title":"Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saol Therapeutics Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Osteoarthritis Knee Pain","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT07226258","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07226258","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:600733c72490c77c6fc49b16ff3bae03fdb068816a3eedee888e6dfbc804dcbb"},{"nct_id":"NCT07256509","title":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Small Cell Lung Cancer","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07256509","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07256509","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:25dcd4c5aa1b4366cbd0c6b6841aca1c62a85cd35e2c3ded2914ed9ed471615a"},{"nct_id":"NCT07280832","title":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Unresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Urinary Tract Tumors","enrollment":500,"url":"https://clinicaltrials.gov/study/NCT07280832","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07280832","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:141518aa0c7607cc27b1d63462116ffd2d5fb1be135b377ad821c22ceb5b90b0"},{"nct_id":"NCT07303465","title":"To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07303465","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07303465","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8bd9673772fe1082bb61ea74f0b15e3d04a82277373eb9a2e0c1e003ecd28460"},{"nct_id":"NCT07365904","title":"Investigating Ovulation Inhibition for Use as a Contraceptive","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Mylan Pharmaceuticals Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Contraception","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07365904","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07365904","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bd47b2f8043a05142c14772265e828d3c1a6539a9b4ac22f8502dd746ae6bf4e"},{"nct_id":"NCT07548840","title":"A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taisho Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":34,"url":"https://clinicaltrials.gov/study/NCT07548840","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07548840","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0e2bec67adf99c02737a364bb8be0aa5470e93b342913877bb4da11bb4de144f"},{"nct_id":"NCT07656727","title":"A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioAge Labs, Inc.","ticker":"BIOA","ticker_confidence":0.9,"conditions":"Obesity and Cardiovascular Risk","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07656727","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07656727","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a96dd3efcce669ff0408ab6578a3daedb6b89f3607d687c21500c6f06df3ef47"},{"nct_id":"NCT07672561","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase \u2162 Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","readout_date":"2026-11-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Zhejiang Wenda Pharma Technology LTD.","ticker":null,"ticker_confidence":0.0,"conditions":"Moderate to Severe Plaque Psoriasis","enrollment":375,"url":"https://clinicaltrials.gov/study/NCT07672561","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07672561","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4e0d7f872717206cfd3de453076ad7f4fba4370f5ee325639e008d007f3a76a9"},{"nct_id":"NCT01761968","title":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Italfarmaco","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Myeloproliferative Neoplasms","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT01761968","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT01761968","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:caa8fef8b9566fa38aad25f37e49f878801005278e5a70c0a612e64f43b4a807"},{"nct_id":"NCT02227251","title":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","ticker":"KPTI","ticker_confidence":0.9,"conditions":"Diffuse Large B-cell Lymphoma","enrollment":244,"url":"https://clinicaltrials.gov/study/NCT02227251","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02227251","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1248662cc1cb5095248d2d5fd09c04172701fa660024669328a4858e685e5776"},{"nct_id":"NCT02340117","title":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"SynerGene Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Pancreatic Cancer","enrollment":28,"url":"https://clinicaltrials.gov/study/NCT02340117","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02340117","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7305812792f6f16e8ba1d1b4764cac96ecb849cf4e6fd972199476e1949b54f5"},{"nct_id":"NCT02584244","title":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Lumicell, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT02584244","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02584244","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f5a66499a4566a734334908e47cad7bc7485b9ad1ff4103993cb7fbcc496a731"},{"nct_id":"NCT03096093","title":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Vaccines Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Cancer; Neoplasms","enrollment":34,"url":"https://clinicaltrials.gov/study/NCT03096093","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03096093","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c2de5d165f377df6c12e07eaa78addcdc482e3e302dc975300c8f599e376f343"},{"nct_id":"NCT03290534","title":"Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet\u00ae","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"CivaTech Oncology","ticker":null,"ticker_confidence":0.0,"conditions":"Lung Cancer; Lung Cancer Stage I; Lung Cancer Stage II","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT03290534","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03290534","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f624fa72fba19e74e63def1e0ed7ea0c264bf7c35e41b31a048b4e6fb8178632"},{"nct_id":"NCT03604198","title":"Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corcept Therapeutics","ticker":"CORT","ticker_confidence":0.9,"conditions":"Cushing Syndrome","enrollment":125,"url":"https://clinicaltrials.gov/study/NCT03604198","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03604198","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8351ae061e831163cae50fd8d543c3c615400a351a05a0ac037471a097849aa0"},{"nct_id":"NCT03683186","title":"A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ENROLLING_BY_INVITATION","sponsor":"United Therapeutics","ticker":"UTHR","ticker_confidence":0.9,"conditions":"PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Disease","enrollment":1000,"url":"https://clinicaltrials.gov/study/NCT03683186","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03683186","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:eea8c4a306f098fca9c5af20005d024be513806d1984dcef835b5b3b9f8aef67"},{"nct_id":"NCT03789552","title":"Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Tasly Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Stable Angina Pectoris","enrollment":765,"url":"https://clinicaltrials.gov/study/NCT03789552","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03789552","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:544ec6e603a960b3cf4022989bfbabf59aa56ef804e209709955a3e2804e1166"},{"nct_id":"NCT03945162","title":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Theralase\u00ae Technologies Inc.","ticker":"TLTFF","ticker_confidence":0.6,"conditions":"Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT03945162","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03945162","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e6dadf483aaf0061c0bd3082d03ee8676d15c615803f17a8d8f933806cd7fed7"},{"nct_id":"NCT03994874","title":"Peritoneal Ultrafiltration in Cardio Renal Syndrome.","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","ticker":null,"ticker_confidence":0.0,"conditions":"Congestive Heart Failure","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT03994874","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03994874","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a498cdffc147d9af861600e4b0fee2141d8f7b8858b37e9b4597ecb8a5aa9c7f"},{"nct_id":"NCT04042844","title":"A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"BioRestorative Therapies","ticker":"BRTX","ticker_confidence":0.9,"conditions":"Lumbar Disc Disease","enrollment":99,"url":"https://clinicaltrials.gov/study/NCT04042844","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04042844","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5dce6c0abc565078c022f76a192ff3cbc46fce1d6950231aa5d84710917d3c92"},{"nct_id":"NCT04115306","title":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Phoenix Molecular Designs","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Breast Cancer","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT04115306","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04115306","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ac36857a739546ff0e70b1af315bae65fb8229317cc2d22a12757667725e5e8a"},{"nct_id":"NCT04344158","title":"A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":648,"url":"https://clinicaltrials.gov/study/NCT04344158","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04344158","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0f9716d86875a88b2572a47629e64f57ee7b28053c1410e2ab283cae6e39bdbc"},{"nct_id":"NCT04435990","title":"Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Inmunotek S.L.","ticker":null,"ticker_confidence":0.0,"conditions":"Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT04435990","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04435990","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cc40ab89fab1959b1cd17daa4f962aa0acbec002eee225489d8affbe85796364"},{"nct_id":"NCT04442022","title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","ticker":"KPTI","ticker_confidence":0.9,"conditions":"Relapsed/Refractory Diffuse Large B-cell Lymphoma","enrollment":501,"url":"https://clinicaltrials.gov/study/NCT04442022","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04442022","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:16541652031f6a7de00e475d7fd2e1c7f591bf44f877d1b191dc1e9036ec8782"},{"nct_id":"NCT04478279","title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sapience Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Prostate Cancer; Melanoma Recurrent; Prostate Cancer Metastatic; Recurrent Glioblastoma; Newly Diagnosed Glioblastoma","enrollment":125,"url":"https://clinicaltrials.gov/study/NCT04478279","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04478279","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b68f2ddc2a391f354a4ab713c374d9355df5cfe97c73f03f28a4ac6bb9fb9655"},{"nct_id":"NCT04604782","title":"A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"GE Healthcare","ticker":null,"ticker_confidence":0.0,"conditions":"Myocardial Ischemia; Coronary Artery Disease","enrollment":54,"url":"https://clinicaltrials.gov/study/NCT04604782","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04604782","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:944da0e741d0cbb5061c2472b1013ddea2e415a6fbe8d66949cd17ee6a041de3"},{"nct_id":"NCT04639986","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","ticker":"GILD","ticker_confidence":0.9,"conditions":"Metastatic Breast Cancer","enrollment":331,"url":"https://clinicaltrials.gov/study/NCT04639986","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04639986","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a62c61abad63c2b283bb7a41cce14eca1aa65208dcddeaaf069543b964049e3c"},{"nct_id":"NCT04704921","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Age-related Macular Degeneration; Choroidal Neovascularization","enrollment":671,"url":"https://clinicaltrials.gov/study/NCT04704921","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04704921","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b08b01aac9894b4fb4f6002592826b061b5f1c0e2b63c562d6f4cab4d31bc028"},{"nct_id":"NCT04829604","title":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ambrx, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT04829604","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04829604","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2c8613220faf6a7e724990feaad1449a1bfd2f4f10ba76adfe07e68681ebe6c9"},{"nct_id":"NCT04853342","title":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Carcinoma","enrollment":318,"url":"https://clinicaltrials.gov/study/NCT04853342","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04853342","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9634ee7879898f07af72eceead1c04f32f07144a35758a40cbf0e23e017a7e07"},{"nct_id":"NCT04944979","title":"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kedrion S.p.A.","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Immunodeficiency Disease","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT04944979","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04944979","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6717e2ed5e079cc291b5bd0bc0c8e440ce46f8968bcdb5c705059bd79958a4be"},{"nct_id":"NCT04969731","title":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GC Cell Corporation","ticker":null,"ticker_confidence":0.0,"conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":408,"url":"https://clinicaltrials.gov/study/NCT04969731","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04969731","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ae1baca58a120cb057e9211d4b4188a894aa5af02309d4d041defa81883bd9ed"},{"nct_id":"NCT04985890","title":"A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"UBP Greater China (Shanghai) Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"HIV-1-infection","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT04985890","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04985890","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:78db40dac3a91d0e1fb9e2393af0b8faf7ca9d07cc141e1a14e7a6a86aa5545b"},{"nct_id":"NCT04986423","title":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Zenith Epigenetics","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT04986423","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04986423","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:056137771cfbfe5aa1d6239ac572680bef57e9ef528e24927b9495733d3e3135"},{"nct_id":"NCT05024214","title":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma","enrollment":170,"url":"https://clinicaltrials.gov/study/NCT05024214","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05024214","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5f02a1d169baeb1295028a99d551d38e380c67f73bcfbea086498bff3b0d39bc"},{"nct_id":"NCT05054439","title":"A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT05054439","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05054439","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0b05fdcdbc8c74df6cbe10a9f1b5db7a71d0dc933ef547ebeeae74e53ce9c64a"},{"nct_id":"NCT05065216","title":"Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"DiaMedica Therapeutics Inc","ticker":"DMAC","ticker_confidence":0.9,"conditions":"Acute Stroke; Ischemic Stroke; Stroke","enrollment":728,"url":"https://clinicaltrials.gov/study/NCT05065216","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05065216","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:efb141545a4a373f879cac229bc900f7412c6b00329b9b66c8faef89f36b6833"},{"nct_id":"NCT05112991","title":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Endometrial Cancer","enrollment":108,"url":"https://clinicaltrials.gov/study/NCT05112991","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05112991","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:29acd0b165782dc1451f8f64f6058acbf66835c7ecdf5751537d5176a8a59249"},{"nct_id":"NCT05139719","title":"A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","ticker":"SBFM","ticker_confidence":0.6,"conditions":"Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)","enrollment":110,"url":"https://clinicaltrials.gov/study/NCT05139719","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05139719","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:88c8d18c0b0b4a18aefc7a9e27d5c42b26094c1216395cb1f947ddb74aa11fe9"},{"nct_id":"NCT05147467","title":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","ticker":"AAPG","ticker_confidence":0.9,"conditions":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT05147467","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05147467","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:25a53bf34586fe9279a0b6d052d763e3a92e06e5f301f1137613758a7e17ba08"},{"nct_id":"NCT05170958","title":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":396,"url":"https://clinicaltrials.gov/study/NCT05170958","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05170958","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:be57ef6d37d3a1da7720d8b4c5d627bf057cafbc7a27a70f3f82705b60b282ba"},{"nct_id":"NCT05195294","title":"Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Lion TCR Pte. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma","enrollment":55,"url":"https://clinicaltrials.gov/study/NCT05195294","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05195294","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e4a056c6648d8279fdc1dbe47357ab286ca8af13b98f6df34e2b41d511310851"},{"nct_id":"NCT05205330","title":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rottapharm Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Cancer; Mismatch Repair Protein Proficient; Metastatic GI Cancers; Gastric Cancer","enrollment":107,"url":"https://clinicaltrials.gov/study/NCT05205330","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05205330","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:618aab029adc455e9c206bf61eb870ee2f0680181cb11812e56ac8564e0f7ada"},{"nct_id":"NCT05262023","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Denali Therapeutics Inc.","ticker":"DNLI","ticker_confidence":0.9,"conditions":"Frontotemporal Dementia","enrollment":85,"url":"https://clinicaltrials.gov/study/NCT05262023","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05262023","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:19c81458f681db83b95d703438137733c75c4eeaab95a5e1d01e4ec7be9797d4"},{"nct_id":"NCT05265052","title":"3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"3D Medicines","ticker":null,"ticker_confidence":0.0,"conditions":"Cancer Pain","enrollment":177,"url":"https://clinicaltrials.gov/study/NCT05265052","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05265052","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b5a8b28ac8a0532c10cbe9621c0c6b2e79ff337d87288b9c123a6b8e3db25bd0"},{"nct_id":"NCT05281471","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Genelux Corporation","ticker":"GNLX","ticker_confidence":0.9,"conditions":"Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma","enrollment":186,"url":"https://clinicaltrials.gov/study/NCT05281471","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05281471","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8ecdfbc00afa7806fea5cb7778d8b8cc20facff92a4b3d3c8c67508f3aaf8071"},{"nct_id":"NCT05299424","title":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT05299424","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05299424","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8b04bd9809756d1bc9467b36179ada327e1527d4fc55c5297294a65952adb230"},{"nct_id":"NCT05312710","title":"Safety and Efficacy of APG-157 in Head and Neck Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aveta Biomics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Head and Neck Cancer; Squamous Cell Carcinoma of Oral Cavity; Squamous Cell Carcinoma of the Oropharynx","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT05312710","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05312710","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2148296c524b0ecad981f3e019b6e09b7862955c22ee09699850f7e0a85303ae"},{"nct_id":"NCT05365672","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"TolerogenixX GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Kidney Transplantation","enrollment":126,"url":"https://clinicaltrials.gov/study/NCT05365672","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05365672","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1bff026b7cf23c4988f0c9ac59b7586e807da9aac7d282e5bb4e05030b364a95"},{"nct_id":"NCT05386108","title":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases","enrollment":73,"url":"https://clinicaltrials.gov/study/NCT05386108","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05386108","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7f2630969635fb644de10772fd345a865641d989fb490f357a763d7236094789"},{"nct_id":"NCT05392114","title":"A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","ticker":"IONS","ticker_confidence":0.9,"conditions":"Hereditary Angioedema","enrollment":154,"url":"https://clinicaltrials.gov/study/NCT05392114","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05392114","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:943b5c4f0178d95b7817bfcc99561b7943dbcc17cd79bdeaf0d8b64367674b63"},{"nct_id":"NCT05396885","title":"Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma","enrollment":136,"url":"https://clinicaltrials.gov/study/NCT05396885","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05396885","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:95e40b11c532e8aa9a915ada5359f643efd931b8c721b2d1103918ca871b9fbe"},{"nct_id":"NCT05397639","title":"Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suven Life Sciences Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Agitation; Alzheimer's Type Dementia","enrollment":375,"url":"https://clinicaltrials.gov/study/NCT05397639","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05397639","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7a3dc8056ed71e420f509b55d39b4f69ab4a801be198611fa65b0526bb925d25"},{"nct_id":"NCT05455619","title":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"SynDevRx, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer","enrollment":52,"url":"https://clinicaltrials.gov/study/NCT05455619","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05455619","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9651d3e2d819e53d45f8a0bc283851add09612bf9f0300e94254b6688c803926"},{"nct_id":"NCT05456256","title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","ticker":"LTRN","ticker_confidence":0.9,"conditions":"Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT05456256","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05456256","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:828f30552aba366e661ba011d803f64ff9b7fc19e58c6265876a481250da5246"},{"nct_id":"NCT05463263","title":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Step Pharma, SAS","ticker":null,"ticker_confidence":0.0,"conditions":"Lymphoma, B-Cell; Lymphoma, T-Cell","enrollment":180,"url":"https://clinicaltrials.gov/study/NCT05463263","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05463263","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:900776450f2abc159c2c3d14e4fc0626a33ecb069291086cf958207dbad7d2b1"},{"nct_id":"NCT05473156","title":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"AP Biosciences Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamous Cell Carcinoma (HNSCC); Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":168,"url":"https://clinicaltrials.gov/study/NCT05473156","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05473156","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49e75d4dd638b3e8eceea7a7050e8f00a1389fdc2a6b720b30a76b517aa41148"},{"nct_id":"NCT05475925","title":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Dren Bio","ticker":null,"ticker_confidence":0.0,"conditions":"LGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma; Hepatosplenic T-cell Lymphoma; Subcutaneous Panniculitis-Like T-Cell Lymphoma; Aggressive NK Cell Leukemia; Systemic EBV1 T-cell Lymphoma, if CD8 Positive; Hydroa Vacciniforme-Like Lymphoproliferative Disorder; Extranodal NK/T Cell Lymphoma, Nasal Type; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma; Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker); Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT05475925","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05475925","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:125b65b668adaf89430203d11cfb6faa896e69cdbbc26ae5c88912947e15b4fe"},{"nct_id":"NCT05477576","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"RayzeBio, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET","enrollment":343,"url":"https://clinicaltrials.gov/study/NCT05477576","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05477576","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:909f684b11899880f245334a8334c55d5a851d947b132ce1eb42d08b81eddd20"},{"nct_id":"NCT05482568","title":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Non-small Cell Lung Cancer","enrollment":324,"url":"https://clinicaltrials.gov/study/NCT05482568","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05482568","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e9d97bf2fb154a6433449a308786615f043adab79427ffa62e69abc3f7b2c170"},{"nct_id":"NCT05500222","title":"A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Madrigal Pharmaceuticals, Inc.","ticker":"MDGL","ticker_confidence":0.95,"conditions":"NASH; Cirrhosis, Liver","enrollment":845,"url":"https://clinicaltrials.gov/study/NCT05500222","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05500222","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ceb31baf87bad92264242eb3933138c337364ab9bf71349a6835aba8a2205071"},{"nct_id":"NCT05557448","title":"To Evaluate the Efficacy and Safety of TYNADOTE\u00ae in the Treatment of Acetaminophen Overdose","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sinew Pharma Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Hepatitis","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT05557448","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05557448","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:681e1b4fa1bdbfe16a815328941f5b8bfaad92c2a5082afcaa289b8dd199877e"},{"nct_id":"NCT05608681","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","ticker":"EPRX","ticker_confidence":0.9,"conditions":"Eosinophilic Esophagitis","enrollment":117,"url":"https://clinicaltrials.gov/study/NCT05608681","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05608681","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:84f6f5708ffdb2c4bfb3cfdfc0a7795b150065f498202cac81409ee94b0bef6a"},{"nct_id":"NCT05623982","title":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-hodgkin's Lymphoma","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT05623982","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05623982","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e63c4acdd65602bb1cabdc30c8da18854921924429b5011f0d04b507f6514047"},{"nct_id":"NCT05652920","title":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"OriCell Therapeutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hepatocellular Carcinoma","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT05652920","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05652920","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f1add2bac66c7b23a482a9d1de8d926d332bde953a2a0a3db691e19010613772"},{"nct_id":"NCT05654454","title":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin\u00ae in Non-Small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Mabscale, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Small Cell Lung Cancer","enrollment":620,"url":"https://clinicaltrials.gov/study/NCT05654454","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05654454","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:907728fe991df4db37aa459307a272bf8f4413c105704fd67c36bb28516df985"},{"nct_id":"NCT05668858","title":"A Study of SI-B001+SI-B003\u00b1 Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":70,"url":"https://clinicaltrials.gov/study/NCT05668858","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05668858","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c12b66edff67df502f10eddc5b0c21dfb18e58126d98cbdf08d5606a0c5c9841"},{"nct_id":"NCT05689853","title":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult","enrollment":87,"url":"https://clinicaltrials.gov/study/NCT05689853","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05689853","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9120e84e86c9dba39469c1c5abc809ff68d5b4670099bf9862725bbe0fe8a8a8"},{"nct_id":"NCT05709314","title":"A Study of AMDX-2011P in Participants With CAA","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Amydis Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Cerebral Amyloid Angiopathy","enrollment":25,"url":"https://clinicaltrials.gov/study/NCT05709314","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05709314","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1970ca51fc99fc15a0440d5c4683ba616bae8a8985b2e8a8587be3ca6e848fd0"},{"nct_id":"NCT05727176","title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT05727176","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05727176","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a8493bbf1060ac9c2eba69796bcb8866d4d0d2f212d3c4dfce06f2e85480b46d"},{"nct_id":"NCT05736731","title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"A2 Biotherapeutics Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Recurrent; Non-Small Cell Squamous Lung Cancer; NSCLC; NSCLC, Recurrent; Colorectal Cancer; Colorectal Neoplasms; Colorectal Adenocarcinoma; CRC; Colorectal Cancer Metastatic; Cancer","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT05736731","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05736731","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:54e6b5f5e572f0e50ef11c176b1f6d278806fe8aedd95d491f478e97c41bf5e4"},{"nct_id":"NCT05762107","title":"A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Zucara Therapeutics Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 1 Diabetes Mellitus With Hypoglycemia","enrollment":186,"url":"https://clinicaltrials.gov/study/NCT05762107","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05762107","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:74c7f2d0acbf891c9a6eb0a76bc57ccd815fed414ed05bb601ad57f56623b7dd"},{"nct_id":"NCT05776277","title":"Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cook MyoSite","ticker":null,"ticker_confidence":0.0,"conditions":"Fecal Incontinence","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT05776277","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05776277","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d23b5da1ae48f9a7c2a4107725be63ea82af1234df33b7f569572729fbba3c81"},{"nct_id":"NCT05778188","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"ReAlta Life Sciences, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Hypoxic-Ischemic Encephalopathy","enrollment":70,"url":"https://clinicaltrials.gov/study/NCT05778188","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05778188","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:403a479a436b7a8d25557477d4582c50348558edfc9508878400458582eae266"},{"nct_id":"NCT05780567","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":1946,"url":"https://clinicaltrials.gov/study/NCT05780567","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05780567","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:71fb871b0c9d94309557baa54c62ffd97fd9ccec72b2b1ce84c023dab866cc51"},{"nct_id":"NCT05784688","title":"Study of TU2218 in Combination With KEYTRUDA\u00ae(Pembrolizumab) in Patients With Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"TiumBio Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT05784688","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05784688","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:38b61b15607840f337d347de6ea854bc3f3eec048e841d200ffd0962035bfaaf"},{"nct_id":"NCT05785039","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Urinary System Tumor; Solid Tumor","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT05785039","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05785039","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6a164317566923be847647d3488e11c01737c4b0bb976d4e583066d3a1719896"},{"nct_id":"NCT05791864","title":"A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Tern Therapeutics, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Neuronal Ceroid Lipofuscinosis Type 2","enrollment":26,"url":"https://clinicaltrials.gov/study/NCT05791864","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05791864","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bdefb418a6e1e54d06bb8a41ffbdee72ba545b0c33d8100b227b74413b12f224"},{"nct_id":"NCT05803018","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Gynecological Malignant Tumor; Solid Tumor","enrollment":38,"url":"https://clinicaltrials.gov/study/NCT05803018","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05803018","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:83437b34bf93f9c8ff0cecfa35a6e5452db8b336fa16473edc5078f67746c25e"},{"nct_id":"NCT05824169","title":"Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"GeneCradle Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Spinal Muscular Atrophy","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT05824169","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05824169","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ee01a6ecd0b64079823f3e21356feffee8f506a5266c509f6ea60cce65a0bc2d"},{"nct_id":"NCT05871970","title":"Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Protara Therapeutics","ticker":"TARA","ticker_confidence":0.9,"conditions":"Lymphatic Malformation","enrollment":38,"url":"https://clinicaltrials.gov/study/NCT05871970","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05871970","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bc098a014a76f8c258410acec44560bc9f1278d862ee7df0d2e5d8397c8dbd9b"},{"nct_id":"NCT05884255","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":220,"url":"https://clinicaltrials.gov/study/NCT05884255","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05884255","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8ebd4af5e371995a72aaa9bbaf26acd958fc5acd08d7d19d99ec4cf8f9dec66d"},{"nct_id":"NCT05885464","title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beam Therapeutics Inc.","ticker":"BEAM","ticker_confidence":0.9,"conditions":"Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia","enrollment":5,"url":"https://clinicaltrials.gov/study/NCT05885464","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05885464","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:416fa788b9811b0e5704fac1d860f5d83291c96ef44e34bd75f59ffb04d97859"},{"nct_id":"NCT05909436","title":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":107,"url":"https://clinicaltrials.gov/study/NCT05909436","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05909436","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9ea360424377bf4a858242362369e00459d0baaf14796b25d406e6497b1c59af"},{"nct_id":"NCT05922878","title":"Study of ALTO-300 in MDD","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Alto Neuroscience","ticker":"ANRO","ticker_confidence":0.9,"conditions":"Major Depressive Disorder","enrollment":325,"url":"https://clinicaltrials.gov/study/NCT05922878","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05922878","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:235f40290e4d52035ce608259a6fb272068a7862aa23d9f20606c560e1cb781d"},{"nct_id":"NCT05924841","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Small Cell Lung Cancer","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT05924841","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05924841","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b41fb30750eca1c0435a6573a319daddf792960beb14dfe7243b7af2e357f5c3"},{"nct_id":"NCT05925608","title":"Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioCardia, Inc.","ticker":"BCDA","ticker_confidence":0.9,"conditions":"Heart Failure, Systolic","enrollment":39,"url":"https://clinicaltrials.gov/study/NCT05925608","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05925608","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:92e347c9aecd74829af1d36eeb0d7e96d7cd848595d133c8765dff4ad77e420d"},{"nct_id":"NCT05948475","title":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Cholangiocarcinoma","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT05948475","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05948475","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9e5cf9e3fe145699f5e6ca5182313f63dbd33ebbfe920228ae53d9d224768abc"},{"nct_id":"NCT05949606","title":"A Study of SI-B001+SI-B003\u00b1 Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer","enrollment":95,"url":"https://clinicaltrials.gov/study/NCT05949606","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05949606","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5311fdce96f0fe5fe9c129f31b7e97d6626cc1cbed99d49efa60dbff870c38a8"},{"nct_id":"NCT05956587","title":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma","enrollment":121,"url":"https://clinicaltrials.gov/study/NCT05956587","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05956587","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c367295269239466f43ae1983f3fff2dc4ba1b6aba648d4a6f059d41b74504ba"},{"nct_id":"NCT05965856","title":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Urothelial Carcinoma; Solid Tumor","enrollment":52,"url":"https://clinicaltrials.gov/study/NCT05965856","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05965856","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8b81e2aee5c5204702598558ac4de2e28ea968007af8b964b203fce969f1672c"},{"nct_id":"NCT05987358","title":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Biliary Carcinoma","enrollment":165,"url":"https://clinicaltrials.gov/study/NCT05987358","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05987358","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:17b65cf4b806ec363753689bade1ceed49665db71d1cace6a85b01a8561984ab"},{"nct_id":"NCT05990803","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Cervical Cancer","enrollment":130,"url":"https://clinicaltrials.gov/study/NCT05990803","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05990803","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bb57341bf57d71f2ef4ccb6b59e6f503463b065ea9011c07f354f3daf48ab32f"},{"nct_id":"NCT05997017","title":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Aadi Bioscience, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Endometrial Cancer; Endometrioid Tumor; Cancer; Tumor; Recurrent Endometrial Carcinoma; Endometrioid Endometrial Cancer","enrollment":29,"url":"https://clinicaltrials.gov/study/NCT05997017","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05997017","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4746d7f773329ef6a9a2628928566602de6efbe20b5cf9020b7a8d8abce352ef"},{"nct_id":"NCT06006169","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":186,"url":"https://clinicaltrials.gov/study/NCT06006169","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06006169","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:75616603f46c2ee6f92ac5adcc69fa1f47041d4d54525201f81159a05564a3a9"},{"nct_id":"NCT06008054","title":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Esophageal Cancer; Gastric Cancer; Colorectal Cancer","enrollment":376,"url":"https://clinicaltrials.gov/study/NCT06008054","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06008054","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2775ee138f83785a2132b05e4876ab79a6d980a6c432b291e55057784bc3e7fe"},{"nct_id":"NCT06031584","title":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Her2-positive/Low-expression Urinary and Digestive Tract Tumors","enrollment":42,"url":"https://clinicaltrials.gov/study/NCT06031584","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06031584","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5fc1c23e7df6e9475ac2f9334ddda5172dbbd9a4bc4b8627580bfde35e138513"},{"nct_id":"NCT06042894","title":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":58,"url":"https://clinicaltrials.gov/study/NCT06042894","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06042894","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:330b6cab77e4f588f7a7403473998d5d1cff9c5cc566d334a3b59561b3ab2876"},{"nct_id":"NCT06046222","title":"Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"NS Pharma, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT06046222","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06046222","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e3617755d063b8c3752cc05dd59b6b730d36a95fc061f4336ff1ea903b008169"},{"nct_id":"NCT06052813","title":"A Study of BN104 in the Treatment of Acute Leukemia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","ticker":null,"ticker_confidence":0.0,"conditions":"ALL, Adult; AML, Adult; Acute Leukaemia; KMT2A Rearrangement; NPM1 Mutation; NUP98 Gene Rearrangement; Menin Inhibitors","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT06052813","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06052813","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ef187cc157ede748515c4ddac9f06d90ecca627bd69604d476e1071b7f150f0e"},{"nct_id":"NCT06066203","title":"A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-hodgkin's Lymphoma","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT06066203","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06066203","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:caa9d4b7b202e26536837c1509935a7950cc484db34653688434605495735373"},{"nct_id":"NCT06075264","title":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Vulvar Diseases; HPV Infection; Vulvar HSIL; Pre-Cancerous Dysplasia; HPV Disease; VIN, Usual Type; VIN 2 of Usual Type; VIN 3 of Usual Type; Vin II; Vin III; VIN Grade 2; VIN Grade 3; High Grade Intraepithelial Neoplasia","enrollment":27,"url":"https://clinicaltrials.gov/study/NCT06075264","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06075264","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3d1165ab3b89e745d7fa6aab365fbd773065a0eb0d01649a89da12d0b92bbced"},{"nct_id":"NCT06080789","title":"A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Panafina, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Pancreatitis","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT06080789","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06080789","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e23cdd0623925d92d7accaf4aaf94b14f26fd7ff95b0140c2c82eadae4cfc329"},{"nct_id":"NCT06097832","title":"Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nexcella Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Light Chain (AL) Amyloidosis","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT06097832","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06097832","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5ad7da999c3f121dd33c0baa70071499bfd46fd227f14cbc35074fe8c116d906"},{"nct_id":"NCT06107413","title":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":280,"url":"https://clinicaltrials.gov/study/NCT06107413","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06107413","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e1d6b2eb43a398d1063f72dcb07fc8318f746fb929b4e24b283b18940f83a631"},{"nct_id":"NCT06109181","title":"Gene Therapy for ACM Due to a PKP2 Pathogenic Variant","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lexeo Therapeutics","ticker":"LXEO","ticker_confidence":0.9,"conditions":"Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC","enrollment":10,"url":"https://clinicaltrials.gov/study/NCT06109181","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06109181","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:54f1db8094a7b9c66411e776bab354bd336becf20ca1fab066301235b4c9476a"},{"nct_id":"NCT06114511","title":"A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer","enrollment":78,"url":"https://clinicaltrials.gov/study/NCT06114511","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06114511","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c2c93091defd2e78b43ff714616fd3fa1b3f8e7c47c3a5ca5b8f213c70ef6efc"},{"nct_id":"NCT06122831","title":"A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Myelofibrosis","enrollment":92,"url":"https://clinicaltrials.gov/study/NCT06122831","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06122831","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1a76eed403d98f37fbb4e63f15e563ae3dfd170e537dda6cf4e5f1505de285a6"},{"nct_id":"NCT06132893","title":"A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","ticker":"BHVN","ticker_confidence":0.9,"conditions":"Focal Epilepsy","enrollment":390,"url":"https://clinicaltrials.gov/study/NCT06132893","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06132893","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:034ce7b582ca18c5212f06470d9e2cca45a771967eed20262496ad03772444d2"},{"nct_id":"NCT06139575","title":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Bivision Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Prostate Cancer","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06139575","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06139575","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8fe4a072a0b7aab62ff7c930ea4f24c962bafe8855f692e6ce758b95b39582ec"},{"nct_id":"NCT06154291","title":"FIH XON7 in Advanced/Metastatic Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Xenothera SAS","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor; Metastatic Cancer","enrollment":255,"url":"https://clinicaltrials.gov/study/NCT06154291","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06154291","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c362d463fba10f0677e4d667d7a5cb12819ede471b9e46a40da54b94cebd9897"},{"nct_id":"NCT06202261","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies","enrollment":154,"url":"https://clinicaltrials.gov/study/NCT06202261","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06202261","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e6e8aab6e1b544490d3ffbfc6e5df2287d97d602239b6d9cd94039fee67eda10"},{"nct_id":"NCT06220773","title":"A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Essential Hypertension; Type 2 Diabetes Mellitus","enrollment":276,"url":"https://clinicaltrials.gov/study/NCT06220773","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06220773","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2738e2b2ceb64ebbc49ec69ef6f03dc935a4d3ee9565f1e2b2e072eccd96cdc0"},{"nct_id":"NCT06221748","title":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06221748","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06221748","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b2ee495e7749469f1125434323fe494d02ca0c529e5d9425c4024ee60530bab9"},{"nct_id":"NCT06234098","title":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Alyssum Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT06234098","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06234098","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ad065eb0fc4c4088a4815a95295a6deed595d0aa52efab6333fad9877a3a5f61"},{"nct_id":"NCT06243354","title":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Safety; Tolerability; Efficacy","enrollment":257,"url":"https://clinicaltrials.gov/study/NCT06243354","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06243354","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:988ccfd5b1ecf8fc05af9cf5c4cf4ae209f639674476e1f8e7650babdb63ab7e"},{"nct_id":"NCT06246110","title":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eikon Therapeutics","ticker":"EIKN","ticker_confidence":0.9,"conditions":"NSCLC","enrollment":70,"url":"https://clinicaltrials.gov/study/NCT06246110","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06246110","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0d96d2224b76c35b3c46d56bbe2995bc4405ebe4aab4d25ec5eb5a50563f3d74"},{"nct_id":"NCT06262139","title":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Songqi Gao","ticker":null,"ticker_confidence":0.0,"conditions":"MRI Scan","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT06262139","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06262139","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1b19a802048016f3f6f8025224f02751cd7d7ed962111d69be609a080055d5bc"},{"nct_id":"NCT06269705","title":"ZILRETTA in Subjects With Shoulder Osteoarthritis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pacira Pharmaceuticals, Inc","ticker":"PCRX","ticker_confidence":0.9,"conditions":"Glenohumeral Osteoarthritis","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT06269705","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06269705","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:70ccc97979755421bf4d42fc15facdeb8980504e21437d5cc2e961764cdee1ad"},{"nct_id":"NCT06274801","title":"Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Gossamer Bio USA, Inc.","ticker":"GOSS","ticker_confidence":0.6,"conditions":"Pulmonary Arterial Hypertension","enrollment":330,"url":"https://clinicaltrials.gov/study/NCT06274801","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06274801","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cc300f0257e38a3909121a751deb2c56c5c6cb6d6fbb9b8c49cad4e48b4590de"},{"nct_id":"NCT06277219","title":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Latticon Antibody Therapeutics, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT06277219","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06277219","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e3c0566e011e03d1e5daa01d27d224a48a002cf6202cef11f1285d3c2c4316ec"},{"nct_id":"NCT06298955","title":"Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omeros Corporation","ticker":"OMER","ticker_confidence":0.9,"conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":25,"url":"https://clinicaltrials.gov/study/NCT06298955","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06298955","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8818f6947d8b84ec0e26c3affad55c45c2cae121600f66757ef001c0969d5299"},{"nct_id":"NCT06302491","title":"A Study of Safety and Efficiency of AND017 in Patients With \u03b2-thalassemia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","ticker":null,"ticker_confidence":0.0,"conditions":"\u03b2 -Thalassemia","enrollment":64,"url":"https://clinicaltrials.gov/study/NCT06302491","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06302491","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:178db9f3545aab63c5905c957866718250a1176d71049fa9e757abb977987c97"},{"nct_id":"NCT06304103","title":"A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Myelodysplastic Syndromes","enrollment":63,"url":"https://clinicaltrials.gov/study/NCT06304103","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06304103","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:da90f2905e21598a7905cec750fe0903fb69305c65f9a3831780994070b428e5"},{"nct_id":"NCT06309485","title":"Phase 2 Study of WGI-0301 for Advanced HCC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06309485","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06309485","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e963258b2308d6dd8594d4d0483a5330cbc62c58b3441c155a00d28735591a30"},{"nct_id":"NCT06340633","title":"SPI-1005 in Adults Receiving Cochlear Implant","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sound Pharmaceuticals, Incorporated","ticker":"SOGP","ticker_confidence":0.9,"conditions":"Hearing Loss; Cochlear Trauma","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT06340633","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06340633","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:df88224d48d50bc634864012b98775a4966ca3bd6a2da47a9a59eb3b66e5cc0b"},{"nct_id":"NCT06343792","title":"Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"ReAlta Life Sciences, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Steroid Refractory GVHD","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT06343792","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06343792","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f62ac8040e3c2129cb03b0351a33fe13f82c67a5ead31f3b2310bd9ebe2fc6c6"},{"nct_id":"NCT06359860","title":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Beijing Scitech-Mq Pharmaceuticals Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Unresectable or Metastatic Melanoma","enrollment":64,"url":"https://clinicaltrials.gov/study/NCT06359860","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06359860","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:18230a5cf3d997df2025ec5ca304c121ef29b86b4ec744f43319f2f363aec784"},{"nct_id":"NCT06361537","title":"Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Octapharma","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Hereditary Angio Edema","enrollment":124,"url":"https://clinicaltrials.gov/study/NCT06361537","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06361537","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7804fdc729b14226973b971744f5b4c5fa3766dd21a6d67c3fd42824d852d75d"},{"nct_id":"NCT06382129","title":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer","enrollment":698,"url":"https://clinicaltrials.gov/study/NCT06382129","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06382129","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:df25f99663dc43737e7d512425fee9aea34493f93b7abd39e224a653cba3a258"},{"nct_id":"NCT06391736","title":"Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"GeneCradle Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Pompe Disease (Late-onset)","enrollment":33,"url":"https://clinicaltrials.gov/study/NCT06391736","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06391736","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:412f8bbace2297e5a67a2589d2f5f36861eb6d9f545c320f36dcc74a6c0e28c2"},{"nct_id":"NCT06395519","title":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"858 Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarian Cancer; BRCA2 Mutation; ER+ Breast Cancer; Castrate Resistant Prostate Cancer; BRCA1 Mutation; BRCA Mutation; Endometrial Cancer; Colorectal Cancer; Gastric Cancer","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06395519","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06395519","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9db1abb9b30f70fcc6c8860c39826dea45c3a0932652544f8ab12182125225d0"},{"nct_id":"NCT06403267","title":"NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"NoNO Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Ischemic Stroke","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06403267","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06403267","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9b97d02d4452b5b19015f69ea5335409c696b1819a0f180f4d795c8403472e07"},{"nct_id":"NCT06405425","title":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Urothelial Carcinoma","enrollment":52,"url":"https://clinicaltrials.gov/study/NCT06405425","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06405425","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c2173fccbcadb1710c95b7b5eeb1144f390a7aa839051749e1c792e9fb4d927c"},{"nct_id":"NCT06413433","title":"Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","ticker":"AXSM","ticker_confidence":0.9,"conditions":"Binge-Eating Disorder","enrollment":450,"url":"https://clinicaltrials.gov/study/NCT06413433","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06413433","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:475895dc7218f1f2a0c64680d5bf146a6a3a84349aeade7f9e41bed3b1f7bd17"},{"nct_id":"NCT06414954","title":"Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"NMD Pharma A/S","ticker":null,"ticker_confidence":0.0,"conditions":"Myasthenia Gravis; Myasthenia Gravis, MuSK","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT06414954","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06414954","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7e40a5ed044955143fc46a7601243f9bd5f96cc599aab6f9754068c895462463"},{"nct_id":"NCT06421831","title":"Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"GeneCradle Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Spinal Muscular Atrophy Type 3","enrollment":21,"url":"https://clinicaltrials.gov/study/NCT06421831","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06421831","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:710d3054f2d5062b79bc88b5b428ad145f327e09eb5801a4118597060378be03"},{"nct_id":"NCT06422936","title":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Highlight Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Basal Cell Carcinoma","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT06422936","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06422936","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:00993660f7c02916c276335848937bd354cbda7444a084f7f0b1a4e1026cb9c9"},{"nct_id":"NCT06425926","title":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Georgiamune Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Melanoma Stage IV; Solid Tumor","enrollment":117,"url":"https://clinicaltrials.gov/study/NCT06425926","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06425926","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4208ef3d0ea0c15aad39d322ed308f6aa2d90c5f7cc0c104814592586f9edaea"},{"nct_id":"NCT06437509","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT06437509","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06437509","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:366c5313ffb597ad18cf8d2195662aaefb6c47713d25b84c7523988c449ff3c8"},{"nct_id":"NCT06443463","title":"Long-term Safety and Tolerability of BHV-7000","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Biohaven Therapeutics Ltd.","ticker":"BHVN","ticker_confidence":0.9,"conditions":"Focal Epilepsy","enrollment":660,"url":"https://clinicaltrials.gov/study/NCT06443463","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06443463","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b7bb7a213f7471ab6814bfe4a3fd7780cab54965073f31c5f4b8e16b3c58e48b"},{"nct_id":"NCT06448143","title":"Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Prove pharm","ticker":null,"ticker_confidence":0.0,"conditions":"Ureter Injury","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT06448143","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06448143","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:50c77b32ae7c6fc8fa7001c0d8199b04698385842892a0e2b89b1c7f2e3017e1"},{"nct_id":"NCT06456593","title":"Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Abivax S.A.","ticker":"ABVX","ticker_confidence":0.9,"conditions":"Moderately to Severely Active Crohn Disease","enrollment":212,"url":"https://clinicaltrials.gov/study/NCT06456593","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06456593","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:30f5426aab3b38fca2b98cea64379868fcb6c4d99b61fa39044a1fc88b3c3f3d"},{"nct_id":"NCT06468228","title":"A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Hidradenitis Suppurativa","enrollment":1400,"url":"https://clinicaltrials.gov/study/NCT06468228","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06468228","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:35fb930c0bb5b5e4186e997fcc18a27101318f776f071e499a4a98976e8415b6"},{"nct_id":"NCT06471205","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Triple-negative Breast Cancer","enrollment":52,"url":"https://clinicaltrials.gov/study/NCT06471205","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06471205","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c0bf842b9ed31e9d32ce74c7ef04ca6251573b851137d3cbdfb18a77fbab31e7"},{"nct_id":"NCT06474442","title":"A Phase \u2161a Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai BDgene Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Herpes Simplex Virus Type I Stromal Keratitis","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT06474442","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06474442","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ac0987e36cdd2145b9e4d5977d0e1d6ea8270b7f977e3d293fc6c0c2b371bc17"},{"nct_id":"NCT06487897","title":"Phase III Presbyopia Correction Using the VIS Opti-K\u2122 System","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"VIS, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Presbyopia","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT06487897","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06487897","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c94ef827a20ae88f08b2ef6c35c573627ee7fb0dd8ec08e6cdac74a4c8d48387"},{"nct_id":"NCT06500026","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Small Cell Lung Cancer","enrollment":722,"url":"https://clinicaltrials.gov/study/NCT06500026","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06500026","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:375ac8287801ae47a775ef390728d4abb1c0881d3db3799f6d116a755403d8e6"},{"nct_id":"NCT06501066","title":"Mesenchymal Stem Cells for Frailty Syndrome","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meribank Biotech Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Pathologic Processes","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT06501066","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06501066","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cc14f8e4186e903618dc5a9126156d34d6b7200455d012cada024888e75bb512"},{"nct_id":"NCT06505551","title":"Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"SCG Cell Therapy Pte. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"HPV-Related Squamous Cell Carcinoma; HPV-Related Cervical Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vaginal Squamous Cell Carcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Head and Neck Cancer","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT06505551","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06505551","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:20b1d87ecc24fd1efe669d1e5e942bd3bb4909c4e06ee0d1b4c782e9687b2c41"},{"nct_id":"NCT06512363","title":"A Study of Ramelteon in Chinese Patients With Chronic Insomnia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Insomnia","enrollment":280,"url":"https://clinicaltrials.gov/study/NCT06512363","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06512363","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f6eaaf99d179c2fb4eb869b16d3d467f2ef3f5dac96ab91bcf9935c1f6bfeb6f"},{"nct_id":"NCT06534437","title":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Ryvu Therapeutics SA","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Hodgkin Lymphoma, B-cell","enrollment":178,"url":"https://clinicaltrials.gov/study/NCT06534437","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06534437","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bfe76968fc2cd3b752957ec46411917bdc50cd6a120846b14885c2eb5828a2e0"},{"nct_id":"NCT06537999","title":"A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dianthus Therapeutics","ticker":"DNTH","ticker_confidence":0.6,"conditions":"Multifocal Motor Neuropathy","enrollment":46,"url":"https://clinicaltrials.gov/study/NCT06537999","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06537999","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c4a37d8b5b4117f6975cbab4a8f9804c966f275e557ba78fc62b0e688bc02036"},{"nct_id":"NCT06568094","title":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Prostate Cancer","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT06568094","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06568094","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1a17c4934ed32090c27a2f1f91383b02195588b3144977080a6bfbae95f40627"},{"nct_id":"NCT06568367","title":"Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","ticker":"AXSM","ticker_confidence":0.9,"conditions":"Excessive Sleepiness; Shift-work Disorder","enrollment":520,"url":"https://clinicaltrials.gov/study/NCT06568367","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06568367","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:60fbcc9b19ddf023494c7fe3ac93dfe495736571226270c517f2ec90d1299e86"},{"nct_id":"NCT06568627","title":"A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"MediWound Ltd","ticker":"MDWD","ticker_confidence":0.9,"conditions":"Venous Leg Ulcer (VLU)","enrollment":216,"url":"https://clinicaltrials.gov/study/NCT06568627","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06568627","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9508748b4934da8d99253286044e4c926cb4297834fac11375222c59df2eac29"},{"nct_id":"NCT06569524","title":"Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-alcoholic Steatohepatitis","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06569524","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06569524","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:64612891c42805f386fe2258a35887eef21a0d3fc07b3e3f97a78a1c65ed3d30"},{"nct_id":"NCT06570291","title":"Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Wuxi Cellular Biopharmaceutical Group Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Knee Osteoarthritis","enrollment":520,"url":"https://clinicaltrials.gov/study/NCT06570291","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06570291","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7fb191eb2d2c0aa2b979fdd627cf54de5d773ec87cfc5cc0ec7f7f2f15e1ce77"},{"nct_id":"NCT06577935","title":"A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angitia Biopharmaceuticals","ticker":null,"ticker_confidence":0.0,"conditions":"Postmenopausal Osteoporosis","enrollment":379,"url":"https://clinicaltrials.gov/study/NCT06577935","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06577935","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4beb83964984a0a81ae818be5071dc31128681e71e2811b455b05f191a539cec"},{"nct_id":"NCT06578624","title":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Lamassu Bio Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":70,"url":"https://clinicaltrials.gov/study/NCT06578624","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06578624","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:edbbf12e1eb0ee2b4c1f3e4cfddd48f386f5fa38d2117ae78fc6edf65c9add3c"},{"nct_id":"NCT06579287","title":"A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunhawk Vision Biotech, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Myopia, Progressive","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT06579287","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06579287","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f37567af01ee5a68980f34ec5f2d2a52eb1a5d0c835decfd22ce13f02bc5f86d"},{"nct_id":"NCT06582485","title":"A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"NOT_YET_RECRUITING","sponsor":"iCoat Medical AB","ticker":null,"ticker_confidence":0.0,"conditions":"Ischemia-reperfusion Injury; Kidney Transplant; Complications","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT06582485","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06582485","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:040f7d23c74b6b02f06ad035dcb68cdfa45df06a242e61d72e4b137499c6f44b"},{"nct_id":"NCT06596252","title":"Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Falk Pharma GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Eosinophilic Esophagitis","enrollment":308,"url":"https://clinicaltrials.gov/study/NCT06596252","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06596252","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ead3b14f2c4ce235c02673b190e0eba363ccd4fda88799e1eeb4502852f02f51"},{"nct_id":"NCT06605222","title":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":201,"url":"https://clinicaltrials.gov/study/NCT06605222","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06605222","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ab5df844c913a9632dd2fd3cff48dcda7a03b6aa56e48eb627af2db67d9aa348"},{"nct_id":"NCT06607458","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Delcath Systems Inc.","ticker":"DCTH","ticker_confidence":0.9,"conditions":"Refractory Metastatic Colorectal Cancer","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06607458","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06607458","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:602711ff96a898b8273996fe4cb60125ec940b6f3bf71dd2ba4b083c238e6df1"},{"nct_id":"NCT06608459","title":"PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Filament Health Corp.","ticker":null,"ticker_confidence":0.0,"conditions":"Opioid Use Disorder","enrollment":10,"url":"https://clinicaltrials.gov/study/NCT06608459","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06608459","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:63fbd69fd26fc6449595c54eddda0f8d6812c29944725c0db9635001d1ff1a13"},{"nct_id":"NCT06650566","title":"Study of LM-299 in Subjects Advanced Malignant Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"LaNova Medicines Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Malignant Tumors","enrollment":108,"url":"https://clinicaltrials.gov/study/NCT06650566","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06650566","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f9cd439220aca7900403af79448a17ef1331f280926980cbc1aaa767f273c085"},{"nct_id":"NCT06667544","title":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"KRAS G12D Mutation","enrollment":152,"url":"https://clinicaltrials.gov/study/NCT06667544","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06667544","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:34b623ba0a25041ebb7bd94fb8d73e1bd10ca2e5c1c1ced6c55de381002e750c"},{"nct_id":"NCT06671379","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer","enrollment":498,"url":"https://clinicaltrials.gov/study/NCT06671379","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06671379","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f2de73cf4700c86c09b405091320c1675f0db56f375bf012fd29009113d6d9a5"},{"nct_id":"NCT06677229","title":"Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Technophage, SA","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Spinal Cord Injury (SCI)","enrollment":28,"url":"https://clinicaltrials.gov/study/NCT06677229","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06677229","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8c8f2643b3353a03a02899987dea633c7e3fa387e336e732b7c40b5d5b182baf"},{"nct_id":"NCT06677255","title":"A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Optics Valley Vcanbiopharma Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":149,"url":"https://clinicaltrials.gov/study/NCT06677255","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06677255","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:eb9d6535d77112229f1ffb5d938a0d91142062b73df7219fac0c806e1c4bcbce"},{"nct_id":"NCT06707103","title":"Tissue Repair Gel in Venous Leg Ulcers in AU/US","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"TR Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Venous Leg Ulcer; Venous Ulcer; Venous Stasis Ulcer; Venous Stasis; Wound Heal; Wound; Venous Insufficiency of Leg; Non-healing Wound","enrollment":312,"url":"https://clinicaltrials.gov/study/NCT06707103","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06707103","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ec54ef9fc3e8beb50a7d1c7f743a529e311d4c04341be9d75619e3b0506a7394"},{"nct_id":"NCT06707883","title":"A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Obstructive Pulmonary Disease","enrollment":258,"url":"https://clinicaltrials.gov/study/NCT06707883","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06707883","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9b034435cc2982dfaeae9ad4daadcbfc57e8876e7bbf5ce033f11c85690285a8"},{"nct_id":"NCT06711900","title":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"SKBBY","ticker_confidence":0.6,"conditions":"Non-Small Cell Lung Cancer","enrollment":432,"url":"https://clinicaltrials.gov/study/NCT06711900","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06711900","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce1580419b49b936310a4f43eb9c027bcf6aab8adf96db63f6f37e61872ccbba"},{"nct_id":"NCT06721871","title":"Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Napo Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Microvillus Inclusion Disease; Congenital Disorders; Rare Diseases","enrollment":6,"url":"https://clinicaltrials.gov/study/NCT06721871","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06721871","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:de99c85c533fc475274fe0c8a6b066dc3fcc513cefe9d425ce7754893380a8ed"},{"nct_id":"NCT06722950","title":"Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","ticker":null,"ticker_confidence":0.0,"conditions":"Colorectal Adenoma","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06722950","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06722950","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2311ff2e25467fa16cd0ba4df0f0d4fd98bc0ea546013194b07c3cc47615e6bc"},{"nct_id":"NCT06752668","title":"A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Centessa Pharmaceuticals (UK) Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia","enrollment":248,"url":"https://clinicaltrials.gov/study/NCT06752668","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06752668","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c3c70929c6e481823cad2832a14abaa0610b8a9c38407ba784b552c585241f78"},{"nct_id":"NCT06754644","title":"A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"NSCLC","enrollment":808,"url":"https://clinicaltrials.gov/study/NCT06754644","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06754644","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9a97dba07cef3142f95b804e81ef6ab93dcd29abbb2d53a70024aee9a5a6c9b1"},{"nct_id":"NCT06767527","title":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":416,"url":"https://clinicaltrials.gov/study/NCT06767527","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06767527","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dd3540b5981f513850e56529d4c526209b9828b0dad6a7121eb1f9ad899409d7"},{"nct_id":"NCT06783309","title":"CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"COUR Pharmaceutical Development Company, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus; Type 1 Diabetes in Adolescence; Type 1 Diabetes in Children; Type 1 Diabetes (Juvenile Onset); Type 1 Diabetes; Type 1 Diabetes Patients; Type 1 Diabetes Mellitis","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT06783309","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06783309","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dcfb7e79070348ae1c5c7178521a70718675dfc1430e19e8572ba6b9bceb4daf"},{"nct_id":"NCT06817096","title":"Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Azidus Brasil","ticker":null,"ticker_confidence":0.0,"conditions":"Covid 19; Influenza","enrollment":340,"url":"https://clinicaltrials.gov/study/NCT06817096","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06817096","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:73465efd8e96ebf89a481476bf92930d53b3a73f854ba2af534a004f70b67d65"},{"nct_id":"NCT06820099","title":"Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity","enrollment":225,"url":"https://clinicaltrials.gov/study/NCT06820099","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06820099","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fcc3085e8899f8308c48dc8d99af5e15a4c02e8ca78299d2736b36e3cf3b7aba"},{"nct_id":"NCT06840002","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Ovarian Cancer","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT06840002","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06840002","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:10074218857be91a7fd303e494c197f0e87e48067f6f237d23c2020d67503d41"},{"nct_id":"NCT06842823","title":"A Study of Navenibart in Participants With Hereditary Angioedema","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astria Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Hereditary Angioedema (HAE)","enrollment":157,"url":"https://clinicaltrials.gov/study/NCT06842823","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06842823","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bf6f049d94cd84df8c1ac53d4a1c396bd097e51de65ba25dfff9ebe21e36dbef"},{"nct_id":"NCT06844474","title":"A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"NSCLC","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT06844474","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06844474","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a97352cde8faac4938ae131705895c2835486c14cea0e7dbf944d9ddb62e2d2d"},{"nct_id":"NCT06848348","title":"Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dogwood Therapeutics Inc.","ticker":"DWTX","ticker_confidence":0.9,"conditions":"Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pain","enrollment":240,"url":"https://clinicaltrials.gov/study/NCT06848348","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06848348","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ad8b7c1e8a2b4e4539d1036b9cc6b0848f21f0a9d1076a9542055f49445d35a9"},{"nct_id":"NCT06851949","title":"Vsling\u2122 I: Clinical Evaluation of the Vsling\u2122 Device for Ventricular Repair in Patients With Heart Failure","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Cardiac Success","ticker":null,"ticker_confidence":0.0,"conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT06851949","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06851949","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:29eb79557362f601faed90bfb54fe97113ed1767d9f3256fdc8de7784a46fe73"},{"nct_id":"NCT06852768","title":"Study of d-MAPPS\u2122 Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regenerative Ocular Immunobiologics LLC","ticker":null,"ticker_confidence":0.0,"conditions":"oGHVD","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT06852768","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06852768","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8409e27aa369d00623ffb8f514582a268fac50fe208dbc388d392cf23cd13688"},{"nct_id":"NCT06859788","title":"SPI-1005 for the Treatment of Meniere's Disease (Open Label)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sound Pharmaceuticals, Incorporated","ticker":"SOGP","ticker_confidence":0.9,"conditions":"Meniere's Disease; M\u00e9ni\u00e8re's Disease","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT06859788","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06859788","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3105e55bc9425bbc30c7a6f5f223f735b1b73fc71998a826f8d1563600a4a694"},{"nct_id":"NCT06859931","title":"Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Systemic Lupus Erythematosus","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06859931","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06859931","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bc254bd47c92246f8f55c63091f8bec12e84e9523081075ed4c8b7ca1945fd70"},{"nct_id":"NCT06874010","title":"A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Design Therapeutics, Inc.","ticker":"DSGN","ticker_confidence":0.9,"conditions":"Friedreich Ataxia","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT06874010","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06874010","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c36c39d6c044d1c1faddf0e0203fd165768cb885f624f29aa5ff7827af90b44b"},{"nct_id":"NCT06890832","title":"A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Jina Pharmaceuticals Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Castration-resistant Prostate Cancer, MCRPC","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT06890832","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06890832","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:094b09cac561894852eb9c394acfaa2bd9403f8bdf9bcd2b698f61d99d602427"},{"nct_id":"NCT06912633","title":"Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"jCyte, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Retinitis Pigmentosa","enrollment":31,"url":"https://clinicaltrials.gov/study/NCT06912633","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06912633","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7c50f8eba15562a8da467feb24593821cdceb696250085c41f965418e8f863b4"},{"nct_id":"NCT06915142","title":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Malignant Tumour","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT06915142","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06915142","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a6f02bcc770eb3cbf9a87c178c8126c6d39ef0d266cfa4bd26d01c226ef09b88"},{"nct_id":"NCT06942767","title":"Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT06942767","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06942767","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:50538e834164ac86efb251e82264d9ec990ca3eecf9ab54e4177fdb00d9f7c8d"},{"nct_id":"NCT06943820","title":"AK129 Combination Therapy for Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal Adenocarcinoma; Advanced Solid Tumors","enrollment":230,"url":"https://clinicaltrials.gov/study/NCT06943820","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06943820","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8ef358788e1aac94010a528fad1295f166b4dc1a683b00fd02f6bce7380ae44a"},{"nct_id":"NCT06972264","title":"Safety and Efficacy of VDPHL01 in Males With AGA","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","ticker":"MANE","ticker_confidence":0.9,"conditions":"Androgenetic Alopecia; AGA; Male Pattern Baldness","enrollment":480,"url":"https://clinicaltrials.gov/study/NCT06972264","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06972264","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:41d9c475b8d060a816dadeeab422fd294210d1a7dac3e1a933c7ce64310eb9d9"},{"nct_id":"NCT06974851","title":"A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Bstructive Sleep Apnea (OSA) and Obesity","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT06974851","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06974851","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0a42f9b93ad3e4c7261854248bfed4196bf7aecfd41677959ce0e8584043cabd"},{"nct_id":"NCT06974929","title":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT06974929","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06974929","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d685fc70518c985bf018a030367f09966046dba3e3c1e8ce132c8ae0dccd9fa5"},{"nct_id":"NCT06987058","title":"RVU120 Rollover Study","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Ryvu Therapeutics SA","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndrome","enrollment":14,"url":"https://clinicaltrials.gov/study/NCT06987058","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06987058","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fdeff89aa0419de7c4815c8fff7b1be035e8c1d9f083bf41642f14f77c82cda9"},{"nct_id":"NCT06989918","title":"MHB018A Treatment in Patients With Active Thyroid Eye Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Thyroid Associated Ophthalmopathies","enrollment":108,"url":"https://clinicaltrials.gov/study/NCT06989918","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06989918","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2d203aeafbb8fe46b9e644a8b3964e82846940adf06e4cc414fee6058f43732b"},{"nct_id":"NCT06994650","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT06994650","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06994650","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2b87e8608b1065dcab765378e042289127640b558e129bbd57ab5ba5673c7a2b"},{"nct_id":"NCT06999733","title":"A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","ticker":"KRYS","ticker_confidence":0.9,"conditions":"Neurotrophic Keratitis","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06999733","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06999733","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:83d502d82e8de335e1730e904e9ef7b06bb291132f91791aa84d98ea27a5ded2"},{"nct_id":"NCT07010471","title":"A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praxis Precision Medicines","ticker":"PRAX","ticker_confidence":0.9,"conditions":"Developmental and Epileptic Encephalopathy 1","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07010471","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07010471","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:990e3bbee9c9e35da530eacae0b0a313a01decadf6101556b5045163b896c1f0"},{"nct_id":"NCT07016750","title":"A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","ticker":"KRYS","ticker_confidence":0.9,"conditions":"Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa","enrollment":16,"url":"https://clinicaltrials.gov/study/NCT07016750","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07016750","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:db2548a06475674aff0f31737f0efbd14e86c35ea6bf961aae3f8e9a62f0727b"},{"nct_id":"NCT07019922","title":"A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Praxis Precision Medicines","ticker":"PRAX","ticker_confidence":0.9,"conditions":"Epileptic Encephalopathy; SCN2A Encephalopathy","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07019922","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07019922","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:07652239309f0cb9d570afb5eb46ec6bcc8ee9aafc57f432bf94d40efbf9a602"},{"nct_id":"NCT07023614","title":"A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Imbria Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-obstructive Hypertrophic Cardiomyopathy","enrollment":165,"url":"https://clinicaltrials.gov/study/NCT07023614","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07023614","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ff63202d4be354ff9df82d9348c25b50be94457703d2d98c7133fc47ec585f5a"},{"nct_id":"NCT07028632","title":"The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Parkinson Disease (PD)","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT07028632","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07028632","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ac44c1d6dfb7cd1bcaed3d68a2d56142825f5a6325dc560a0cbf211fede15463"},{"nct_id":"NCT07037277","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","ticker_confidence":0.9,"conditions":"HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection; Hepatitis C","enrollment":880,"url":"https://clinicaltrials.gov/study/NCT07037277","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07037277","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:69f388e546050e956976b96d9d38db9b4fb31b8d1c631833c7cff36a517c6a0c"},{"nct_id":"NCT07059000","title":"A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Kedrion S.p.A.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Primary Immune Thrombocytopenia (ITP)","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07059000","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07059000","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:38eb356d9d70c1c26849011c3235fa748c47261fb2387295a7c159400457633e"},{"nct_id":"NCT07074977","title":"Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galderma R&D","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Pruritus of Unknown Origin","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT07074977","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07074977","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:18717b743ae4efe0eccbc7f2729df768ca49ea08d0234eae4a4ead3820efa2da"},{"nct_id":"NCT07089186","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI); Complicated Urinary Tract Infection (cUTI); Bloodstream Infection (BSI)","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT07089186","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07089186","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:daec17615ed9d9709a63f8f16486bf6147829a418e943a2b6c4b5b990b21f1b9"},{"nct_id":"NCT07093476","title":"Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Celltrion","ticker":null,"ticker_confidence":0.0,"conditions":"T2DM; Diabete Type 2; DM","enrollment":171,"url":"https://clinicaltrials.gov/study/NCT07093476","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07093476","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ab9707e72c247057677cc6e36f7423ce581d67b6413e05d41800c5ab6117702f"},{"nct_id":"NCT07128550","title":"A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","ticker":"VIR","ticker_confidence":0.9,"conditions":"Viral Hepatitis","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT07128550","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07128550","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:72849a5cc46f8e72e36067ae794bbf92cd98536633caec44a730f5bd4a55d3a8"},{"nct_id":"NCT07136285","title":"Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"SCLC, Extensive Stage","enrollment":27,"url":"https://clinicaltrials.gov/study/NCT07136285","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07136285","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d2ba1280c0bf8a285762d0d2274e26bbca66f691a1b8fa57f3db16ae800dfc47"},{"nct_id":"NCT07142044","title":"Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"EicOsis Human Health Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Parkinson&#39;s Disease (PD)","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT07142044","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07142044","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4cf57ef2bd66899c847f408496192858f2a53ff612e6c27fe41a45084fa3d2de"},{"nct_id":"NCT07151040","title":"Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"One-carbon Therapeutics AB","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung Cancer (NSCLC); Gastrooesophageal Junction Cancer; Gastric Cancer","enrollment":43,"url":"https://clinicaltrials.gov/study/NCT07151040","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07151040","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e4fa3e8ae4fc786318066008ecff8df41f65a6241850989e1c6aa01b57c05074"},{"nct_id":"NCT07169851","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Eli Lilly and Company","ticker":"LLY","ticker_confidence":0.95,"conditions":"Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions; Neoplasms","enrollment":204,"url":"https://clinicaltrials.gov/study/NCT07169851","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07169851","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:eaf3caa3d19adc7f381dae9039a0a39b17077754c062c52b4ee953acd104e04c"},{"nct_id":"NCT07173478","title":"A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Atopic Dermatitis (AD)","enrollment":156,"url":"https://clinicaltrials.gov/study/NCT07173478","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07173478","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:56fefbb905738716d0219f7cb7bca218748d9a9ac88f6bd05066c4420083893b"},{"nct_id":"NCT07194382","title":"AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Avalyn Pharma Inc.","ticker":"AVLN","ticker_confidence":0.9,"conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07194382","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07194382","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8e2b68f0e4d158c1456135d733c085a8966a4dfbbd4608ceb890a1ea6e163183"},{"nct_id":"NCT07198633","title":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Prostate Cancer","enrollment":212,"url":"https://clinicaltrials.gov/study/NCT07198633","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07198633","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b7c9489a9143b701a3cab50dc354e622d4801260cc1c79a1db3356838f5d7356"},{"nct_id":"NCT07215273","title":"Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Invasive Mould Infection","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07215273","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07215273","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:63b21e8cb435cad55be1bc1b1968cea43a3b8058bfeda84ef7a4c44a333bd429"},{"nct_id":"NCT07221578","title":"Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanda Pharmaceuticals","ticker":"VNDA","ticker_confidence":0.9,"conditions":"Social Anxiety Disorder (SAD)","enrollment":500,"url":"https://clinicaltrials.gov/study/NCT07221578","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07221578","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:13f8a7a2758a5262c63e6aea88efeaa9708ad5ef41531069951a2b5e5d388bb3"},{"nct_id":"NCT07229950","title":"A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Adult Patients With Moderately to Severely Active Ulcerative Colitis","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT07229950","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07229950","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d7114740f9a82d12925985cc82153d65b87874f40fbf4f1314652051378a812e"},{"nct_id":"NCT07231679","title":"A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Ingenia Therapeutics INC","ticker":null,"ticker_confidence":0.0,"conditions":"Healthy Volunteers; Chronic Kidney Disease","enrollment":94,"url":"https://clinicaltrials.gov/study/NCT07231679","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07231679","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8523304bd9ea6888fed71c16baa41c7d4ffe2daec559459f0ce3df03538d2a9d"},{"nct_id":"NCT07233213","title":"An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Grand Shuyang Life Sciences (Chengdu) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT07233213","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07233213","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dcc2c979388a13f85d1af5b2d6c3cba3e793972a3bf6e878b853cd780ff9646d"},{"nct_id":"NCT07233850","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","ticker":null,"ticker_confidence":0.0,"conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Oesophageal Cancer","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT07233850","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07233850","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:10a6ea29ba8e9232ecada780157de06fc2d6cb9a7dd183a08b0c54003d0b3325"},{"nct_id":"NCT07239440","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Dong-A ST Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Diabete Mellitus","enrollment":288,"url":"https://clinicaltrials.gov/study/NCT07239440","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07239440","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6164e256ac74464b6a82ecae6094979f70253323ecb8c55ecd7912fec97952c7"},{"nct_id":"NCT07260877","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Ventus Therapeutics U.S., Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Cutaneous Lupus Erythematosus (CLE); Systemic Lupus Erythematosus; SLE; SLE (Systemic Lupus); CLE","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07260877","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07260877","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:48797c6ea3020291fff0c9ef85338ccfec764eec8052026fdf8b4029398dc4c0"},{"nct_id":"NCT07290088","title":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Intra-IMMUSG Pte Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Cancers","enrollment":52,"url":"https://clinicaltrials.gov/study/NCT07290088","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07290088","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8439d15dc5ca495ce745f652bc6d5bdb64b9204f367ff758cf37e07f888b704b"},{"nct_id":"NCT07297797","title":"Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Mild to Moderate Hypertension","enrollment":238,"url":"https://clinicaltrials.gov/study/NCT07297797","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07297797","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0f67de03d09a2928c288e36d3f9c6c12465b4d5bc71997d1f8286d308f7c83cf"},{"nct_id":"NCT07298395","title":"Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Enveda Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Atopic Dermatitis (AD)","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT07298395","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07298395","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1b8a547329f99a7ee029198ef309e3347a4b77cadbc46149e8d41fb74fc13d35"},{"nct_id":"NCT07301255","title":"ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Enveda Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Asthma","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT07301255","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07301255","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3fdacf3941253f65423e890a362d7fb1d8084227e2007a0f77dbb1345a5e4340"},{"nct_id":"NCT07308782","title":"A Phase \u2161a Clinical Study of CL-197 Capsules","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Henan Genuine Biotech Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"HIV-1 Infection","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07308782","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07308782","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:737fc74c22d708ad92e0b52577c3bebb0e6a33149b4795f2a350bf076392525c"},{"nct_id":"NCT07322432","title":"The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"VapeAway","ticker":null,"ticker_confidence":0.0,"conditions":"Addiction Nicotine","enrollment":70,"url":"https://clinicaltrials.gov/study/NCT07322432","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07322432","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d274e8e7e9a4a455221c640066776958b3f79709853431668f32baf01680a163"},{"nct_id":"NCT07333183","title":"A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Pulmovant, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovascular Diseases; Fibrosis","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT07333183","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07333183","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3714e296b8afaf8b89e6c471d4ac3e8c2027bba773e7b404b5430b7ac0eb09d2"},{"nct_id":"NCT07361120","title":"Plan A Occlusion and Reversal System Feasibility Study","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Next Life Sciences","ticker":null,"ticker_confidence":0.0,"conditions":"Fertility; Fertility, Male; Healthy Male Adults","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07361120","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07361120","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:be4fac1fa5e1e8b4a2292a9509d91d170ec0a29175d978a27895b64445397cae"},{"nct_id":"NCT07371650","title":"This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Traws Pharma, Inc.","ticker":"TRAW","ticker_confidence":0.9,"conditions":"Influenza","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT07371650","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07371650","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:22e9599f2a82df442d58ebf1a9711c3a5c3f30f4e10a21c55ebd18a03d301ced"},{"nct_id":"NCT07402876","title":"A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","ticker_confidence":0.9,"conditions":"Primary Vitreoretinal Lymphoma","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT07402876","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07402876","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce930dc133b02fc6751ee40931f00b66f82d102d7d858aa87fd31825693017a3"},{"nct_id":"NCT07408024","title":"Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Toll Biotech Co. Ltd. (Beijing)","ticker":null,"ticker_confidence":0.0,"conditions":"Rheumatoid Arthritis (RA)","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07408024","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07408024","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:641ae73904ee40ca23693bcd862bb74ee0b95c8c55fea953f3236ab5df406bfa"},{"nct_id":"NCT07413094","title":"Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Sepsis","enrollment":309,"url":"https://clinicaltrials.gov/study/NCT07413094","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07413094","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0da491751ec4c6d73e21ab721fc3a17700b9b65d308ce0a8f7f622b15146178f"},{"nct_id":"NCT07439848","title":"Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"PT. Prodia Stem Cell Indonesia","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Respiratory Distress Syndrome","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT07439848","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07439848","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d06b72ba0770364633a1c2d67853604300f4871e2b3fc16e104c1bab56a75236"},{"nct_id":"NCT07472725","title":"A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Diabetes Mellitus, Type 2","enrollment":102,"url":"https://clinicaltrials.gov/study/NCT07472725","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07472725","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bb68bde11c564b0dbe920de09d024dcd49fa4d9788037c1964cd0de812a38a82"},{"nct_id":"NCT07482657","title":"A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged \u226528 Days to \u226436 Months of Age Infected With Respiratory Syncytial Virus","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Enanta Pharmaceuticals, Inc","ticker":"ENTA","ticker_confidence":0.9,"conditions":"RSV Infection; RSV; Respiratory Syncytial Virus (RSV)","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT07482657","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07482657","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cdb57281edda92919da557fa60d8704d1f602c2812745c05e14d18990c8f3d11"},{"nct_id":"NCT07487103","title":"Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 2 Diabetes","enrollment":478,"url":"https://clinicaltrials.gov/study/NCT07487103","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07487103","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:35ca24ee4937372abea15ec8626737f835f9a50f7e28598739a6f4e31c62350d"},{"nct_id":"NCT07489586","title":"A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":356,"url":"https://clinicaltrials.gov/study/NCT07489586","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07489586","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cb94dabda58592db2670db9081a6da7c52bd64f6af12c232526ae258ef794d32"},{"nct_id":"NCT07489612","title":"QLS1410 in Participants With Uncontrolled Hypertension","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hypertension (HTN)","enrollment":260,"url":"https://clinicaltrials.gov/study/NCT07489612","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07489612","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0e47e83f6d90bdd0fddf34687f0758db67143a91c398e9ce510390ceef1eecd9"},{"nct_id":"NCT07499674","title":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Vergent Bioscience, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Lung Cancer; Lung Metastases","enrollment":132,"url":"https://clinicaltrials.gov/study/NCT07499674","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07499674","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:737aa84a38978117893ad1333089b7ad300be06dad0df74db4a07199fd44356e"},{"nct_id":"NCT07511361","title":"Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Kardigan, Inc.","ticker":"KARD","ticker_confidence":0.9,"conditions":"Hypertension; Acute Severe Hypertension; Hypertensive Emergency; Hypertensive Urgency","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT07511361","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07511361","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:593fc40d0746cc8ff3dabf0511ae1f115a33a9fa84a9085736d11ff7249f867b"},{"nct_id":"NCT07513454","title":"A Phase 2 Study of HW211026","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Actinic Keratosis","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT07513454","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07513454","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:617bce234d53335abe39f3ddfca0978291b9bf8238d1fb7606e5be3dcd706aad"},{"nct_id":"NCT07540338","title":"A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Alzamend Neuro, Inc.","ticker":"ALZN","ticker_confidence":0.9,"conditions":"Bipolar I Disorder","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT07540338","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07540338","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9b1ad974f0bb187e29346cca94fc2c93b9a84232ad2781828fbcc79375b1c545"},{"nct_id":"NCT07548632","title":"A Clinical Study Evaluating Licaminlimab for Dry Eye Disease","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","ticker":"OCS","ticker_confidence":0.6,"conditions":"Dry Eye Disease (DED)","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07548632","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07548632","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2de3b8e32ce1839d26d79ece89a99e4c1baa9f6491ce6ca7d864674fa8429fe4"},{"nct_id":"NCT07576608","title":"A Phase II Study of 9MW3811 in Patients With Pathological Scar","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Scar","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT07576608","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07576608","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9eef6cf347a4f4ba62f5c1616f0ab893b18538188ccdd7d077dff7c0af84726c"},{"nct_id":"NCT07613866","title":"A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Spontaneous Urticaria","enrollment":190,"url":"https://clinicaltrials.gov/study/NCT07613866","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07613866","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cf9b9d01d5da59e9454a20fb9e5559137fd09dacc8dfb09d061dc51b083c6161"},{"nct_id":"NCT07678931","title":"Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Chengdu Kangnuoxing Biopharma,Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":136,"url":"https://clinicaltrials.gov/study/NCT07678931","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07678931","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6c80c86902ade925ddc348916ff6b096d5002025746668ff0d70b185aaaca97f"},{"nct_id":"NCT07688772","title":"A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Seasonal Allergic Rhinitis","enrollment":220,"url":"https://clinicaltrials.gov/study/NCT07688772","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07688772","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a716a6d2bb5656968ebefcea7a214c207c23bebc8ee5dd0dc82c26a96254173c"},{"nct_id":"NCT07691775","title":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Heron Neutron Medical Corp.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT07691775","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07691775","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8e0b6b9ea4a619a815697affa896d5099001c95d98372cad0bc2d2acb5933c0f"},{"nct_id":"NCT07705737","title":"Rademikibart IV for Acute Asthma and COPD Exacerbation","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Connect Biopharm LLC","ticker":"CNTB","ticker_confidence":0.6,"conditions":"Asthma Acute; COPD Exacerbation Acute","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07705737","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07705737","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8740f09051afe5e1837f7a60bb268568892b535939c1351300c562970777bbc2"},{"nct_id":"NCT07709897","title":"A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Prevention of Postoperative Nausea and Vomiting","enrollment":260,"url":"https://clinicaltrials.gov/study/NCT07709897","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07709897","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:603398280427eab588d8f9c6cd41b3b589402080a15e009c239ba2fe766c473b"},{"nct_id":"NCT07832552","title":"A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE\u00ae (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ENROLLING_BY_INVITATION","sponsor":"Harrow Inc","ticker":"HROW","ticker_confidence":0.9,"conditions":"Postoperative Ocular Inflammation; Postoperative Ocular Pain","enrollment":250,"url":"https://clinicaltrials.gov/study/NCT07832552","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07832552","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a75a3a98d48564947873ee49da9b359750c376610a0a823826a21e82aeb46b41"},{"nct_id":"NCT07837726","title":"Pilot Study of TTI-0102 in Cystinosis","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Thiogenesis Therapeutics, Inc.","ticker":"TTIPF","ticker_confidence":0.9,"conditions":"Nephropathic Cystinosis; Cystinosis","enrollment":6,"url":"https://clinicaltrials.gov/study/NCT07837726","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07837726","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6d348c27734e9b6abed90351c37290427c5f845195d6733c9765f028eb58eef8"},{"nct_id":"NCT07893288","title":"A Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health Adults","readout_date":"2026-12","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Danisco","ticker":null,"ticker_confidence":0.0,"conditions":"Digestive Symptoms; Gastrointestinal Symptoms; Healthy; Impaired Pancreatic Function","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT07893288","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07893288","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a302375a0219374d82aac78919c915d3a62347adf82a18542f9a722ff696da29"},{"nct_id":"NCT03767244","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Prostatic Neoplasms","enrollment":2517,"url":"https://clinicaltrials.gov/study/NCT03767244","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03767244","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:15bc112c1656c197991b460a1ef911a160aaf2ba7a7150e0ce9e993750f9fe9e"},{"nct_id":"NCT04452955","title":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intra-IMMUSG Pte Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":51,"url":"https://clinicaltrials.gov/study/NCT04452955","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04452955","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4a15b127eee84b87e25ad096df1c71634b26d26b452d1e4a7bd81fb68c41598f"},{"nct_id":"NCT04627428","title":"Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Luxa Biotechnology, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Dry Age-related Macular Degeneration","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT04627428","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04627428","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:488be3f7c76b574e463473eb410713c58c6717e3faf096cd8c5292e7b644fe85"},{"nct_id":"NCT04673942","title":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"EpicentRx, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult; Cancer; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Chondrosarcoma","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT04673942","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04673942","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:89ef423cb57cfa1ce0abc55b63bc0668558f6508a7790ecbce42a6ff80a4b00e"},{"nct_id":"NCT04918173","title":"Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Octapharma","ticker":null,"ticker_confidence":0.0,"conditions":"Congenital Antithrombin Deficiency","enrollment":38,"url":"https://clinicaltrials.gov/study/NCT04918173","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04918173","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d7c9773986e0d8d2cb26135704d2b8fc0944b44e117a398e3bc9d982ba466afb"},{"nct_id":"NCT05128825","title":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","enrollment":310,"url":"https://clinicaltrials.gov/study/NCT05128825","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05128825","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1d1eaff6025bda2e1516ad9ba262d1976ffc51311fb2bfcf809eb170f49e169f"},{"nct_id":"NCT05860465","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":254,"url":"https://clinicaltrials.gov/study/NCT05860465","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05860465","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f12baaebd647c647051fae6aade094433fd3f80059dfd100c76075cd07ef5ed3"},{"nct_id":"NCT06000956","title":"A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Ankylosing Spondylitis","enrollment":408,"url":"https://clinicaltrials.gov/study/NCT06000956","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06000956","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49211f7f1d62b4705f6ec9fbb38427699269d2b3a3f50056940f44591487b52b"},{"nct_id":"NCT06038474","title":"Descartes-08 for Patients With Systemic Lupus Erythematosus","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cartesian Therapeutics","ticker":"RNAC","ticker_confidence":0.9,"conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":6,"url":"https://clinicaltrials.gov/study/NCT06038474","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06038474","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0ef1a338f76962e950768acd8855c2158608da6e6656d56d814881281a2af55c"},{"nct_id":"NCT06283979","title":"A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Biocomposites Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Pressure Ulcer, Stage IV; Osteomyelitis","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06283979","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06283979","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:316a3fb02ff124f7ee705b1a1610fefda0d731200c4099624a12b672a115b58f"},{"nct_id":"NCT06499350","title":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"FindCure Biosciences (ZhongShan) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Malignant Solid Tumors","enrollment":33,"url":"https://clinicaltrials.gov/study/NCT06499350","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06499350","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ef78dca114f4fc72de07d404506d67a73af57362c1292c12f0da3425d16a8361"},{"nct_id":"NCT06669975","title":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"AP Biosciences Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":85,"url":"https://clinicaltrials.gov/study/NCT06669975","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06669975","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bc9764826851e049d9095feb6a41e83c6f87708f8c698921ae9f947aa775f006"},{"nct_id":"NCT06683703","title":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-small Cell Lung Cancer Patients with Brain Metastases","enrollment":118,"url":"https://clinicaltrials.gov/study/NCT06683703","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06683703","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b8e94a2b41b6694c68513d9be9ffd74bef46a7c4d3751c5ba97e8fb584cbcae5"},{"nct_id":"NCT06685757","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","ticker":"BIIB","ticker_confidence":0.9,"conditions":"Antibody-mediated Rejection","enrollment":132,"url":"https://clinicaltrials.gov/study/NCT06685757","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06685757","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0687bab804c4667ca7f90a4531ba589918adcce841f8d505e5694d280f3f92e0"},{"nct_id":"NCT06699108","title":"Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Bietti Crystalline Dystrophy; Inherited Retinal Diseases","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT06699108","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06699108","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7252d8d62fadbdf69b614fedf7ba6eaff736cbf2d10d83084486f89c415d834e"},{"nct_id":"NCT06838000","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","ticker":"SNY","ticker_confidence":0.6,"conditions":"Pneumococcal Infections","enrollment":1268,"url":"https://clinicaltrials.gov/study/NCT06838000","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06838000","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9de6e95051313f7d9ece471f6d94f7c79f2df4417f959efaf4af7406b916e5ee"},{"nct_id":"NCT06841861","title":"Spermatogonial Differentiation Via Testicular Organoid","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"CellARTs Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Infertility, Male; Gene Abnormality; Sterility, Male","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT06841861","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06841861","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:59ff2cc37ffc41eb3aaaf2b844c1e476589223848e9bb828e7289e1c6f158959"},{"nct_id":"NCT06858618","title":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Safety; Antitumor Activity; PK Profile","enrollment":47,"url":"https://clinicaltrials.gov/study/NCT06858618","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06858618","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cf5b984cde1866b610f9a4324ab1bcb01d19eaa8996d9a425f55451bc6e6360b"},{"nct_id":"NCT06907511","title":"Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Pandemic Influenza Immunization; Healthy Volunteers","enrollment":720,"url":"https://clinicaltrials.gov/study/NCT06907511","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06907511","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:431a432e81a915dea36329886a2d59cb3cd8f413c3123c311c01240886b6a967"},{"nct_id":"NCT06974084","title":"A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"NOT_YET_RECRUITING","sponsor":"HealthBio, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Long COVID","enrollment":252,"url":"https://clinicaltrials.gov/study/NCT06974084","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06974084","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:31c17d8eea6b32f3b7a8911ccfa382f997d307ca8ba2d8661654b39d56f2d88c"},{"nct_id":"NCT07017036","title":"Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Virchow Group","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":44,"url":"https://clinicaltrials.gov/study/NCT07017036","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07017036","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:17fb91c974ffd980044d57b8e287dc24c51672fba6c7b5a3a11d0f39865777eb"},{"nct_id":"NCT07090759","title":"To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Hepatitis b","enrollment":526,"url":"https://clinicaltrials.gov/study/NCT07090759","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07090759","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:07df57586a75e2ee9abbafc89cf7d43c18122fd8d993eb964e0423d7be25e899"},{"nct_id":"NCT07139535","title":"A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"T2DM","enrollment":350,"url":"https://clinicaltrials.gov/study/NCT07139535","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07139535","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bc4d104e9456c8f8804935e22292b732e0e0c7c74b9d48f36f3f7ff95e9ecec2"},{"nct_id":"NCT07139548","title":"A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"T2DM","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT07139548","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07139548","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f8eec9d5599f77718bed4fd170faf37c4055a21cca63e593f99f75ba57b6aeea"},{"nct_id":"NCT07168603","title":"EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"ASTEROGENE Biomedical Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Intervertebral Disc Degeneration","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT07168603","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07168603","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ef9454c6b2e3c26b552aff35a36eded77df528f998902c5edccf188840c4d6b5"},{"nct_id":"NCT07422857","title":"Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"JYAMS PET Research & Development Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia","enrollment":316,"url":"https://clinicaltrials.gov/study/NCT07422857","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07422857","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1693f9cda8ef1afd25b286662cf52e3ed6aeaab77df730048bad819f0158e401"},{"nct_id":"NCT07446439","title":"A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Vanda Pharmaceuticals","ticker":"VNDA","ticker_confidence":0.9,"conditions":"Nausea and Vomiting; Obesity","enrollment":280,"url":"https://clinicaltrials.gov/study/NCT07446439","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07446439","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bdf914a2312292a574cee52aa0e576380881c80a5de0d75d0d265c7b34de53d2"},{"nct_id":"NCT07487727","title":"A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)","readout_date":"2026-12-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Anemia Due to Chronic Kidney Disease","enrollment":240,"url":"https://clinicaltrials.gov/study/NCT07487727","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07487727","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b427fd2d05c99f8ee18163edcf9b5a5831be3e3fc0ba393d2a06e9e9422e09d1"},{"nct_id":"NCT06629779","title":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","readout_date":"2026-12-02","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":900,"url":"https://clinicaltrials.gov/study/NCT06629779","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06629779","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4f4dbaeb5740e7905505f0ffe53eb9ddcd28cedb3292fc0a37f5bd1cc6450359"},{"nct_id":"NCT07029711","title":"A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata","readout_date":"2026-12-02","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Severe Alopecia Areata","enrollment":208,"url":"https://clinicaltrials.gov/study/NCT07029711","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07029711","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:abff9b0dce82a28330e72090a4d8e31fbf87a380487cd23687c6ea31d4a0f1e1"},{"nct_id":"NCT06421636","title":"A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent \u03b2-thalassemia, Using MRI Scans to Measure Iron Levels in the Body","readout_date":"2026-12-03","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","ticker":"REGN","ticker_confidence":0.9,"conditions":"Non-Transfusion Dependent Beta-Thalassemia (NTDT)","enrollment":19,"url":"https://clinicaltrials.gov/study/NCT06421636","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06421636","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2a1e0a37c38fc099b7a79add49c3627d0c1aca9ae4c48cc76b855c6a6e02f7f2"},{"nct_id":"NCT06602258","title":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","readout_date":"2026-12-03","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Alzheimer's Disease","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT06602258","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06602258","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:134930c471fb5e3d6d068773225dbf27fb9c5a133733b876fb821c870eb11ff2"},{"nct_id":"NCT07500506","title":"A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine","readout_date":"2026-12-04","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Lyme Disease","enrollment":1712,"url":"https://clinicaltrials.gov/study/NCT07500506","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07500506","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e56fa8e276103478c2039d55ec1e64e0eed5c93a8dd6ce58e25e1d5891a8ddb5"},{"nct_id":"NCT07131202","title":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","readout_date":"2026-12-05","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":130,"url":"https://clinicaltrials.gov/study/NCT07131202","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07131202","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f4c4907a87e7c5c40bf37c1c34633647de9754ede971023b9fc68bbc08a7f13b"},{"nct_id":"NCT07616700","title":"A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy","readout_date":"2026-12-05","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"IgA Nephropathy (IgAN)","enrollment":73,"url":"https://clinicaltrials.gov/study/NCT07616700","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07616700","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ff0ad14923a9d74be9d3c635bdd2241355fda825c00c514d3590e30d542825dc"},{"nct_id":"NCT06724809","title":"Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD","readout_date":"2026-12-07","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"NMOSD; Neuromyelitis Optica Spectrum Disorders","enrollment":21,"url":"https://clinicaltrials.gov/study/NCT06724809","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06724809","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6787bba4ec49568168f80f172447769d040e041d8ba95cf203e8c3a46a8f68bb"},{"nct_id":"NCT05757869","title":"A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation","readout_date":"2026-12-08","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Atrial Fibrillation","enrollment":20284,"url":"https://clinicaltrials.gov/study/NCT05757869","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05757869","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce5a8e1ee4fc6d47ff84c2935b4046811a92676bea2ddf24b3450959ff38de3e"},{"nct_id":"NCT07228390","title":"A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.","readout_date":"2026-12-08","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Hidradenitis Suppurativa","enrollment":128,"url":"https://clinicaltrials.gov/study/NCT07228390","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07228390","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:54cf5d3b827881924d64ecad4a92a6d702786b0ff6b6c23c26462391b676a113"},{"nct_id":"NCT06126224","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)","readout_date":"2026-12-09","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","ticker":null,"ticker_confidence":0.0,"conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":500,"url":"https://clinicaltrials.gov/study/NCT06126224","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06126224","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:633a397df9af44ef3bf65445a7625aaa3471a7ec85318896c4039fe07b1eb835"},{"nct_id":"NCT07280858","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","readout_date":"2026-12-09","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Healthy Participants; Sarbecovirus","enrollment":368,"url":"https://clinicaltrials.gov/study/NCT07280858","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07280858","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9efb5cb09ebbbfd569f9a2242c06c86e8244b2803fb95271db35823e10e2198c"},{"nct_id":"NCT05686642","title":"Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke","readout_date":"2026-12-10","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Ischemic Stroke","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT05686642","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05686642","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:13b0ad2022a1d657b1e2a0adfebfacfcb176be7c7513954229dbc200477961d8"},{"nct_id":"NCT06151574","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","readout_date":"2026-12-10","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","ticker":null,"ticker_confidence":0.0,"conditions":"Lung Cancer, Non-squamous, Non-small Cell","enrollment":428,"url":"https://clinicaltrials.gov/study/NCT06151574","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06151574","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b59571f64b776689a15fbaac27151fc05b4f627aac9812f317f18a3262bec30a"},{"nct_id":"NCT07222917","title":"A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.","readout_date":"2026-12-10","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Chronic Kidney Disease and Hypertension","enrollment":222,"url":"https://clinicaltrials.gov/study/NCT07222917","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07222917","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:97098d127d35082951e983531e420a881fe273eca329bef7dd841eaaa2eb72fb"},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","readout_date":"2026-12-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Myelofibrosis","enrollment":237,"url":"https://clinicaltrials.gov/study/NCT03441113","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03441113","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e47a31df8cd2015745110c51147eacf274ad9a56b1075459929cf23247661a27"},{"nct_id":"NCT04879329","title":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","readout_date":"2026-12-11","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","ticker":null,"ticker_confidence":0.0,"conditions":"Urothelial Carcinoma","enrollment":372,"url":"https://clinicaltrials.gov/study/NCT04879329","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04879329","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1805ef5e1a2ce59bff8cee0f17aa1760a942c6ebd1006fb928736a0884a6b299"},{"nct_id":"NCT06778967","title":"A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus","readout_date":"2026-12-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","ticker":null,"ticker_confidence":0.0,"conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1100,"url":"https://clinicaltrials.gov/study/NCT06778967","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06778967","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:16e0a7f8abce5bafb9dc6c2c485f9d71feb1f703ff04978e2e93313b7b0bc1f8"},{"nct_id":"NCT07137910","title":"A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","readout_date":"2026-12-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Hepatitis B","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT07137910","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07137910","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f54a043f8503bf5f719f24e7a92e5328936698b8f519431eb6c579876219e7df"},{"nct_id":"NCT07230132","title":"Efficacy and Safety of ZT006 in Overweight and Obese Participants","readout_date":"2026-12-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Overweight , Obesity","enrollment":184,"url":"https://clinicaltrials.gov/study/NCT07230132","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07230132","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7d56ecf293ffe654577ce91cd372ecaf1523d11feb084cda4912ad049c674158"},{"nct_id":"NCT07376382","title":"A Phase \u2162 Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","readout_date":"2026-12-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"NSCLC","enrollment":680,"url":"https://clinicaltrials.gov/study/NCT07376382","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07376382","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:155bb2ea83f4923cecda272a56cb8d97dc5a78de8797df7f82ac64e2aa7b2fcb"},{"nct_id":"NCT07729475","title":"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events","readout_date":"2026-12-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Elevated Lipoprotein(a)","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07729475","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07729475","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b5983a65e47fc52432b74cce052ee5f7b3e80dde61c28fcbab00320d2d2f4a83"},{"nct_id":"NCT04957550","title":"To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis","readout_date":"2026-12-13","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Psoriatic Arthritis","enrollment":418,"url":"https://clinicaltrials.gov/study/NCT04957550","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04957550","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f8477f5e96f52350ab0af767f2f9f26e00d1e810678ee7de2fe35b3ef98e802b"},{"nct_id":"NCT06004661","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","readout_date":"2026-12-14","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":23,"url":"https://clinicaltrials.gov/study/NCT06004661","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06004661","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4c0dd26a48843f6f247d42e0e9322be7585bf8cee0a3acab385f8461cf2974c0"},{"nct_id":"NCT06122779","title":"Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)","readout_date":"2026-12-14","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","ticker":"BMY","ticker_confidence":0.9,"conditions":"Heart Failure","enrollment":227,"url":"https://clinicaltrials.gov/study/NCT06122779","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06122779","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:550322770752dbf0f66af39965ecbae99723e9b1bd2f9b28da8607e158afc468"},{"nct_id":"NCT06430866","title":"Pharmacokinetic Similarity Between ABP 234 and Keytruda\u00ae (Pembrolizumab)","readout_date":"2026-12-14","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","ticker":"AMGN","ticker_confidence":0.9,"conditions":"Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)","enrollment":163,"url":"https://clinicaltrials.gov/study/NCT06430866","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06430866","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:242fa9820d4ef89dde4974b6fa66eacb945e2b2bfcae21cd222907bf56f3cc95"},{"nct_id":"NCT06806137","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","readout_date":"2026-12-14","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Chickenpox","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06806137","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06806137","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ea9eff9f0edd9babeac00753d8706ff43d2bb6cabb30dfb8689f51417f12ebaa"},{"nct_id":"NCT07013201","title":"A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis","readout_date":"2026-12-14","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"LEO Pharma","ticker":null,"ticker_confidence":0.0,"conditions":"Palmoplantar Pustulosis","enrollment":135,"url":"https://clinicaltrials.gov/study/NCT07013201","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07013201","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2cbd9603ea398c0dc466b72f05b482e293e353d730cb6cf7c05a456db3c3f731"},{"nct_id":"NCT07184632","title":"A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity","readout_date":"2026-12-14","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","ticker":"NVO","ticker_confidence":0.95,"conditions":"Overweight; Obesity","enrollment":224,"url":"https://clinicaltrials.gov/study/NCT07184632","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07184632","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:10f305311eb1b7062037510721efc73c328973b808054de6b6e5a619817627e1"},{"nct_id":"NCT03817502","title":"Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Gedeon Richter Plc.","ticker":null,"ticker_confidence":0.0,"conditions":"Schizophrenia","enrollment":330,"url":"https://clinicaltrials.gov/study/NCT03817502","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03817502","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bfb3cdeda4ff55d9f460efba14634b3360267c851d18736bb8298532769baeb2"},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","ticker":"PMVP","ticker_confidence":0.9,"conditions":"Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Cancer; Ovarian Cancer; Endometrial Cancer; Prostate Cancer; Colorectal Cancer; Breast Cancer; Other Cancer; Locally Advanced; Head and Neck Cancer; Gall Bladder Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Small Cell Lung Carcinoma; NSCLC; NSCLC (Non-small Cell Lung Cancer); SCLC; Non-Small Cell Lung Carcinoma; Triple Negative Breast Cancer; TNBC; HER2+ Breast Cancer; Non-Small Cell Lung Cancer; ER/PR Positive Breast Cancer; HER2- Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; ER/PR(+), Her2(-) Breast Cancer","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT04585750","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04585750","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:48d41aa233d13d33e452e0fab86c30ec78dd4da46385abac2cc0814e6fdf081c"},{"nct_id":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"GV20 Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; pMMR/MSS Adenocarcinoma of the Colon or Rectum; Cutaneous Melanoma; Non-Small Cell Lung Cancer","enrollment":365,"url":"https://clinicaltrials.gov/study/NCT05669430","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05669430","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0fc348e11cac8ed358bf7fee6e6b777be96f36dcc97580da07ca6af31645289f"},{"nct_id":"NCT05678673","title":"Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","ticker":"EXEL","ticker_confidence":0.9,"conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":317,"url":"https://clinicaltrials.gov/study/NCT05678673","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05678673","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3f381f1fd76ffe9b82789b0b56aad3aeb7e7143994bf4f18c5c08c8acbef2aad"},{"nct_id":"NCT06513546","title":"A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"PLL TX AUSTRALIA PTY LTD","ticker":null,"ticker_confidence":0.0,"conditions":"Amyotrophic Lateral Sclerosis; ALS","enrollment":153,"url":"https://clinicaltrials.gov/study/NCT06513546","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06513546","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fc444a4cf0bd2314c090b92e084c413a32f7fda7f84959bcb105e36599e43312"},{"nct_id":"NCT06607627","title":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Generalized Myasthenia Gravis; gMG","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT06607627","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06607627","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8c21c3c64bf4368a2c23e58c4c0393001a92b0f1a91665fbc105a6c0e2c7ed23"},{"nct_id":"NCT06850623","title":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"EXACT Therapeutics AS","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":25,"url":"https://clinicaltrials.gov/study/NCT06850623","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06850623","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f2e851f199befb7371890a4a6facdbc92e2506e63ce24d7d4a3972fe12e8c976"},{"nct_id":"NCT07015437","title":"A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Cerus Corporation","ticker":"CERS","ticker_confidence":0.9,"conditions":"Healthy Subjects","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07015437","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07015437","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:56fe3256e1acc11947254eaba0b0164941296481e45cd06fbdfe16299e18a442"},{"nct_id":"NCT07427797","title":"A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","ticker":null,"ticker_confidence":0.0,"conditions":"Moderate to Severe Glabellar Lines","enrollment":309,"url":"https://clinicaltrials.gov/study/NCT07427797","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07427797","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a9e680a2ad9e831afc1c9dd87e8b11bcdb5751a0b21b616bc0e3439db2ab6766"},{"nct_id":"NCT07435428","title":"A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","readout_date":"2026-12-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","ticker":null,"ticker_confidence":0.0,"conditions":"Moderate to Severe Glabellar Lines","enrollment":1300,"url":"https://clinicaltrials.gov/study/NCT07435428","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07435428","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fe5f9d51483a9a39b350c1fffdc291c7e5be56e1c8043a48f827beefa0f4ddb4"},{"nct_id":"NCT05503264","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","readout_date":"2026-12-16","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis","enrollment":122,"url":"https://clinicaltrials.gov/study/NCT05503264","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05503264","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6884884f4c4069067d8dff80e460934384cf89583e7d75b041fd33c9c53d5582"},{"nct_id":"NCT06747338","title":"A Phase III Study of KN026 in Combination With HB1801 \u00b1 Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","readout_date":"2026-12-16","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Early or Locally Advanced HER2-positive Breast Cancer","enrollment":520,"url":"https://clinicaltrials.gov/study/NCT06747338","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06747338","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2acceb6410632054ee4bfc6e298cb5644645d8ee4119bcf0dda7e54280b31807"},{"nct_id":"NCT06730061","title":"A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)","readout_date":"2026-12-17","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Biliary Cholangitis","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT06730061","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06730061","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1e97e5756a7d545118d4c22a569b36f309af6973a44a0a768fd43122c712f5b0"},{"nct_id":"NCT06958536","title":"A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease","readout_date":"2026-12-17","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Crohn's Disease","enrollment":99,"url":"https://clinicaltrials.gov/study/NCT06958536","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06958536","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2f1cd7759245434410ca9d8aa02ee878d2b3b79f7ac1dc2ece36b75834447d28"},{"nct_id":"NCT06975722","title":"A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis","readout_date":"2026-12-17","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Ulcerative Colitis","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT06975722","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06975722","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:79a1488c3dd32129553b1ccaadb8a871c2aeaaf071bc40c1c8aa29196bf0fa64"},{"nct_id":"NCT06062810","title":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","readout_date":"2026-12-18","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06062810","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06062810","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:79a64d4a1d2bfcbaa79d67c22b5bd7c05b589ee7b729f6d5b83e32c9958de0f7"},{"nct_id":"NCT07145333","title":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","readout_date":"2026-12-18","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair","ticker":null,"ticker_confidence":0.0,"conditions":"SCLC","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT07145333","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07145333","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a864ea14036a6f9b4f32413fe1fd5bf71d773ae65babfd92ab3fa6b96d29983f"},{"nct_id":"NCT07246889","title":"Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)","readout_date":"2026-12-18","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Hepatitis B","enrollment":577,"url":"https://clinicaltrials.gov/study/NCT07246889","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07246889","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:552bd9a69abf88cc9264a18db160825e929d795d3e9f5bffa18c4ecfd5c74508"},{"nct_id":"NCT07158268","title":"A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis","readout_date":"2026-12-20","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Plaque Psoriasis","enrollment":220,"url":"https://clinicaltrials.gov/study/NCT07158268","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07158268","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9d7c2293f3d22b6716efe945e510f804485c36a4da8164f48a901c2ba1ecdaa7"},{"nct_id":"NCT07208058","title":"A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])","readout_date":"2026-12-20","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT07208058","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07208058","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1c8aa799798df884104a6cae9525cf594cc0b62634ebdba1ae1128445c8d6df9"},{"nct_id":"NCT06921850","title":"A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa","readout_date":"2026-12-21","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","ticker":null,"ticker_confidence":0.0,"conditions":"Hidradenitis Suppurativa","enrollment":43,"url":"https://clinicaltrials.gov/study/NCT06921850","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06921850","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:04a08adaeebf6d7b925c3d063b3aff82b4bbb7f7d3491b0fdf8a23030734488c"},{"nct_id":"NCT05468697","title":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)","readout_date":"2026-12-22","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","ticker":"MRK","ticker_confidence":0.6,"conditions":"Renal Cell Carcinoma","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT05468697","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05468697","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:80c6131be83102e7ffae91ef6b7a3dede37b39903ef7b6c58df30dbc429ec184"},{"nct_id":"NCT06544616","title":"A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease","readout_date":"2026-12-22","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","ticker":null,"ticker_confidence":0.0,"conditions":"Alzheimer Disease","enrollment":55,"url":"https://clinicaltrials.gov/study/NCT06544616","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06544616","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b9f1d6cdccd80b2de2c11ad780555c5aa99eb33265754e99e1d1d003f831247e"},{"nct_id":"NCT06769048","title":"A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy","readout_date":"2026-12-22","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","ticker":null,"ticker_confidence":0.0,"conditions":"Geographic Atrophy","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT06769048","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06769048","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b922a27e850ef0661a7d788f782a193fc12480467280acd91c2fddde50c7bbba"},{"nct_id":"NCT06856577","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","readout_date":"2026-12-22","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD","enrollment":311,"url":"https://clinicaltrials.gov/study/NCT06856577","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06856577","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:380f159c808c79940c5e306e63ef23276f3592eb99c4b9987ab3dc142e26a72c"},{"nct_id":"NCT07285291","title":"A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders","readout_date":"2026-12-22","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Taisho Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07285291","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07285291","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fb8cf550bfde54e2f470bf21c99c1c71b0ab1d4b994d9b707adee0a1473e15cb"},{"nct_id":"NCT07893600","title":"Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.","readout_date":"2026-12-22","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Healthgen Biotechnology Corp.","ticker":null,"ticker_confidence":0.0,"conditions":"Gastric Mucosal Lesion","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07893600","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07893600","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e5821d4001517b5cd4b58d0eaee5f34a5bfc3f6d40c3d2a75b0e3bfb5e5ff8b4"},{"nct_id":"NCT04427930","title":"Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Bio","ticker":null,"ticker_confidence":0.0,"conditions":"Knee Osteoarthritis","enrollment":129,"url":"https://clinicaltrials.gov/study/NCT04427930","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04427930","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c08b6b13a01b19e95357b4ebf7c708a46c991e33eeaef04bf65e98960d031f81"},{"nct_id":"NCT05692180","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Asthma","enrollment":94,"url":"https://clinicaltrials.gov/study/NCT05692180","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05692180","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c0aa1a149739b971d304941e9c2f3ae9807bc16dd6b28c73cda99c2cff3b3464"},{"nct_id":"NCT05849298","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"Prostatic Neoplasm","enrollment":49,"url":"https://clinicaltrials.gov/study/NCT05849298","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05849298","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d5a308efc4f7460242d55b1fce4b53831c1f20b1363bd02d37d1beecaba32ff0"},{"nct_id":"NCT05950165","title":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cho Pharma Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Hodgkin Lymphoma","enrollment":37,"url":"https://clinicaltrials.gov/study/NCT05950165","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05950165","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6a0386cdd9e80274c9f56ac33cbaddde109f962c6af82cfb54e6335f5b9ca6c0"},{"nct_id":"NCT06402331","title":"FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fusion Pharmaceuticals Inc.","ticker":"HTOO","ticker_confidence":0.6,"conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110,"url":"https://clinicaltrials.gov/study/NCT06402331","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06402331","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dac7928c026c6f7fbe901c8e0551bc4f0610c03a78de22f95fa5eb2e5b399223"},{"nct_id":"NCT06500702","title":"A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT06500702","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06500702","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bf47954f39b64e4939871e85074b07b4d25701e41b2410100baf2eebf743ed85"},{"nct_id":"NCT07260500","title":"A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Short Stature Children Born Small for Gestational Age (SGA)","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT07260500","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07260500","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:89d6a129d005d57e983d733265e52611b5cfe929990f86fec2e8f2ba4022bdbf"},{"nct_id":"NCT07672236","title":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","readout_date":"2026-12-23","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"OncoZenge AB","ticker":null,"ticker_confidence":0.0,"conditions":"Head & Neck Cancer; Oral Mucositis","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT07672236","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07672236","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c65243533648a3e58d41088905da0dc10d4f617bff8583d468fb179877a53d7c"},{"nct_id":"NCT06008119","title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","readout_date":"2026-12-24","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Shanghai Kechow Pharma, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Colorectal Cancer Metastatic","enrollment":165,"url":"https://clinicaltrials.gov/study/NCT06008119","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06008119","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b8b7f68bbfff70036308dbda687e4b08037f89798d3917214fad18cc74843fc8"},{"nct_id":"NCT06014528","title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","readout_date":"2026-12-24","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Ovarian Cancer Recurrent","enrollment":168,"url":"https://clinicaltrials.gov/study/NCT06014528","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06014528","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:913adc0567529cec8e414d89544c3ce4d6a9db44f095d13749299b9f3a3f7b8a"},{"nct_id":"NCT06783647","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","readout_date":"2026-12-24","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumour","enrollment":250,"url":"https://clinicaltrials.gov/study/NCT06783647","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06783647","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5fd506396434102b5154344f790c6ca303d7164f5d7f5ff693d6bbf6a04dbca5"},{"nct_id":"NCT05653453","title":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","readout_date":"2026-12-25","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced Pancreatic Cancer","enrollment":512,"url":"https://clinicaltrials.gov/study/NCT05653453","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05653453","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fd1d9809746eb0d034ced0b95e172c48a2a885f7ac1a7baeccd4119040c25f68"},{"nct_id":"NCT06525350","title":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel\uff08Albumin Bound\uff09Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer","readout_date":"2026-12-25","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression","enrollment":256,"url":"https://clinicaltrials.gov/study/NCT06525350","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06525350","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e39e7bab6d2835915c9c1720a4223c80bc6cb133835e544a571d2845a8eb9ddb"},{"nct_id":"NCT06740630","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","readout_date":"2026-12-25","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Chickenpox","enrollment":1840,"url":"https://clinicaltrials.gov/study/NCT06740630","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06740630","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f3206f1d08e7c4c28a5e0cd7a64df65d395d9465c6b194889f390ad3fcff5031"},{"nct_id":"NCT07219615","title":"A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.","readout_date":"2026-12-25","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Chronic Spontaneous Urticaria","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT07219615","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07219615","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8d15b32cd3c64d83aef299a83967f60606979734fae59b65d15f31873bc122ea"},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","readout_date":"2026-12-26","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanariaBio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Fallopian Tube Neoplasms; Fallopian Tube Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Peritoneal Cancer; Peritoneal Carcinoma; Peritoneal Neoplasms","enrollment":615,"url":"https://clinicaltrials.gov/study/NCT04498117","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04498117","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3a59d5744b1e4dbdff29ea40ca6234a215c0e6269fdf8448c9423a46d49db6b6"},{"nct_id":"NCT06212999","title":"A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa","readout_date":"2026-12-26","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","ticker":"INCY","ticker_confidence":0.9,"conditions":"Hidradenitis Suppurativa (HS)","enrollment":617,"url":"https://clinicaltrials.gov/study/NCT06212999","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06212999","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2d2b37db6139519f4782df5bf657fb82627605763c2f78f81bcdfac1a306286f"},{"nct_id":"NCT05563220","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","readout_date":"2026-12-27","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stemline Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer; Metastatic Breast Cancer","enrollment":435,"url":"https://clinicaltrials.gov/study/NCT05563220","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05563220","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:362ec8583631106163fe0b5ce2881ac8efc46270435476b5f3896ebd53793abd"},{"nct_id":"NCT07436221","title":"A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma","readout_date":"2026-12-27","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Asthma","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07436221","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07436221","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:54e93d8bce57fad16cd0319e62b3df51543f9e883fb050c7788914422486a9c0"},{"nct_id":"NCT07503886","title":"An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease","readout_date":"2026-12-27","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Domp\u00e9 Farmaceutici S.p.A","ticker":null,"ticker_confidence":0.0,"conditions":"Dry Eye Disease (DED)","enrollment":417,"url":"https://clinicaltrials.gov/study/NCT07503886","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07503886","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:092338fd5e3e354d208460c2d50bad7c4323a40ddf6e08e030d52b7087466360"},{"nct_id":"NCT07572396","title":"Phase II Study of Dysplasix\u2122 Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","readout_date":"2026-12-27","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Amplexd Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"High-risk HPV (Any Strain); LSIL, Low Grade Squamous Intraepithelial Lesion; ASC-US; HPV Infection; Cervical Abnormalities; Uterine Cervical Dysplasia","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT07572396","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07572396","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:146ebb976f98ebf83cb7d5819aa1aef178d3cf23189931b91888119eb4f5437b"},{"nct_id":"NCT04641247","title":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Ovarian Neoplasms; Breast Neoplasms","enrollment":37,"url":"https://clinicaltrials.gov/study/NCT04641247","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04641247","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3e987749108b79aad7fd9a30c2ed43d88b60fa50290b6f095acc721a2c48b4a3"},{"nct_id":"NCT05210868","title":"A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hematoma","enrollment":184,"url":"https://clinicaltrials.gov/study/NCT05210868","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05210868","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c00cb081907b39a791e51f9c5b8edbe12f3528547ed829960f8094eb53af0ba5"},{"nct_id":"NCT05555862","title":"Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Anal High Grade Squamous Intraepithelial Lesion; Anal Precancerous Condition; AIN 2/3; HPV Infection; Anal Dysplasia; HPV Disease","enrollment":17,"url":"https://clinicaltrials.gov/study/NCT05555862","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05555862","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:236520c08e96a5a6c460567df1f0fe0d9f6368a4e209819ccb3002973694109e"},{"nct_id":"NCT05672121","title":"Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Chengdu Origen Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Age-Related Macular Degeneration","enrollment":42,"url":"https://clinicaltrials.gov/study/NCT05672121","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05672121","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c45f0041c377ad8919c3ceab884ccd6cb082c03128657ea7f90bcb4bc217399c"},{"nct_id":"NCT06157827","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178,"url":"https://clinicaltrials.gov/study/NCT06157827","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06157827","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5c9d83c71c20188d8d72d64a6e9e1d1ebf7107442f08f0b2df8314c7ae2791ab"},{"nct_id":"NCT06551324","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06551324","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06551324","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bcaf7ebff7c296b3ce955eba8613fe600e5c33bbcd4a71e0682f023e2018e031"},{"nct_id":"NCT06925594","title":"Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease","readout_date":"2026-12-28","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Crohn's Disease","enrollment":228,"url":"https://clinicaltrials.gov/study/NCT06925594","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06925594","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0813d7268529d9b4cfb11f654d572bd42ba070f9549259c6d78b0ebc91d53e46"},{"nct_id":"NCT06786338","title":"A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases","readout_date":"2026-12-29","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Sanegene Bio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"IgA Nephropathy (IgAN); C3 Glomerulopathy; IC-MPGN","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT06786338","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06786338","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3255b400ddf137f9481ed275fa575b58e4ece3ff0c477400d7d67ee3b6aaa2e1"},{"nct_id":"NCT07477704","title":"A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia","readout_date":"2026-12-29","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","ticker":"REGN","ticker_confidence":0.9,"conditions":"Hypercholesterolemia","enrollment":438,"url":"https://clinicaltrials.gov/study/NCT07477704","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07477704","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:34f8c8c55bfffc1f0e2c90f76b6da56cf7d26b022742f53ca0d55e2e6ad007f4"},{"nct_id":"NCT07716865","title":"Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)","readout_date":"2026-12-29","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arctic Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Hereditary Cystatin C Amyloid Angiopathy (HCCAA); Hemorrhage Brain; Hemorrhage Cerebral","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT07716865","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07716865","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bf3fcc589b51b74d95ff2631a5435c52c1fa2c76e705f511a1c7ccff356f77a5"},{"nct_id":"NCT02962414","title":"Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"Tuberous Sclerosis Complex","enrollment":206,"url":"https://clinicaltrials.gov/study/NCT02962414","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02962414","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b4939dd1aca6735ea40dfde15c4758ed1c44343fe9af408190afd1eb071dd2a9"},{"nct_id":"NCT03259867","title":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Teclison Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hepatocellular Carcinoma; Gastric Cancer","enrollment":54,"url":"https://clinicaltrials.gov/study/NCT03259867","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03259867","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:04ff941d0a0a5b70d86b83e779423aba9fde74f1314f87ab70a24fd78b7a1fe3"},{"nct_id":"NCT03474770","title":"BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","ticker":"SUPN","ticker_confidence":0.9,"conditions":"Focal Impaired Awareness Seizures","enrollment":16,"url":"https://clinicaltrials.gov/study/NCT03474770","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03474770","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a4533512f424812dbdd7dd5ab8ef51fe6d6a72d8e714616d946dc4fc8da1c112"},{"nct_id":"NCT03592472","title":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Xynomic Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Renal Cell Carcinoma","enrollment":413,"url":"https://clinicaltrials.gov/study/NCT03592472","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03592472","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:422fde8b477e119d02c29563737d24a8fe18777720c45deef05cf7ee0ebbeb70"},{"nct_id":"NCT03667170","title":"KN035 for dMMR/MSI-H Advanced Solid Tumors","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":188,"url":"https://clinicaltrials.gov/study/NCT03667170","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03667170","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:77d65cb75e3a3c24efb1140f64dc82ca1e88578162b78cfb8ef02a56621e0510"},{"nct_id":"NCT04278131","title":"BS01 in Patients With Retinitis Pigmentosa","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Bionic Sight LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Retinitis Pigmentosa","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT04278131","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04278131","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:72c41633de606580f4e59332b2da23b083f78497de50b9518e46c76614299d23"},{"nct_id":"NCT04588922","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sellas Life Sciences Group","ticker":"SLS","ticker_confidence":0.9,"conditions":"Hematologic Malignancies","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT04588922","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04588922","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8ebed2936f876f962d1c34f37bb970fe4f19331ad507e109d9362b6fe62046be"},{"nct_id":"NCT04658862","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Urinary Bladder Neoplasms","enrollment":518,"url":"https://clinicaltrials.gov/study/NCT04658862","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04658862","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2ca806831d3e3c18a3fc728b4433c02efaf199e06ae7b5bcc1aa6805a4155d31"},{"nct_id":"NCT05023018","title":"NEO100 and High-Grade Meningioma","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","ticker":"NTHI","ticker_confidence":0.9,"conditions":"Residual, Progressive or Recurrent Grade II or III Meningioma","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT05023018","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05023018","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:de467e76f4628460bcbebf406a05de820b6dcbd3cc0bfbca83b8a50fffeb3b0c"},{"nct_id":"NCT05227664","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT05227664","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05227664","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6b55e6a029a1752e875c6ccbf831debd2abbca58959671696105e09fa51d63dc"},{"nct_id":"NCT05283226","title":"Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"NATCO Pharma Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":21,"url":"https://clinicaltrials.gov/study/NCT05283226","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05283226","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7c914c55e25044ea89a2c139a9181d7466d19b98257efcfe55e67f548bd397e2"},{"nct_id":"NCT05335993","title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanariaBio Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Recurrent Ovarian Cancer; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Ovarian Cancer; Recurrent Fallopian Tube Cancer; Peritoneal Cancer; Recurrent Carcinoma of Ovary; Adenocarcinoma of Ovary","enrollment":10,"url":"https://clinicaltrials.gov/study/NCT05335993","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05335993","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bd847ab348f59c91b58b48e08b7b67593719104dbc41cce0fc7d2e4a8f608f50"},{"nct_id":"NCT05486104","title":"Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Moderate to Severe Ulcerative Colitis","enrollment":92,"url":"https://clinicaltrials.gov/study/NCT05486104","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05486104","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8171cd1badef2ab34a507a5244bf57d6db70f5cc28d2b38efa51f489bb403de2"},{"nct_id":"NCT05563844","title":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Diffuse Large B Cell Lymphoma\uff0cDLBCL","enrollment":74,"url":"https://clinicaltrials.gov/study/NCT05563844","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05563844","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:925b94a8e421c5de901f0b653fa9321174235dae9a7861b78d98339f8b291d68"},{"nct_id":"NCT05631262","title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"SKBBY","ticker_confidence":0.6,"conditions":"Selected Subjects With Advanced Solid Tumors","enrollment":321,"url":"https://clinicaltrials.gov/study/NCT05631262","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05631262","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:44264ecf13fddc66d5b3b4023f095c38a8af6a50d2f043a5116ad037baf779a2"},{"nct_id":"NCT05789056","title":"Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Quoin Pharmaceuticals","ticker":"QNRX","ticker_confidence":0.9,"conditions":"Netherton Syndrome","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT05789056","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05789056","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8a1b0e5d69c05e995f61a37e0fdaedf72bc9bb931230d2ee8de05f25423c18a3"},{"nct_id":"NCT05909397","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Breast Cancer","enrollment":59,"url":"https://clinicaltrials.gov/study/NCT05909397","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05909397","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:126ff6cac34e9107aa7ef1380a8663ef3ec91c8a3f4c4c76632d002a60f30072"},{"nct_id":"NCT06088004","title":"Phase \u2160/\u2161 Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult","enrollment":218,"url":"https://clinicaltrials.gov/study/NCT06088004","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06088004","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2f8ab7108d8b887f9d74c8dc64ad15c193d0bb7cb374af30d35b8d88c23c3b6a"},{"nct_id":"NCT06194734","title":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Esophageal Squamous Cell Carcinoma","enrollment":490,"url":"https://clinicaltrials.gov/study/NCT06194734","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06194734","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:102f1f845ab6bf8f1fb61a3043c4c0082292b7a83115299a7b99fdd085bd3a98"},{"nct_id":"NCT06206733","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma","enrollment":780,"url":"https://clinicaltrials.gov/study/NCT06206733","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06206733","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4f05f04ccc547fe932c1584722dc1d94883fa067d032d762c2a51098443377c2"},{"nct_id":"NCT06238843","title":"A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":464,"url":"https://clinicaltrials.gov/study/NCT06238843","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06238843","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3bcff6a1bc65254cf16974553b979f1daf66fa4878d295645377d9156b74fd94"},{"nct_id":"NCT06388941","title":"Iptacopan in Patients With ANCA Associated Vasculitis","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT06388941","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06388941","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:77cbfd3d6704a02ffb3902851059b8dd213b469222531707b467ee095227e5c1"},{"nct_id":"NCT06447597","title":"A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Generalized Myasthenia Gravis","enrollment":104,"url":"https://clinicaltrials.gov/study/NCT06447597","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06447597","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7090960e26cd39756168cb37e81b2bf4ae5e6d4a0162e3d6824059e8cca5b1e3"},{"nct_id":"NCT06465563","title":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Biliary Tract Cancer","enrollment":93,"url":"https://clinicaltrials.gov/study/NCT06465563","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06465563","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9bbb691c0298cbab4cc394f6d91eb6b4f50e57c9e9328a7304d8bd49c4bf376e"},{"nct_id":"NCT06468358","title":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"L & L Bio Co., Ltd., Ningbo, China","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor","enrollment":194,"url":"https://clinicaltrials.gov/study/NCT06468358","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06468358","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:45769517eb7572e8c1399302128953198e89a0faf36127907db4b013bbff9517"},{"nct_id":"NCT06491043","title":"Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Meribank Biotech Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Obstructive Pulmonary Disease","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06491043","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06491043","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:13a37b919dfdbb888543a8470cf2c8672838eaf7fbf2c8a46b2f469f4929ac06"},{"nct_id":"NCT06514794","title":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Allotera Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma","enrollment":125,"url":"https://clinicaltrials.gov/study/NCT06514794","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06514794","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:df1640e493bdd2e68cbc1b9f6c50cb6799608704f678d6312df06470a747f0ac"},{"nct_id":"NCT06516055","title":"Study of S1B-408 in Women With Orgasmic Dysfunction","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"S1 Biopharma, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Orgasmic Disorder","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT06516055","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06516055","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b91e07b06c5d32f510548d942b9af73dc9539753d04816b593f737492ac0be22"},{"nct_id":"NCT06547151","title":"Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amorphical Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hypoparathyroidism","enrollment":62,"url":"https://clinicaltrials.gov/study/NCT06547151","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06547151","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2a6919f79d2eae9d3be69ddfe41d448ac5bc308a8a3423fb5e644934f7131254"},{"nct_id":"NCT06559306","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Depressive Disorder, Major","enrollment":752,"url":"https://clinicaltrials.gov/study/NCT06559306","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06559306","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0bc25856a581fa6d686691d6f9762f7a694658fdb1af21632c45e88aa73dfab4"},{"nct_id":"NCT06577519","title":"Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","enrollment":1000,"url":"https://clinicaltrials.gov/study/NCT06577519","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06577519","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:76910fce4a46f43bc10be2dff9d49a27013ccffb46e2f5c7d8860a61be6cbb7c"},{"nct_id":"NCT06646055","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":110,"url":"https://clinicaltrials.gov/study/NCT06646055","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06646055","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c6ebf3ca6a95f339708ec9544c724ef2f4e103cae6ed0cfbd24a358427c4fd6b"},{"nct_id":"NCT06658353","title":"Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced Solid Tumor","enrollment":54,"url":"https://clinicaltrials.gov/study/NCT06658353","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06658353","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ef42466fe478ee8715cd7c335689a854ce79553cf63a801e205d03b9c00c34d7"},{"nct_id":"NCT06751485","title":"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers","enrollment":430,"url":"https://clinicaltrials.gov/study/NCT06751485","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06751485","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3fc15cfd8b52b3fd1aec064340bb39b7a880fc6fbe0df8bf045e0731ff77d456"},{"nct_id":"NCT06782373","title":"A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","ticker":null,"ticker_confidence":0.0,"conditions":"VEXAS; VEXAS Syndrome","enrollment":156,"url":"https://clinicaltrials.gov/study/NCT06782373","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06782373","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8291111bd36753901603687ce49060cdc59ca6ab03a6c77d3264517566b03cc0"},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastatic; Biliary Tract Cancer; Gastric Carcinoma; Gastroesophageal Junction Adenocarcinoma","enrollment":240,"url":"https://clinicaltrials.gov/study/NCT06792435","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06792435","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:998d4e20664776325b6249ccfd579c657ce20c553791b1a71a121b57ee69ec7a"},{"nct_id":"NCT06799247","title":"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cartesian Therapeutics","ticker":"RNAC","ticker_confidence":0.9,"conditions":"Myasthaenia Gravis","enrollment":128,"url":"https://clinicaltrials.gov/study/NCT06799247","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06799247","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cea3e477076872f2d4ebe426b098806f200ddc24ee10bc7784e3adc5a97e40f8"},{"nct_id":"NCT06813651","title":"Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"ThromBio Pty. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Ischemic Stroke; Tandem Occlusion","enrollment":78,"url":"https://clinicaltrials.gov/study/NCT06813651","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06813651","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e56cf46189a2ce1e51f30dfc42afc355e6dde71024ba745c7fb97201bf536272"},{"nct_id":"NCT06832722","title":"A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"4TEEN4 Pharmaceuticals GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Shock, Cardiogenic","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06832722","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06832722","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d356d4e390f15f4dc6cc526f082445f31ddb94e55d2c29bd05f9d0d401ea5248"},{"nct_id":"NCT06933914","title":"Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06933914","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06933914","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:864e256a42b1a3c8c501d9a4a2ed746acd058384e4935e9bb9e88776f65ad943"},{"nct_id":"NCT06953466","title":"Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Quoin Pharmaceuticals","ticker":"QNRX","ticker_confidence":0.9,"conditions":"Netherton Syndrome","enrollment":8,"url":"https://clinicaltrials.gov/study/NCT06953466","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06953466","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:221a406ab38c06d7a5ea74784ff8d5dee0c32c0dff90b6408670081731350c8a"},{"nct_id":"NCT07055295","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","ticker":"SVA","ticker_confidence":0.9,"conditions":"Rabies","enrollment":390,"url":"https://clinicaltrials.gov/study/NCT07055295","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07055295","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:593939fcc41f568c67647efdc2509998fc7d8629cabb12812ccb6a4234e85b8d"},{"nct_id":"NCT07072728","title":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Psyence Australia Pty Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Adjustment Disorder; Adjustment Disorder With Anxious Mood; Cancer; Cancer Cachexia; Cancer of Endometrium; Cancer of Kidney; Cancer of Prostate; Cancer of the Breast; Cancer of Stomach; Cancer Melanoma Skin; Cancer Pancreas","enrollment":87,"url":"https://clinicaltrials.gov/study/NCT07072728","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07072728","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c5c1d0ca6cde4a4f9ef4461f74c7935609c830534dacc77c8f0fcb38fa1f7d06"},{"nct_id":"NCT07106892","title":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Colorectal Cancer (CRC)","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07106892","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07106892","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f147c477f6b00d771a224c6531513151b209bbb57b22f25e6d647642e594610e"},{"nct_id":"NCT07118241","title":"A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 \u00b5G/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJ\u00d6GREN'S RELATED DRY EYE DISEASE","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Lubris Bio Pty Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Sj\u00f6gren's Syndrome","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT07118241","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07118241","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5b9d813d36cc779eb1d7e880a321f3833a7d3695e6be6257251916830afb3d81"},{"nct_id":"NCT07118449","title":"Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"XyloCor Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Coronary Artery Disease (CAD)","enrollment":116,"url":"https://clinicaltrials.gov/study/NCT07118449","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07118449","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8473eab3d5983e51cb14f801d34ab0c9e55b36cabf423a1f36ae81f2ddfeec1c"},{"nct_id":"NCT07161843","title":"Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Ebima Clifford Okundaye","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Renal Failure (ARF); Acute Tubular Necrosis","enrollment":500,"url":"https://clinicaltrials.gov/study/NCT07161843","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07161843","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c2ee961c34f938f6bfbcb740ce221e8709c8080b92a7d0d471f9cb5cc2b6ac90"},{"nct_id":"NCT07169552","title":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"HC Biopharma Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"NSCLC","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT07169552","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07169552","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d91a482c505c1c851f5a45999664d7f2e8fef2d016449d76b5597aaf03ffc9dc"},{"nct_id":"NCT07174297","title":"Acotiamide vs Itopride in Postprandial Distress Syndrome","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Getz Pharma","ticker":null,"ticker_confidence":0.0,"conditions":"Postprandial Distress Syndrome","enrollment":152,"url":"https://clinicaltrials.gov/study/NCT07174297","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07174297","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ef95873f4fbfc2af7cee68ce9f2d4fdf4d3f55dfec03d03f2c5143be32bedc33"},{"nct_id":"NCT07214571","title":"A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shionogi","ticker":null,"ticker_confidence":0.0,"conditions":"Respiratory Syncytial Virus Infections","enrollment":192,"url":"https://clinicaltrials.gov/study/NCT07214571","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07214571","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c6e15bc979e08d2434c49ee3a5f7de53430a2d95e01b195e25192be91edff60e"},{"nct_id":"NCT07388680","title":"Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Radiation-induced Lung Injury; Immune-related Pneumonia","enrollment":298,"url":"https://clinicaltrials.gov/study/NCT07388680","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07388680","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0d52b3b4ba0ff15dd0c1e9d58fb03aea965804ab4e878fd09d74aed4035db6d8"},{"nct_id":"NCT07459738","title":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer","readout_date":"2026-12-30","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07459738","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07459738","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ac64c108c56770fc3e3842d28a7e13c36c9eb896559d94ea282407c38d708c06"},{"nct_id":"NCT01297400","title":"Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Skingenix, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Burns","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT01297400","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT01297400","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:176eb81482e0e201c9576754dad4e6c63db64699a36e860d8097572a50a251e9"},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Waldenstrom Macroglobulinemia; Chronic Graft Versus Host Disease","enrollment":539,"url":"https://clinicaltrials.gov/study/NCT01804686","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT01804686","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:41cd2f8701a7ea45372af10ff064dc790e6ec58aff93cd24a55458ffd48545c2"},{"nct_id":"NCT02320435","title":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumors","enrollment":154,"url":"https://clinicaltrials.gov/study/NCT02320435","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02320435","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:874911a220c2b7313c95f3ef5a1c210acca50842c16757c6dc8d97994aaa013d"},{"nct_id":"NCT02912949","title":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Partner Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Fusion; NRG1 Fusion","enrollment":250,"url":"https://clinicaltrials.gov/study/NCT02912949","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT02912949","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7a0253a2c98a399de8367671cb06576f90f6e2fe21efe5ff3f1577f7f74429d5"},{"nct_id":"NCT03708965","title":"An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"JCR Pharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Mucopolysaccharidosis II","enrollment":19,"url":"https://clinicaltrials.gov/study/NCT03708965","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03708965","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:97c0b4b1bcc54122c2476b763e0a24d58130ef519e6fb69a7d02907d9154c64d"},{"nct_id":"NCT03887455","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Early Alzheimer's Disease","enrollment":1906,"url":"https://clinicaltrials.gov/study/NCT03887455","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03887455","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4486f46b51db56276563f0b6de0c73650fd026fbb9179febd44fb94b0f5f41c7"},{"nct_id":"NCT03994471","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","ticker":null,"ticker_confidence":0.0,"conditions":"End Stage Renal Disease","enrollment":170,"url":"https://clinicaltrials.gov/study/NCT03994471","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT03994471","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c8468828609700f31d3af620b588040b0d26c4f9691cb0df3f8adfa5a419e447"},{"nct_id":"NCT04020055","title":"A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amicus Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Fabry Disease","enrollment":14,"url":"https://clinicaltrials.gov/study/NCT04020055","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04020055","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:38eae947c60ed67ea32e43abb7e403e530a81d2c288027481c647dc8cd5571f3"},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoC4, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma","enrollment":733,"url":"https://clinicaltrials.gov/study/NCT04140526","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04140526","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:358ff91ea6ed3393998423ed0740655512da548b9ec5512915816bcd399ca1f9"},{"nct_id":"NCT04170283","title":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","ticker":"ONC","ticker_confidence":0.9,"conditions":"B-cell Malignancies","enrollment":955,"url":"https://clinicaltrials.gov/study/NCT04170283","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04170283","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fc5263b937e62ce144e2317a80eee51c399891adaf46a2f01520833964df1fb9"},{"nct_id":"NCT04180371","title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"BicycleTx Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer; Non-small Cell Lung Cancer; Head and Neck Cancer; Triple Negative Breast Cancer; Gastric/Upper Gastrointestinal Cancer","enrollment":288,"url":"https://clinicaltrials.gov/study/NCT04180371","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04180371","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:df4f08ec84b9fd35049e910233a391c89b2c9f25b43401548eb00d95c7b3286a"},{"nct_id":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapse","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT04271644","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04271644","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:605a032b540a1a74aa7b4f39cb62ad81def53b97dafa1f93b9f3673c12efe7d0"},{"nct_id":"NCT04318041","title":"Evaluation of the Structural Modification Effect of Diacerein (Artrodar\u00ae) in Knee Osteoarthritic Patients","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"TRB Chemedica","ticker":null,"ticker_confidence":0.0,"conditions":"Knee Osteoarthritis","enrollment":128,"url":"https://clinicaltrials.gov/study/NCT04318041","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04318041","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9eb8275b0d110098025ba59e0bfa19a54d788e14fbb44447162d052609872e26"},{"nct_id":"NCT04553133","title":"PF-07104091 as a Single Agent and in Combination Therapy","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer","enrollment":157,"url":"https://clinicaltrials.gov/study/NCT04553133","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04553133","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49cffda93a1454af88c92131729097517df93877e780917e7ecd6c271abd9cea"},{"nct_id":"NCT04691804","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496,"url":"https://clinicaltrials.gov/study/NCT04691804","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04691804","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a2cd3274c35f88fa55501192e869f24b030d6285d496c1be12b9c63614d4cdfb"},{"nct_id":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapse","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT04776330","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04776330","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:610146fdb411a0faae471eb2ad033fdea6d200fa057afc3d7143e3ad9f4dccb9"},{"nct_id":"NCT04781634","title":"a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"B-ALL","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT04781634","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04781634","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c191bf0cccddb53835d8c05ce18dd22130fada5ae9863eda0cdd09d8b009236a"},{"nct_id":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Miltenyi Biomedicine GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Lymphoma; Central Nervous System Lymphoma; Mantle Cell Lymphoma (MCL); Richter Transformation; Transplant-ineligible 2nd Line DLBCL","enrollment":315,"url":"https://clinicaltrials.gov/study/NCT04792489","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04792489","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c3818b7030d7d2745c2e350892f40d4e4cf868c4193ecfedff9fe53becfcdb7a"},{"nct_id":"NCT04819841","title":"Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Kamau Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Sickle Cell Disease","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT04819841","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04819841","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:64fb3fdcd73182c274062c9a3d66b10f0aa09fb658b211d88fd892c08e772c11"},{"nct_id":"NCT04862468","title":"Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Mercator MedSystems, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Thrombosis, Deep Vein; Iliofemoral; Thrombosis","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT04862468","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04862468","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f28ea9f0ac4beb27b3ea09d4af14e21104284129d97a59b0eba40dea6dcc8726"},{"nct_id":"NCT04977024","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"GeoVax, Inc.","ticker":"GOVX","ticker_confidence":0.6,"conditions":"COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myeloma","enrollment":63,"url":"https://clinicaltrials.gov/study/NCT04977024","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04977024","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cf316224395f091f2ed47ff90de7d148a1ca4bbe02b83ca6a7cc9d0fecb62505"},{"nct_id":"NCT05004129","title":"Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"AMO Pharma Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Congenital Myotonic Dystrophy","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT05004129","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05004129","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e81bcb2cad2ecdb9fc18f6933e97baff581634b96772c396b5995dfc89a46282"},{"nct_id":"NCT05059522","title":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors","enrollment":77,"url":"https://clinicaltrials.gov/study/NCT05059522","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05059522","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f974f76672fc4474ed163e2a77a0b07b30bce4d43cfc5043a57a91cd6246b4f9"},{"nct_id":"NCT05198323","title":"A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lumosa Therapeutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Ischemic Stroke","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT05198323","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05198323","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b5636ef14f24b94fc581cd91152512460c28e7269e9bd9a4cddb41c9ad810513"},{"nct_id":"NCT05229497","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Malignant Tumors","enrollment":154,"url":"https://clinicaltrials.gov/study/NCT05229497","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05229497","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8143bbc5e474ce2abff6642fd237f8b52d96b72ac25a64c17f18cccbf7ca16ba"},{"nct_id":"NCT05257590","title":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"TaiRx, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Hepatocellular Carcinoma; Advanced Cancer","enrollment":95,"url":"https://clinicaltrials.gov/study/NCT05257590","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05257590","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cb700ba65a6a91d637dfc435137e0b08c1a55a623f5d483d6f04f7e46813ecbc"},{"nct_id":"NCT05265091","title":"A Study of KL590586 in Patients With Advanced Solid Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"SKBBY","ticker_confidence":0.6,"conditions":"Advanced Solid Tumor","enrollment":414,"url":"https://clinicaltrials.gov/study/NCT05265091","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05265091","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:52ae9f4c3b0df68970f5fff7552c30f4e0b281c49c4a3d415eda222d9cca7431"},{"nct_id":"NCT05269316","title":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Impact Therapeutics, Inc.","ticker":"IBO","ticker_confidence":0.6,"conditions":"Solid Tumor; Advanced Solid Tumor","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT05269316","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05269316","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:73c1dd75be184c8ab28cf2927a4bbf762fb9619c375032d52cca6fa6fe3ed155"},{"nct_id":"NCT05302284","title":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Urothelial Carcinoma; HER2-expressing","enrollment":452,"url":"https://clinicaltrials.gov/study/NCT05302284","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05302284","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1eb430866eea981b1aea557382876bbfe9234340c80576742d7f1e993d3eb716"},{"nct_id":"NCT05303532","title":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ENROLLING_BY_INVITATION","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Cancer","enrollment":214,"url":"https://clinicaltrials.gov/study/NCT05303532","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05303532","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f6e92558906f98d6aa924906e06140dcaab6ac03ec31d22aafc100f5ba258d34"},{"nct_id":"NCT05326243","title":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pell Bio-Med Technology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Follicular Lymphoma Grade 3A; Follicular Lymphoma Grade 3B","enrollment":49,"url":"https://clinicaltrials.gov/study/NCT05326243","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05326243","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f009a4d467bc7ee2f91cb74e955166c0a42317bb92c86ca1a976964f7d10b88a"},{"nct_id":"NCT05413655","title":"A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Excelsior","ticker":null,"ticker_confidence":0.0,"conditions":"Alzheimer Disease","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT05413655","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05413655","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:db39d4a66857035f335af5a0278fc7f74106bfe987f14f2dda7a0ea6f2b67b75"},{"nct_id":"NCT05424835","title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","enrollment":381,"url":"https://clinicaltrials.gov/study/NCT05424835","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05424835","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8c56209b291d137c75ba78f79fcacfc4add2c43160fcf29bee25c0f09cad4583"},{"nct_id":"NCT05456425","title":"A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cloudbreak Therapeutics, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Pterygium","enrollment":660,"url":"https://clinicaltrials.gov/study/NCT05456425","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05456425","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:74620cc3d4581c1ae6eb20274a20a77679b2e2bb095d3cf947701c1f6cd7a19d"},{"nct_id":"NCT05464784","title":"MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"MediciNova","ticker":"MNOV","ticker_confidence":0.9,"conditions":"Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT05464784","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05464784","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:af008989f2372571add18e82499bb70630f8661b6d92fb9ea7a97704ec7a1962"},{"nct_id":"NCT05565807","title":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT05565807","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05565807","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cea1f0544283d7c5c6307b04b674315a48e2c7a166cf1110d9d32716d0b3714f"},{"nct_id":"NCT05645692","title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Urothelial Cancer","enrollment":204,"url":"https://clinicaltrials.gov/study/NCT05645692","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05645692","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:edb18c6fe14879f7b82aa5003d3756a94002641d4f4d14f204d1dfabac647f5a"},{"nct_id":"NCT05649748","title":"An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insmed Incorporated","ticker":"INSM","ticker_confidence":0.9,"conditions":"Pulmonary Arterial Hypertension","enrollment":91,"url":"https://clinicaltrials.gov/study/NCT05649748","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05649748","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a13f9f2cf20c1327949e37a93a03b4730c0095cfb05dd137355a7ea9367f4099"},{"nct_id":"NCT05658575","title":"Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Olatec Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Gout Flare; Gout Attack; Gout Flare; Gouty Arthritis; Gout; Arthritis; Joint Pain","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT05658575","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05658575","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f18234e7c303ecff3f247df9cd454113f3e92c7d57fec1a4d835568c3c5cea9c"},{"nct_id":"NCT05672576","title":"A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viatris Innovation GmbH","ticker":"VTRS","ticker_confidence":0.6,"conditions":"Lupus Erythematosus, Systemic","enrollment":451,"url":"https://clinicaltrials.gov/study/NCT05672576","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05672576","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5e31799c1fcb082ea9dd962ac61d5a586e8672c685f713b87877494053f18d9f"},{"nct_id":"NCT05754450","title":"An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"AUG Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Leukocyte Adhesion Deficiency","enrollment":2,"url":"https://clinicaltrials.gov/study/NCT05754450","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05754450","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0eeae70b64116aeca2293058c09c592b144e86eccf08613a684be67b5a91be9a"},{"nct_id":"NCT05756322","title":"The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Lin BioScience, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsed or Resistant Acute Leukaemias","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT05756322","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05756322","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:368b7ba228f449d7299ac6a348ca5cd891f4ed1a02622162fa4f4697502d809a"},{"nct_id":"NCT05867420","title":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"AskGene Pharma, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":594,"url":"https://clinicaltrials.gov/study/NCT05867420","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05867420","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fd19b6104dbde3b45f474639c57d54a9133ffe22746c7b7d8aa4b94c634d177d"},{"nct_id":"NCT05872347","title":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer Brain Metastases","enrollment":52,"url":"https://clinicaltrials.gov/study/NCT05872347","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05872347","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5d9763902a41c3262d4d789802bbeb1cdcae875f139aa104b7bb705a0bb9d5a1"},{"nct_id":"NCT05894239","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Breast Cancer","enrollment":230,"url":"https://clinicaltrials.gov/study/NCT05894239","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05894239","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:873a69df5e815f473109b1298d398f522271b5747f2497256caa29c2ab901626"},{"nct_id":"NCT05910528","title":"Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","ticker":null,"ticker_confidence":0.0,"conditions":"Crohns Disease","enrollment":21,"url":"https://clinicaltrials.gov/study/NCT05910528","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05910528","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b8161bf73c36677b6198142f56ca5d63c1f9e180e5bd0ab4470e6422649f5469"},{"nct_id":"NCT05913752","title":"A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Clearmind Medicine Inc.","ticker":"CMND","ticker_confidence":0.9,"conditions":"Alcohol Use Disorder","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT05913752","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05913752","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a89499cfc1fca5a79bea89f1d25f95ec5abce843a91d8fcf44bab3098b6fce07"},{"nct_id":"NCT05944224","title":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":63,"url":"https://clinicaltrials.gov/study/NCT05944224","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05944224","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49a1dfafc36e615717d994c7b97182855e31058fc5d9511ed13b678e9ac35316"},{"nct_id":"NCT05948982","title":"Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Asia Cell Therapeutics (Shanghai) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Decompensated Liver Cirrhosis","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT05948982","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05948982","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6c74e03b2236b20e73aea844b8049349560dd7408c65b45279d077159a01b4cb"},{"nct_id":"NCT06008288","title":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"KRAS P.G12C; Pancreatic Cancer; Solid Tumor","enrollment":88,"url":"https://clinicaltrials.gov/study/NCT06008288","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06008288","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a9fd15b7068512fb1c6018547e676e0b861ee20ae7423155d38942a624dafed9"},{"nct_id":"NCT06011109","title":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aveta Biomics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Glioma; Glioblastoma Multiforme","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT06011109","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06011109","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ac6ae01310adb30775968b02b98c29d2584751969fa10acdbd63133923150338"},{"nct_id":"NCT06055439","title":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chimeric Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer","enrollment":135,"url":"https://clinicaltrials.gov/study/NCT06055439","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06055439","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:464e247fdc059d6d64234c02489d009a9cb6e51e9cc67763368f2eefb255cf96"},{"nct_id":"NCT06079112","title":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Urothelial Carcinoma","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT06079112","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06079112","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:767fec1b8f482e81aaa1c31a915a23917e044d4da41df772e63037586e0881fd"},{"nct_id":"NCT06081959","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"SKBBY","ticker_confidence":0.6,"conditions":"Metastatic Breast Cancer","enrollment":376,"url":"https://clinicaltrials.gov/study/NCT06081959","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06081959","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e8df0972b3fbd3ea245ed772fa1c6a672ba2ed227dbe1646b822dacbda3d96ae"},{"nct_id":"NCT06094179","title":"Evaluate the Safety, Tolerability of BAT6026","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bio-Thera Solutions","ticker":null,"ticker_confidence":0.0,"conditions":"Dermatitis, Atopic","enrollment":33,"url":"https://clinicaltrials.gov/study/NCT06094179","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06094179","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d012c0f548125df20760640034712c3399ec362fe97b9ad6e93b84d3917ebae2"},{"nct_id":"NCT06104566","title":"Global Trial in APG2575 for Patients With CLL/SLL","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","ticker":"AAPG","ticker_confidence":0.9,"conditions":"CLL/SLL","enrollment":400,"url":"https://clinicaltrials.gov/study/NCT06104566","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06104566","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:213b44dd0b8a334cb10c817fba398aeab527392532286cce85d89ad62d6a5bf7"},{"nct_id":"NCT06125327","title":"SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Guangzhou JOYO Pharma Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Idiopathic Pulmonary Fibrosis","enrollment":210,"url":"https://clinicaltrials.gov/study/NCT06125327","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06125327","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9d5c3ff2ec2517074f72fca8a425a9d3cd8d915ca135df644dac3e533d84fbac"},{"nct_id":"NCT06136507","title":"Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Gensciences Biopharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Severe Hemophilia A","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT06136507","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06136507","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:07a74e9b465ca3f3b01cb1f5cadc2e732ef6c13eb9b3c20fe5ee03354f98590c"},{"nct_id":"NCT06138743","title":"Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Sarepta Therapeutics, Inc.","ticker":"SRPT","ticker_confidence":0.9,"conditions":"Myotonic Dystrophy 1","enrollment":78,"url":"https://clinicaltrials.gov/study/NCT06138743","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06138743","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8981d8a48f94ed89baf671854829441c1725426be3608cfcb1cbdd760e66e2a7"},{"nct_id":"NCT06189209","title":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Rhizen Pharmaceuticals SA","ticker":null,"ticker_confidence":0.0,"conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT06189209","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06189209","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ab2bced2bf4505b9d4b105058e88b65103bc2bfd52744e8f7a472b02d05b49f8"},{"nct_id":"NCT06197568","title":"Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Azure Biotech Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Vulvo Vaginal Atrophy (VVA)","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06197568","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06197568","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b150ae7bd48edaa193d0bd4fa88b7df60cd41837061d1af1e631e368ef93cbe4"},{"nct_id":"NCT06206564","title":"Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Anal High-grade Squamous Intraepithelial Lesion; Anal HSIL; Anal HPV Infection; AIN","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT06206564","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06206564","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0083e93e246b219c327fbc420d08c283d31a1d8b739844cc058204a460dda42a"},{"nct_id":"NCT06214143","title":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":68,"url":"https://clinicaltrials.gov/study/NCT06214143","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06214143","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:685ff93ea2e75b6424c86ee1ae2db48aa8dec254abbaf52eb9571755fe8f8b12"},{"nct_id":"NCT06281119","title":"Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC\u00ae) in Women Living With HIV Aged 15-25 Years","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Human Papillomavirus Infection","enrollment":450,"url":"https://clinicaltrials.gov/study/NCT06281119","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06281119","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:01472b25f04edea4643014fe268f7735bf136ccd2e541238d0945a3878257ae5"},{"nct_id":"NCT06284265","title":"Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Materia Medica Holding","ticker":null,"ticker_confidence":0.0,"conditions":"Cystitis Chronic; Cystitis Bacterial; Recurrence of Chronic Bacterial Cystitis","enrollment":415,"url":"https://clinicaltrials.gov/study/NCT06284265","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06284265","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3dbcb63ed94840fd8f5f62767c0af8d90922733c58b994f6d83cd9ef68ad8688"},{"nct_id":"NCT06328712","title":"Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"ENCell","ticker":null,"ticker_confidence":0.0,"conditions":"Charcot-Marie-Tooth Disease Type 1A","enrollment":27,"url":"https://clinicaltrials.gov/study/NCT06328712","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06328712","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e6cdb3291891a5ca99175fc46b754f22f54453c1bf40721abd8cb83192c6e837"},{"nct_id":"NCT06343064","title":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Small-Cell Lung Cancer","enrollment":156,"url":"https://clinicaltrials.gov/study/NCT06343064","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06343064","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:90b3f06f8698e90cf15dc8c9e217e8554da221b6a8adcceb325ca9d0c205e7d1"},{"nct_id":"NCT06369831","title":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Abscint NV/SA","ticker":null,"ticker_confidence":0.0,"conditions":"Metastatic Breast Cancer; Metastatic Solid Cancer","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06369831","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06369831","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8f004122b86799e27a644885ecd994471cb9dde53f97942d8d0c2365a0ece263"},{"nct_id":"NCT06375733","title":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Large B-cell Lymphoma","enrollment":51,"url":"https://clinicaltrials.gov/study/NCT06375733","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06375733","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fec40d1bb1cb238495b851e1bc92771d8b8d34665d61fb1181c4f6d555c91a10"},{"nct_id":"NCT06413745","title":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"HER2 Expression / Amplification in Patients With Biliary Tract Cancer","enrollment":59,"url":"https://clinicaltrials.gov/study/NCT06413745","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06413745","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a6a250b44e120b0a88e50c57ac76926aae909b9d783b8de1b9bad52715014c86"},{"nct_id":"NCT06434597","title":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Biliary Tract or Colorectal Cancer With Her2-positive/Mutated","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06434597","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06434597","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2b210ee703508486084567c0516be75f118e418ea91ef6cf1bf9066471cda778"},{"nct_id":"NCT06434610","title":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Platinum-resistant Recurrent Ovarian Cancer","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06434610","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06434610","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b477500645deff517c38c3145470d2390812c21c5b4aa158c77426d3f9db60e3"},{"nct_id":"NCT06454357","title":"A Clinical Study of B007 in the Treatment of Pemphigus.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Pemphigus","enrollment":132,"url":"https://clinicaltrials.gov/study/NCT06454357","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06454357","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:17b6c0f1d9d2f29b020d56a79951f9f887f3b4a90d5ab8ac3b3d07acc95d1292"},{"nct_id":"NCT06470191","title":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Primary Membranous Nephropathy","enrollment":216,"url":"https://clinicaltrials.gov/study/NCT06470191","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06470191","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ef348aade6e17cc5beac714f3704e3c1df632c968109ea603661d92ed3ac3c50"},{"nct_id":"NCT06479135","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na\u00efve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06479135","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06479135","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:191d46ab05db1f66d66b8b360a30ed1f59da7c95365d0fec72dbe04559c4e7c6"},{"nct_id":"NCT06495723","title":"Polyspecific Antibodies in Lymphoproliferative T-cell Disorders","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Xenothera SAS","ticker":null,"ticker_confidence":0.0,"conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":54,"url":"https://clinicaltrials.gov/study/NCT06495723","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06495723","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:590d40465c74a097151c937ec477a445b3fca9b354ccea600cc723f550f8acb0"},{"nct_id":"NCT06496971","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin\u00ae Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"NaviFUS Corporation","ticker":null,"ticker_confidence":0.0,"conditions":"Glioblastoma Multiforme; Glioblastoma; Glioblastoma Multiforme, Adult; Glioma; Brain Tumor; Brain Tumor, Recurrent; Neoplasms; Neoplasms, Nerve Tissue","enrollment":32,"url":"https://clinicaltrials.gov/study/NCT06496971","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06496971","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:eaa5de658013512eeb39b7d9cff6febd93a98d330ce0ccbadd95940cb2398b8b"},{"nct_id":"NCT06526923","title":"A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Spirovant Sciences, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Cystic Fibrosis","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT06526923","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06526923","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f8f6d33b5cff237c974c8cd2c009cf921bb4ec8722bc1506427c1cf6bc62b0f8"},{"nct_id":"NCT06531824","title":"EASi-KIDNEY\u2122 (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","ticker":null,"ticker_confidence":0.0,"conditions":"Kidney Disease, Chronic","enrollment":8371,"url":"https://clinicaltrials.gov/study/NCT06531824","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06531824","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e0c2c45d864275c278de23a649a41fec0dcc497d5257ea02cf96b9dcb3c15a36"},{"nct_id":"NCT06580301","title":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Excyte Biopharma Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":46,"url":"https://clinicaltrials.gov/study/NCT06580301","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06580301","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:05b7eea2f54f11bc16763e81000a2423940120055a39bc817adcd6fd7eaafa21"},{"nct_id":"NCT06660394","title":"A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Longboard Pharmaceuticals","ticker":null,"ticker_confidence":0.0,"conditions":"Dravet Syndrome","enrollment":108,"url":"https://clinicaltrials.gov/study/NCT06660394","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06660394","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c7e8785cb0e0ab45a9015525627c724a4a4892169e3138a6d2b0a8819dbc6c2e"},{"nct_id":"NCT06664775","title":"A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Corza Medical GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Hemorrhage","enrollment":116,"url":"https://clinicaltrials.gov/study/NCT06664775","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06664775","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2faa94b96a5af28e31b745264fec1effa373d13a92f96c17e9fcc60ef4241f70"},{"nct_id":"NCT06669169","title":"Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Heart Failure","enrollment":288,"url":"https://clinicaltrials.gov/study/NCT06669169","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06669169","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:73551c983aa61c6ea6f8bacbd5625d545df4bab3f08461db71a4bba714823759"},{"nct_id":"NCT06695845","title":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","ticker":"JAZZ","ticker_confidence":0.9,"conditions":"Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT06695845","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06695845","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8efae7074dd8dc1b9308a3a8b12b8d71dd6cd55ac933c110239677b663bd8a15"},{"nct_id":"NCT06696261","title":"A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Postprandial Distress Syndrome","enrollment":342,"url":"https://clinicaltrials.gov/study/NCT06696261","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06696261","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:36efb1c5a05034c1938425da72ef7b65ba3941596f7f65248b87cc28207524d2"},{"nct_id":"NCT06703255","title":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Glioma","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT06703255","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06703255","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b7de0f7d57539fc6f19d315d571f0fbfbbf24076eb0bc40bfdfe361fd4c6ca31"},{"nct_id":"NCT06730581","title":"Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer; Bile Duct Cancer","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT06730581","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06730581","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4e8365a271109eacd4969f5e9e216d34f1a46027890574ff09c38b3e171064fb"},{"nct_id":"NCT06769152","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Cervical Cancer; Ovarian Cancer","enrollment":190,"url":"https://clinicaltrials.gov/study/NCT06769152","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06769152","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6de44d4a02695da3b902f0520f2a34b4beb29d6c579c2ab25e154fd32c36c211"},{"nct_id":"NCT06770881","title":"JSKN033 in Chinese Subjects with Advanced Malignant Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Malignant Tumors","enrollment":430,"url":"https://clinicaltrials.gov/study/NCT06770881","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06770881","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:46e41fb5ee7f4e267cf721f525b2f56fb5eefe4c8265c3b481cfe2cb3066c2a6"},{"nct_id":"NCT06776432","title":"Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shionogi","ticker":null,"ticker_confidence":0.0,"conditions":"Sleep Apnea","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT06776432","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06776432","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:135bd03373bfc1cf688bf8da39b232f7f939a0dbfd284665bd1d034057f38cbc"},{"nct_id":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancers","enrollment":350,"url":"https://clinicaltrials.gov/study/NCT06799637","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06799637","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:976c92a1ea5f87c3a11c309afc8cd6d285dbf7c776f43ba90111815d5570cf2c"},{"nct_id":"NCT06803823","title":"A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Agitation Associated With Alzheimer's Disease Dementia","enrollment":90,"url":"https://clinicaltrials.gov/study/NCT06803823","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06803823","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:887ff30608ba136f1db664714514c7e2aff3adf9c36752ce39216226d97bf9a8"},{"nct_id":"NCT06819826","title":"A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Biocity Biopharmaceutics Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"IgA Nephropathy (IgAN)","enrollment":360,"url":"https://clinicaltrials.gov/study/NCT06819826","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06819826","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:140f0ceb7709770b88b3e77d12fb2f66d374c3f1429dbca1c21364c4af43c662"},{"nct_id":"NCT06842966","title":"Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Valenta Pharm JSC","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Cholecystitis; Biliary Dyskinesia","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT06842966","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06842966","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:21e550419ff2c3f79d7889c8d03345ec3b35ba75d0a7ffa1f1041b3038268a69"},{"nct_id":"NCT06843018","title":"Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Valenta Pharm JSC","ticker":null,"ticker_confidence":0.0,"conditions":"Pharyngitis Acute; Pharyngitis; Nasopharyngitis; Exacerbation of Chronic Pharyngitis","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT06843018","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06843018","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c512b010404c318f86f9ccb3410e9506905b2ef38be2be66dffebbac71b08610"},{"nct_id":"NCT06863701","title":"Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Laboratorios Silanes S.A. de C.V.","ticker":null,"ticker_confidence":0.0,"conditions":"Gout Arthritis; Gout Attack","enrollment":72,"url":"https://clinicaltrials.gov/study/NCT06863701","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06863701","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:070920289a7e667becb908d6264f0d0e479eb5a5f9dfc89289a607d31de7886c"},{"nct_id":"NCT06884293","title":"A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease \uff08MAFLD\uff09","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","enrollment":479,"url":"https://clinicaltrials.gov/study/NCT06884293","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06884293","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ea7e4d0e65e9967a599e93592fe75538eb4b4a3f919a9b150e1db85faf1f8ea1"},{"nct_id":"NCT06887127","title":"A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Rheumatoid Arthritis","enrollment":350,"url":"https://clinicaltrials.gov/study/NCT06887127","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06887127","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a1dc79b1708709a0979b3d4eb92bc6c027d522fcc01efce63c83e97d7c103dfc"},{"nct_id":"NCT06903338","title":"A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","ticker":"VIR","ticker_confidence":0.9,"conditions":"Viral Hepatitis","enrollment":124,"url":"https://clinicaltrials.gov/study/NCT06903338","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06903338","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b3acf442aca452c74ecc672e172aded81d49f731b52dec4ca2b15d46ced6d9e3"},{"nct_id":"NCT06908876","title":"A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema\uff08DME\uff09","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics Technology Limited (Shanghai R&D Center)","ticker":null,"ticker_confidence":0.0,"conditions":"Diabetic Macular Oedema","enrollment":150,"url":"https://clinicaltrials.gov/study/NCT06908876","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06908876","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ed8f376802c86239231ec5c58be685df75fc482cbc50d7a4ff820ae1112ca1e0"},{"nct_id":"NCT06931405","title":"Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blueprint Medicines Corporation","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Inducible Urticaria; Chronic Spontaneous Urticaria","enrollment":105,"url":"https://clinicaltrials.gov/study/NCT06931405","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06931405","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0886b922576882b32d2da8a45ca65205ced3c89b6cde229e672bea4290b41c95"},{"nct_id":"NCT06959615","title":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":334,"url":"https://clinicaltrials.gov/study/NCT06959615","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06959615","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:221147055cbeff56c29600a99f97758b02f085127d4f6b77b9d2f404988f1332"},{"nct_id":"NCT06961201","title":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy","enrollment":94,"url":"https://clinicaltrials.gov/study/NCT06961201","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06961201","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:112f05bb52b24d647862c08ee457f2e51e721517fc9c048f4e036d3bd37fab4c"},{"nct_id":"NCT06970847","title":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Clarity Pharmaceuticals Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Prostate Cancer; Prostate Cancer Patients With Detectable PSA Following Prostatectomy; Prostate Cancer Recurrent; Prostate Cancer Patients Who Have Brachytherapy Seed Implant; Prostate Cancer Patients Treated by Radiotherapy; Cryotherapy","enrollment":220,"url":"https://clinicaltrials.gov/study/NCT06970847","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06970847","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0185faf206965deeae3ee4cb45753d8f5425894a1d73a90e4f6cca181d97c58f"},{"nct_id":"NCT06971094","title":"Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GeneCradle Inc","ticker":null,"ticker_confidence":0.0,"conditions":"SMA - Spinal Muscular Atrophy","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT06971094","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06971094","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:34d52df131485714946735b15119b73de79a0ad602d8145c344f4af4b34a5340"},{"nct_id":"NCT07005180","title":"Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Hillhurst Biopharmaceuticals, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Parkinson Disease","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT07005180","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07005180","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:297a3023a55903bc5f23b64687b250bc3123a1e1381402a63e710260f6b452b9"},{"nct_id":"NCT07010926","title":"A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"EL3 Bio, LLC.","ticker":null,"ticker_confidence":0.0,"conditions":"Crohn&Amp;#39;s; Crohn&Amp;#39;s Disease (CD)","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07010926","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07010926","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fdf788ca799f8df4120a8919506c085e177cf6dbf5d3129bab9b7965d520fafb"},{"nct_id":"NCT07022002","title":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced, Recurrent or Metastatic Malignancies","enrollment":340,"url":"https://clinicaltrials.gov/study/NCT07022002","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07022002","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1e6b6428789fe0cb0d126af5d4330eeda7184d25ff19a3aadfda960d3ea7abe3"},{"nct_id":"NCT07087158","title":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Renal Cell Carcinoma (RCC)","enrollment":30,"url":"https://clinicaltrials.gov/study/NCT07087158","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07087158","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ce57951971d4d438cdfe401702168f696044ec1c0638bcf22054354dc33b2cf1"},{"nct_id":"NCT07113262","title":"A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Thyroid Eye Disease","enrollment":111,"url":"https://clinicaltrials.gov/study/NCT07113262","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07113262","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:47ca9738d6347bfa9b2384a11534fb4d63ba9d4a7a73ca09a0b7cb37f3d509e2"},{"nct_id":"NCT07121413","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Synvida Biotechnology Co.,Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Idiopathic Pulmonary Fibrosis(IPF)","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT07121413","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07121413","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:84fb53d37a796fc6737d69fba99d36eea930080970eee11941be5726c6944098"},{"nct_id":"NCT07127042","title":"Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty\uff08TKA\uff09","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"ScinnoHub Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Total Knee Arthroplasty","enrollment":270,"url":"https://clinicaltrials.gov/study/NCT07127042","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07127042","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d0bf2f52bbb5518c1a5bf1e0b8aadac8b5dccd8d3df406342b65349e874739d2"},{"nct_id":"NCT07136805","title":"A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"VivaVision Biotech, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Non-infectious Anterior Uveitis","enrollment":154,"url":"https://clinicaltrials.gov/study/NCT07136805","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07136805","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:64e354df308069cbe5d829b884a77b1ad30de9cc808676e21414d7eca8fa8de0"},{"nct_id":"NCT07146672","title":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor Cancer","enrollment":12,"url":"https://clinicaltrials.gov/study/NCT07146672","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07146672","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7818e10924ce5ad3eb3c099bd47c74b6e81dcefbfbc4357d6d028fa38c3c1672"},{"nct_id":"NCT07162883","title":"Pharmacokinetic Study of QL2107 Versus Keytruda\u00ae for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":146,"url":"https://clinicaltrials.gov/study/NCT07162883","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07162883","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7759f80cc70e8847b6278d36217645f28887e104097c08cdb04b2acbb25ddefc"},{"nct_id":"NCT07185815","title":"Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Mapi Pharma Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Schizophrenia; Bipolar I Disorder; Major Depressive Disorder","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07185815","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07185815","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:12bcc5e7969bcb1d227293761df024c31c2d7f4fc3437ba6c2897a1cb1365ee9"},{"nct_id":"NCT07186413","title":"A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galderma R&D","ticker":null,"ticker_confidence":0.0,"conditions":"Acne Vulgaris","enrollment":561,"url":"https://clinicaltrials.gov/study/NCT07186413","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07186413","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:76cb5ef2062a8a1d719b4778e6af43098aa3fc21aa8cf7c936e174d28f7919b9"},{"nct_id":"NCT07192263","title":"Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"HK inno.N Corporation","ticker":null,"ticker_confidence":0.0,"conditions":"Obesity &Amp; Overweight","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT07192263","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07192263","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c3771318af658addd251484cd4fb97e3c3ec2fa4fe2f130fc1dfbf22fc2a24c2"},{"nct_id":"NCT07223229","title":"Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Elixiron Immunotherapeutics (Hong Kong) Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-segmental Vitiligo","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT07223229","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07223229","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2e2ae1a744af2b4509793c99bdce9a1689161aab9f0fb5bb335a6d677d91d0be"},{"nct_id":"NCT07226661","title":"Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","ticker":"SUPN","ticker_confidence":0.9,"conditions":"Major Depressive Disorder (MDD)","enrollment":230,"url":"https://clinicaltrials.gov/study/NCT07226661","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07226661","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:84d98b044e1771a81435a2213ce0738607bf739fbe2ef8f3b633e7c775ab8890"},{"nct_id":"NCT07249632","title":"A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Myasthenia Gravis, Ocular","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07249632","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07249632","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2f65985fc51609b54035d3c54faf681140dcbf876ab06980bf296dbcb50cc12b"},{"nct_id":"NCT07256743","title":"Efficacy of SALI-10 Oral Probiotics in Experimental Gingivitis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ostia Sciences","ticker":null,"ticker_confidence":0.0,"conditions":"Gingivitis","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07256743","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07256743","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:97c6d8d827020086f1fff1a5e41a758ec613f362771a7b0ea0af19d34df46ff8"},{"nct_id":"NCT07265349","title":"A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Coronary Artery Bypass Grafting (CABG); Chronic Heart Failure; Chronic Ischemic Cardiomyopathy","enrollment":51,"url":"https://clinicaltrials.gov/study/NCT07265349","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07265349","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5a9fcc50eb7b7727329e7af73add467069c9a0eec279791b93a87a86ae80177f"},{"nct_id":"NCT07388069","title":"Study of TN-001 Topical Eyedrops for Keratoconus","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Keratoconus","enrollment":20,"url":"https://clinicaltrials.gov/study/NCT07388069","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07388069","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:316c0c686dbddfd89c1e84bb328f8d9a446e02b76d5f3b9e732e49672de6d8a2"},{"nct_id":"NCT07402070","title":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Resectable Stage II-III Non-small Cell Lung Cancer","enrollment":10,"url":"https://clinicaltrials.gov/study/NCT07402070","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07402070","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8c10482add673255f39313013a108b8fcdf799c19125da20b1a909e3e600fa44"},{"nct_id":"NCT07413549","title":"Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Beijing Tuohua Weiye Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Decompensated Hepatitis B Cirrhosis","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT07413549","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07413549","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7500fee4ff2da8adbc2f00b24b1d2d4ae7273d7b643592850f47f08eee0a849a"},{"nct_id":"NCT07443202","title":"Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","ticker_confidence":0.9,"conditions":"Ocular Rosacea","enrollment":155,"url":"https://clinicaltrials.gov/study/NCT07443202","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07443202","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2007825cdf3423d4b191293f77e8642a58b9c7be2a478d42233fb52b9c8befdc"},{"nct_id":"NCT07485595","title":"A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Depression","enrollment":180,"url":"https://clinicaltrials.gov/study/NCT07485595","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07485595","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5f328abcc25d48261d79a5a751ee07552ad319a7b1acec1f0ba8858454dfb5b0"},{"nct_id":"NCT07521137","title":"Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sano Chemicals Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Candidiasis, Vulvovaginal","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT07521137","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07521137","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2ce069b6b0795e51d7c8d335e9be36bb550e0e2c7c4163295ee03580b3df2fe7"},{"nct_id":"NCT07644832","title":"An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Shanghai RAAS Blood Products Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Hemophilia A; Hemophilia B; Factor VII Deficiency","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT07644832","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07644832","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d994d191eba76a8917c9f861118e51bf308cc478726cd4c8445ce8efba2677f8"},{"nct_id":"NCT07712523","title":"A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Adult Subjects With Non-Segmental Vitiligo","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT07712523","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07712523","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9faf30ab528fe2b3d14dcc451da8fcc068a8eddc7f1b6a5d0e3f0468a1b7f498"},{"nct_id":"NCT07719530","title":"Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Psoriasis","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07719530","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07719530","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0b37f31daf57504b2db2fef4c43a9061ffc51668ec753d6373e89f8c8b7c7bf4"},{"nct_id":"NCT07746726","title":"Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Neuromuscular Blockade","enrollment":320,"url":"https://clinicaltrials.gov/study/NCT07746726","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07746726","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fc518f0f1de5b024b8fc6ebeef07884f051ebdc6787d7d6a67a848ebb63dc0aa"},{"nct_id":"NCT07764861","title":"A Open-Label Phase in Participants With Multiple Myeloma","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Multiple Myeloma","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07764861","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07764861","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:92abc31d8bfbe4499ce39dc04570f617142cbd9f0fb096c2a3d825a829d6d145"},{"nct_id":"NCT07824310","title":"Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children","readout_date":"2026-12-31","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","ticker":null,"ticker_confidence":0.0,"conditions":"Human Papillomavirus (HPV) Infection","enrollment":266,"url":"https://clinicaltrials.gov/study/NCT07824310","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07824310","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:eb82697793f8f3a03c148dca68afdc7a77a47851fdfbaa295559860063d05c6b"},{"nct_id":"NCT04485949","title":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imvax","ticker":null,"ticker_confidence":0.0,"conditions":"Glioblastoma","enrollment":99,"url":"https://clinicaltrials.gov/study/NCT04485949","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04485949","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7b79caadcd8b8394dbb1d2f919fcf4c84aa9da8004c525ffc33aa773a6e8fcd5"},{"nct_id":"NCT04561362","title":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"BicycleTx Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative Neoplasms; Hormone Receptor Positive, HER2-low Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Neoplasms; Ovarian Neoplasm; Advanced Solid Tumor","enrollment":329,"url":"https://clinicaltrials.gov/study/NCT04561362","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04561362","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dd79001c3d3bfe1a5535329cc641b904e963fecad099df158639b0a39e4bb16d"},{"nct_id":"NCT05027906","title":"Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Eledon Pharmaceuticals","ticker":"ELDN","ticker_confidence":0.9,"conditions":"Prevention of Rejection in Kidney Transplant","enrollment":48,"url":"https://clinicaltrials.gov/study/NCT05027906","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05027906","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a1992a3e13b348cbc900d60184c5cb83905720f5730bcb2c945187e34c380dd0"},{"nct_id":"NCT05050136","title":"A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","ticker_confidence":0.9,"conditions":"Primary Biliary Cholangitis; PBC","enrollment":333,"url":"https://clinicaltrials.gov/study/NCT05050136","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05050136","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8e421e58bf5f772b714d6718446a148674e0b063542c2ed4fbe79ba39b6985c0"},{"nct_id":"NCT05171894","title":"A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Port-wine Birthmarks; Port-Wine Stain; Nevus Flammeus","enrollment":84,"url":"https://clinicaltrials.gov/study/NCT05171894","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05171894","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1e600879ccf48daff8ea42d1fbf9fd99cf6031bbe403f1712b40668f40ea3c1e"},{"nct_id":"NCT05399537","title":"Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Vantive Health LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Regional Citrate Anticoagulation (RCA); Continuous Renal Replacement Therapy (CRRT); Acute Kidney Injury (AKI)","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT05399537","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05399537","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f93f6fb66eed46933f866fa5aee75aa5493a4d55bc8db79e6f476df06a6bea98"},{"nct_id":"NCT05406362","title":"Assess Safety and Efficacy of VAD044 in HHT Patients","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaderis Therapeutics AG","ticker":null,"ticker_confidence":0.0,"conditions":"Hereditary Hemorrhagic Telangiectasia (HHT)","enrollment":75,"url":"https://clinicaltrials.gov/study/NCT05406362","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05406362","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:993707320c11089e8b20f91c9bcacf0979bfdb589dccb32b42158cd797d14242"},{"nct_id":"NCT05540860","title":"A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edgewise Therapeutics, Inc.","ticker":"EWTX","ticker_confidence":0.9,"conditions":"Duchenne Muscular Dystrophy","enrollment":76,"url":"https://clinicaltrials.gov/study/NCT05540860","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05540860","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d63d26d43948b23a2252c3c12478e8d009f342e61d7c3378b8e9e08ea050d7bd"},{"nct_id":"NCT05751928","title":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","ticker":null,"ticker_confidence":0.0,"conditions":"Melanoma Stage III; Melanoma (Skin)","enrollment":411,"url":"https://clinicaltrials.gov/study/NCT05751928","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05751928","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f751fab1e30eed91cebc1b6c1594eb5a54f6e31a88a80c58aaa7e32fb78e3786"},{"nct_id":"NCT05755113","title":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"QBiotics Group Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Soft Tissue Sarcoma","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT05755113","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05755113","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:de716cd413f07a09c9c0822b2fb695551b6aa745d5491999e66e695f81e653b7"},{"nct_id":"NCT05824065","title":"Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"EMS","ticker":null,"ticker_confidence":0.0,"conditions":"Female Pattern Baldness","enrollment":504,"url":"https://clinicaltrials.gov/study/NCT05824065","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05824065","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:de3b5760dde8300fe4408ed114af75f01ec8f5f6775df581739d08895378760d"},{"nct_id":"NCT05941507","title":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"LigaChem Biosciences, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT05941507","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05941507","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:583264e89cb31c881a9ab15aef2a66497d4869d8dd798ba09e0b9ee3f1e83dc8"},{"nct_id":"NCT05986864","title":"Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Skyline Therapeutics (US) Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Neovascular Age-related Macular Degeneration","enrollment":68,"url":"https://clinicaltrials.gov/study/NCT05986864","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05986864","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:35fef596c029f9305a4165d46c69d72ed3bcbe40c48945c356028580d6bfefa0"},{"nct_id":"NCT06029972","title":"Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","ticker":"GILD","ticker_confidence":0.9,"conditions":"Ulcerative Colitis","enrollment":176,"url":"https://clinicaltrials.gov/study/NCT06029972","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06029972","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e4eb4c41392d8194af4a2ae858f3af8481e96960ab379946f0791e558542258d"},{"nct_id":"NCT06032195","title":"Study of Organ Perfusion in Heart Transplantation in Children","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Dr. F. K\u00f6hler Chemie GmbH","ticker":null,"ticker_confidence":0.0,"conditions":"Heart Transplantation","enrollment":15,"url":"https://clinicaltrials.gov/study/NCT06032195","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06032195","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1d6c74678a180d516f002a4bfd59897fb35e1eccdbf64e0262662b577ff7a89b"},{"nct_id":"NCT06109272","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Hepatocellular Carcinoma","enrollment":89,"url":"https://clinicaltrials.gov/study/NCT06109272","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06109272","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d2ced504d2855734814689f25edbf66b4b4282f53f9778dd31289513f59c99ed"},{"nct_id":"NCT06131450","title":"A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Gynecological Malignancies","enrollment":158,"url":"https://clinicaltrials.gov/study/NCT06131450","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06131450","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bcc497d8e30397386ac806d68834922c2a2c6983da2ee7976879b43e2040c57b"},{"nct_id":"NCT06384261","title":"A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoVerity, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Leukemia, Myeloid, Acute","enrollment":140,"url":"https://clinicaltrials.gov/study/NCT06384261","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06384261","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:63130280d408c0f140027e17f88e242e8a44a7ea2c42fc879ad1ad4301a201d2"},{"nct_id":"NCT06386146","title":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumors","enrollment":144,"url":"https://clinicaltrials.gov/study/NCT06386146","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06386146","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1581c666144534cbd11b44ed76d05b6c1a8f1d06b07d220700435f8ba31bae47"},{"nct_id":"NCT06447025","title":"An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Larimar Therapeutics, Inc.","ticker":"LRMR","ticker_confidence":0.9,"conditions":"Friedreich Ataxia","enrollment":85,"url":"https://clinicaltrials.gov/study/NCT06447025","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06447025","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f4a23a170dbd0c7541b596e2924a05c8056d2e5b3a38bac61b1eb6f21f39f7d5"},{"nct_id":"NCT06481891","title":"A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lexicon Pharmaceuticals","ticker":"LXRX","ticker_confidence":0.9,"conditions":"Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy","enrollment":500,"url":"https://clinicaltrials.gov/study/NCT06481891","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06481891","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0b71647a0b65e2172f04b483045c5ecd9b6b2f206ccabfb560b58123d3bbb0ea"},{"nct_id":"NCT06561607","title":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Breast Cancer","enrollment":542,"url":"https://clinicaltrials.gov/study/NCT06561607","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06561607","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5a32649da252355b1f3d5beae1434928c33ac93ccfd4db4311be9a408c68617b"},{"nct_id":"NCT06601335","title":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":510,"url":"https://clinicaltrials.gov/study/NCT06601335","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06601335","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:054dec40927b5605cfd5abd266ade75f263d123b04c179f1b7e85dcbdd323397"},{"nct_id":"NCT06636071","title":"Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","ticker":"RARE","ticker_confidence":0.9,"conditions":"Osteogenesis Imperfecta","enrollment":6,"url":"https://clinicaltrials.gov/study/NCT06636071","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06636071","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8f2416706e54d69d82c08388d64443089b28f46f18d3c57569a19854675c9688"},{"nct_id":"NCT06672978","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","ticker":null,"ticker_confidence":0.0,"conditions":"Acute Pyelonephritis; Complicated Urinary Tract Infection","enrollment":66,"url":"https://clinicaltrials.gov/study/NCT06672978","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06672978","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ff4a4c897ec3a89aa3d303128a27fae70a4989ab64bc9377c192f1a7e0f70fc5"},{"nct_id":"NCT06701331","title":"Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","ticker":"ABBV","ticker_confidence":0.9,"conditions":"Atopic Dermatitis","enrollment":99,"url":"https://clinicaltrials.gov/study/NCT06701331","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06701331","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6f0eebb09a2d4bf0a78347a212059dbf23a7c1c2eb08a18d8b252c15d463b567"},{"nct_id":"NCT06702605","title":"To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Evopoint Biosciences Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsed/Refractory Peripheral T Cell Lymphoma","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT06702605","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06702605","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8151905c3bd5663770c387208e4938c268faa57329f86caf68d942ceb9f3855d"},{"nct_id":"NCT06721143","title":"A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"AION Healthspan, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Chronic Kidney Disease Stage 3","enrollment":36,"url":"https://clinicaltrials.gov/study/NCT06721143","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06721143","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a4c58adfbe6dfb6a61ba0ec1f71ec25595012953e7bf9036a2dd9e8f7925a015"},{"nct_id":"NCT06741644","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors","enrollment":800,"url":"https://clinicaltrials.gov/study/NCT06741644","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06741644","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:406166fe9a9979e349e8d8deb6263b5e78dfb09e1e5d86133fa96493dd60255c"},{"nct_id":"NCT06800404","title":"\"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis\"","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hope Biosciences Research Foundation","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis","enrollment":10,"url":"https://clinicaltrials.gov/study/NCT06800404","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06800404","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c5152d1268e8cf1bf535595d697a2976b866fe418e2b2f7582451db466f03599"},{"nct_id":"NCT06827613","title":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Marengo Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Triple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancer","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT06827613","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06827613","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8b82ed0b5bbf4ffa2f94dbab875616b512d0a022906b2b5fecf50b2e127e7a2a"},{"nct_id":"NCT06860971","title":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Thyroid Cancer","enrollment":144,"url":"https://clinicaltrials.gov/study/NCT06860971","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06860971","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5254e46f34158b481fafdfbfbb690540534422bc17dc29f77ae6069725634544"},{"nct_id":"NCT06867705","title":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Resilience","ticker":null,"ticker_confidence":0.0,"conditions":"Cancer","enrollment":1458,"url":"https://clinicaltrials.gov/study/NCT06867705","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06867705","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:505a3262a99fe4cb72694b5acf5d2a951d5d429f3f3d3f801dccc67aa267bc32"},{"nct_id":"NCT06873035","title":"An Interventional Study of Infigratinib in Children With Hypochondroplasia","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ENROLLING_BY_INVITATION","sponsor":"QED Therapeutics, a BridgeBio company","ticker":null,"ticker_confidence":0.0,"conditions":"Hypochondroplasia","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT06873035","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06873035","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5325b94225e07169df1e6f4872ae7a165a3d923f378706d6dc355ba9dfdd7b9e"},{"nct_id":"NCT06879717","title":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"iOnctura","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT06879717","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06879717","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a1c5a215292a6ec5c9d28f52d314e00f3dd94acda46061e9d5f27c002dac9f87"},{"nct_id":"NCT06886139","title":"A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"CD20-positive Diffuse Large B-Cell Lymphoma","enrollment":139,"url":"https://clinicaltrials.gov/study/NCT06886139","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06886139","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:42afcc171d648464087706d4072f20095f88c6be30c5ee9842ec70f72d72955a"},{"nct_id":"NCT06889701","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33,"url":"https://clinicaltrials.gov/study/NCT06889701","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06889701","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ad5fcc83e3cbefefa1ac20df57db2ccadd79f40fe1e66e3c76a22a0c94db6908"},{"nct_id":"NCT06922110","title":"An Open-Label Study of Azetukalner in Major Depressive Disorder","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xenon Pharmaceuticals Inc.","ticker":"XENE","ticker_confidence":0.9,"conditions":"Major Depressive Disorder","enrollment":460,"url":"https://clinicaltrials.gov/study/NCT06922110","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06922110","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f155371a5de1c8261b109230af7794a426e026fe44dcc69c37333177ea7fc35a"},{"nct_id":"NCT07027345","title":"A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"BioMendics, LLC","ticker":null,"ticker_confidence":0.0,"conditions":"Epidermolysis Bullosa Simplex","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07027345","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07027345","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:fc3a669004a7289440a1b040507e1cadc1aeedb72911ac9c2d84eded7609bd53"},{"nct_id":"NCT07032649","title":"Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Greg Bew","ticker":null,"ticker_confidence":0.0,"conditions":"HSV","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07032649","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07032649","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7f429fe64ffd8fab92b362d2e4218b905f10a2d73d4a5ac21f5c9c5a07998224"},{"nct_id":"NCT07036510","title":"Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"EyeD Pharma","ticker":null,"ticker_confidence":0.0,"conditions":"Glaucoma; Ocular Hypertension","enrollment":42,"url":"https://clinicaltrials.gov/study/NCT07036510","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07036510","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:6e48fe5eab67a5f5f3ce6bd359786c1c5875f52b771039d5e8cdfba3e68a2d6d"},{"nct_id":"NCT07038382","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","ticker":null,"ticker_confidence":0.0,"conditions":"Membranous Nephropathy; Lupus Nephritis (LN)","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07038382","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07038382","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e756a5d302dcdbfe025814690ca8cc28903fe633d760ec9eb25de7285b6cfdf4"},{"nct_id":"NCT07052214","title":"PSMA PET Combined With MRI for the Detection of PCa","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","ticker":"TLX","ticker_confidence":0.6,"conditions":"PCA; Prostate Cancer; Prostatic Neoplasm; PSMA PET; Diagnostic Imaging; Elevated PSA; Positron Emission Tomography; Prostate Biopsy; Carcinoma of the Prostate","enrollment":338,"url":"https://clinicaltrials.gov/study/NCT07052214","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07052214","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:070fe3ebfd9acb96b22abd36de27013c9208e583abe8d95c218df8cf43ad3e0e"},{"nct_id":"NCT07062978","title":"A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia\u00ae","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Postmenopausal Women With Osteoporosis at High Risk of Fracture","enrollment":278,"url":"https://clinicaltrials.gov/study/NCT07062978","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07062978","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a574950a719d0f999e5d62f35cc35d6dd284160b04d5173bbbd7105de60dceb7"},{"nct_id":"NCT07080034","title":"Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Biocad","ticker":null,"ticker_confidence":0.0,"conditions":"Ulcerative Colitis (UC)","enrollment":198,"url":"https://clinicaltrials.gov/study/NCT07080034","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07080034","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:be88a5128610fc80dae84ad3760bc1c423b1260d86cd49ae1bd43df79a15d216"},{"nct_id":"NCT07144345","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sun Pharmaceutical Industries, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Actinic Keratosis","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07144345","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07144345","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:46a7f95bae4041b62409c6ca53278b46ae670ebc4027eb3330e7e820340cb6ef"},{"nct_id":"NCT07144852","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sun Pharmaceutical Industries, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Actinic Keratosis","enrollment":260,"url":"https://clinicaltrials.gov/study/NCT07144852","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07144852","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bcf577f94952fb90fbd4946bd4f1a59c5af6d777484b2a3a3a1bfb4d1816e0bf"},{"nct_id":"NCT07146386","title":"A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huilun Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Benign Prostatic Hyperplasia; Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","enrollment":728,"url":"https://clinicaltrials.gov/study/NCT07146386","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07146386","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:45922361f018945645402e885ccceefe346e7732bf3c66bef394435bfa8151f5"},{"nct_id":"NCT07179640","title":"A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Alesta Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Hypophosphatasia (HPP)","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07179640","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07179640","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9eb0f4f5ba4fb60b072af5d736d14d90c143e524c9a8a023aacf91a0780f0a22"},{"nct_id":"NCT07205900","title":"Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","ticker":"HAFC","ticker_confidence":0.6,"conditions":"Obese; Obesity","enrollment":267,"url":"https://clinicaltrials.gov/study/NCT07205900","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07205900","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2312c3e4c51a169acc2a2ec70775d305b34e5838616a1d6b579e5146deb3d42a"},{"nct_id":"NCT07208773","title":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancer","enrollment":260,"url":"https://clinicaltrials.gov/study/NCT07208773","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07208773","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49167bf6605a96ba9baa0c23f75ce51d9e2af5d1f43e16199040cde5fba4d995"},{"nct_id":"NCT07298772","title":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Solid Tumor","enrollment":198,"url":"https://clinicaltrials.gov/study/NCT07298772","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07298772","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e056a7102de8ff715f7e1b73971b05888a33ec61da12b9ddd33504f764811c83"},{"nct_id":"NCT07323784","title":"A Study of NTX-1472 in Social Anxiety Disorder","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Newleos Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Social Anxiety Disorder (SAD)","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07323784","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07323784","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7249168181f7629d39d410f5ffc607d3c402eee77a6fe4f6fcf7feedbac3dbbf"},{"nct_id":"NCT07396818","title":"Kamlanoflast In Amyotrophic Lateral Sclerosis","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Inflammasome Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"ALS (Amyotrophic Lateral Sclerosis); ALS; Neuro-Degenerative Disease; Neuro-Degenerative Diseases; Motor Neuron Disease (MND)","enrollment":40,"url":"https://clinicaltrials.gov/study/NCT07396818","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07396818","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5eebf920584f0ba9f4fdb311e01b0be41454de5f257e2c95e66635c1915fc888"},{"nct_id":"NCT07478744","title":"A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Synendos Therapeutics AG","ticker":null,"ticker_confidence":0.0,"conditions":"Generalized Anxiety Disorder","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07478744","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07478744","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:922444b3626148da5bf4a4366b7180b824115cdb117864408ff6b112153221f6"},{"nct_id":"NCT07481604","title":"Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aribio Lab Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Herpes Zoster","enrollment":135,"url":"https://clinicaltrials.gov/study/NCT07481604","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07481604","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:384d59edf91e9e26752c318ad55199ad95665121d432798d4d3e359164c92fd6"},{"nct_id":"NCT07505004","title":"Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praxis Precision Medicines","ticker":"PRAX","ticker_confidence":0.9,"conditions":"Focal Epilepsy","enrollment":300,"url":"https://clinicaltrials.gov/study/NCT07505004","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07505004","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2d48bfea0898d432eea493d51ce75837b327866fb15a06edfec2a309b1792aef"},{"nct_id":"NCT07505836","title":"Phase \u2162 Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","ticker":"SVA","ticker_confidence":0.9,"conditions":"Epidemic Meningitis; Meningococcal Vaccines","enrollment":1040,"url":"https://clinicaltrials.gov/study/NCT07505836","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07505836","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:056f1a9a180ff7aa59ad4ddb3713cf25c562f7c9e0ff3280d71f504b57dafc93"},{"nct_id":"NCT07543224","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Reistone Biopharma Company Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Plaque Psoriasis Subjects","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT07543224","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07543224","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5487295dd096b0c66de5ba19db7d3b2bdb30ec0dd8ca3babcb536537f1f4d61a"},{"nct_id":"NCT07565506","title":"Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Lakewood-Amedex Inc","ticker":"LABT","ticker_confidence":0.9,"conditions":"Diabetic Foot Ulcers (DFUs)","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07565506","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07565506","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:70ad01d4f6580a7e1b7affd8c18b92fc0abc2690efd6b9853441340ac2309e7f"},{"nct_id":"NCT07576868","title":"A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Hyundai Bioscience Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Dengue","enrollment":210,"url":"https://clinicaltrials.gov/study/NCT07576868","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07576868","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:c618d9b79b8dbfa218b175485a3fc85ebfb0cf1f65da5e7d4df882e5d357ed45"},{"nct_id":"NCT07578363","title":"An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Alcon Research","ticker":"ALC","ticker_confidence":0.6,"conditions":"Ocular Hyperemia","enrollment":178,"url":"https://clinicaltrials.gov/study/NCT07578363","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07578363","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:946108239dc6d13061a59088542e1fbf1e032df10d0e2ca1d863c03cb01bfd57"},{"nct_id":"NCT07600736","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Actio Biosciences, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"KCNT1-Related Epilepsy","enrollment":61,"url":"https://clinicaltrials.gov/study/NCT07600736","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07600736","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:287e7ad5ab16801f4bc6bea4fdc665b0eedee6595f1046d45c62f4765f855495"},{"nct_id":"NCT07614958","title":"Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"A. Menarini International Licensing S.A.","ticker":null,"ticker_confidence":0.0,"conditions":"Mixed Dyslipidemia; Hypercholesterolaemia","enrollment":426,"url":"https://clinicaltrials.gov/study/NCT07614958","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07614958","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ee1b1a36a228250a15f48ed3994b791b049466cc821851d9718df682dbaa8187"},{"nct_id":"NCT07641634","title":"A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Prolium Bioscience, Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Healthy Volunteers; Systemic Sclerosis (SSc); Scleroderma, Systemic; Scleroderma","enrollment":44,"url":"https://clinicaltrials.gov/study/NCT07641634","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07641634","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:086f88509098304e061b0f171bea110d70638abf7e1a18306d3cd252a45e7a3e"},{"nct_id":"NCT07690059","title":"A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Sensory Cloud, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Refractory Chronic Cough and Unexplained Chronic Cough","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07690059","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07690059","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4fa03f22026f75b96bf91db204c501fa8759dab1d67c51752a0087b118d18040"},{"nct_id":"NCT07694375","title":"A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Caravel Oculus Pty Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Corneal Endothelial Cell Loss; Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery","enrollment":200,"url":"https://clinicaltrials.gov/study/NCT07694375","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07694375","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:19c9e97eb3bd31bf9f9614c7e56bc1371d15d7919423e7a76cd5c018bb185066"},{"nct_id":"NCT07842991","title":"Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Colgate Palmolive","ticker":"CL","ticker_confidence":0.9,"conditions":"Plaque; Dental Plaque; Gingivitis","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07842991","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07842991","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b29fcef7727663c04b245598ef3198d0f459fe111eaadc3540ae6125540d7b87"},{"nct_id":"NCT07845071","title":"An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin","readout_date":"2027-01","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Adneuris Therapeutics, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Pain","enrollment":160,"url":"https://clinicaltrials.gov/study/NCT07845071","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07845071","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d76dff424a7e48ea9f063aac2156238553f16ebc1ea1fdbe89d5ddb20d189bec"},{"nct_id":"NCT04957485","title":"Study to Assess the Safety and Immunogenicity of TPOXX\u00ae When Administered Orally for 28 Days With JYNNEOS","readout_date":"2027-01-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"SIGA Technologies","ticker":"SIGA","ticker_confidence":0.9,"conditions":"Smallpox","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT04957485","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04957485","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5ef68eb4f589ab350e6113d8fda7b5c319f2b0be0c8b89e880716049073b508f"},{"nct_id":"NCT05879055","title":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","readout_date":"2027-01-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"Neuroendocrine Neoplasm","enrollment":31,"url":"https://clinicaltrials.gov/study/NCT05879055","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05879055","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:006ee1762d58538b5cd2bfb3755adec9a9cdc30b7dde24e45b0bdea727efa58f"},{"nct_id":"NCT06838546","title":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","readout_date":"2027-01-01","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Advanced Colorectal Cancer","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT06838546","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06838546","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bd248657d869a7f7a2e664d0c14ab92116456226ad3571c83a266fd54b3634b8"},{"nct_id":"NCT07341737","title":"SL-28 for Advanced Solid Tumours","readout_date":"2027-01-01","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Second Life Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancer (NSCLC); Lung Cancer (Non-Small Cell); Esophageal Cancer; Stomach (Gastric) Cancer; Liver Cancer; Intestinal Cancer; Bladder Cancer; Renal Cancer; Prostate Cancer; Melanoma (Skin Cancer); Breast Cancer; Ovarian Cancer; Endometrial Cancer; Colorectal Cancer","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07341737","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07341737","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:83d1490e220c3bec995f1bf238cdd3c512e2e5cb2cf2c9032417e727a2da06d2"},{"nct_id":"NCT07402369","title":"Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia","readout_date":"2027-01-03","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Shenzhen Kangzhe Biotechnology Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Uterine Fibroids With Menorrhagia","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07402369","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07402369","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3d5e3c61be2b2b607bddd3c0bfdff20bda49a0b7107cd0c6852f36b2f36127aa"},{"nct_id":"NCT06641089","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNF\u03b1 Inadequate Response","readout_date":"2027-01-04","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","ticker":"MLTX","ticker_confidence":0.9,"conditions":"Arthritis, Psoriatic","enrollment":600,"url":"https://clinicaltrials.gov/study/NCT06641089","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06641089","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9cbaba7bcb6efa783b47189f3fe2310a49bf0adc9742fffcb05eb29b0c69de44"},{"nct_id":"NCT07000136","title":"A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH","readout_date":"2027-01-04","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Heterozygous Familial Hypercholesterolaemia","enrollment":473,"url":"https://clinicaltrials.gov/study/NCT07000136","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07000136","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:39ea2d880ed9e192cc4f6a73809c3f80860083216fc3a2c8137e9bded44137e2"},{"nct_id":"NCT07243171","title":"A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","readout_date":"2027-01-05","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Overweight and/or Obesity; Weight Management","enrollment":126,"url":"https://clinicaltrials.gov/study/NCT07243171","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07243171","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:46ac1cc47dd4dc789d8de569933abd7620f8cdffc60042668ba7ae05ab3dc088"},{"nct_id":"NCT07540442","title":"A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis","readout_date":"2027-01-05","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Mabgeek Biotech.Co.Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Dermatitis, Atopic","enrollment":180,"url":"https://clinicaltrials.gov/study/NCT07540442","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07540442","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8d0baed0c3cbb04b1ccfb6f7b69df33a2382836d17d031c0291d5ba0b9fcdd44"},{"nct_id":"NCT05925803","title":"Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)","readout_date":"2027-01-06","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Systemic Sclerosis; Scleroderma","enrollment":314,"url":"https://clinicaltrials.gov/study/NCT05925803","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05925803","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e6dc4ba5b676a8edf47adca3633b2f323817a176b9a9e0bcb2e55be3eec83b34"},{"nct_id":"NCT06401044","title":"A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease","readout_date":"2027-01-06","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","ticker":"AMGN","ticker_confidence":0.9,"conditions":"Thyroid Eye Disease","enrollment":94,"url":"https://clinicaltrials.gov/study/NCT06401044","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06401044","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0d3b871bc8240b29a95580915a52e62cadefacab16977eeea615793d314007cb"},{"nct_id":"NCT06481306","title":"A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease","readout_date":"2027-01-06","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","ticker":"BMY","ticker_confidence":0.9,"conditions":"Anemia, Sickle Cell; Healthy Volunteers","enrollment":224,"url":"https://clinicaltrials.gov/study/NCT06481306","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06481306","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2a502f084d86e16fab21e51380f938adaa902a01abe65a23d6585c779246ba9e"},{"nct_id":"NCT06843408","title":"A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD","readout_date":"2027-01-06","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","ticker":"INCY","ticker_confidence":0.9,"conditions":"Chronic Graft-versus-host-disease","enrollment":32,"url":"https://clinicaltrials.gov/study/NCT06843408","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06843408","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:f578a3ceef8a4d9a5862f93a52efcafe82b56305b33a7c529ff80c6dacf37b4a"},{"nct_id":"NCT07218523","title":"A Study to Investigate Bowel Cleansing With PLENVU\u00ae Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy","readout_date":"2027-01-06","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Norgine","ticker":null,"ticker_confidence":0.0,"conditions":"Bowel Cleansing Prior to Clinical Procedures","enrollment":212,"url":"https://clinicaltrials.gov/study/NCT07218523","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07218523","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:45cf0780785f3b48fc508a0466a2e7c3ced2d1d6409d039726fb12b00d17d4cd"},{"nct_id":"NCT07247188","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","readout_date":"2027-01-07","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Sickle Cell Disease","enrollment":100,"url":"https://clinicaltrials.gov/study/NCT07247188","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07247188","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7c8f5cb30a97615b29f1efa52b7181e0e18a45d60f4a18080fa20b7d9614e09e"},{"nct_id":"NCT06495918","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration","readout_date":"2027-01-08","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","ticker":"OCUL","ticker_confidence":0.9,"conditions":"Neovascular Age-related Macular Degeneration","enrollment":825,"url":"https://clinicaltrials.gov/study/NCT06495918","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06495918","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:4009a92a7645290893bcd5e588893a52f67d482e2be0757e4e5a90a5148758e0"},{"nct_id":"NCT06981091","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis","readout_date":"2027-01-08","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Non-Cystic Fibrosis Bronchiectasis","enrollment":234,"url":"https://clinicaltrials.gov/study/NCT06981091","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06981091","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:1347cdf6bbb86d03802376c9231214b99b9e1b4f944daea14bb8b5bdbec7f838"},{"nct_id":"NCT07673029","title":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","readout_date":"2027-01-09","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"HER2-positive Breast Cancer","enrollment":228,"url":"https://clinicaltrials.gov/study/NCT07673029","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07673029","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ee5d096023bc4d4aa571bca8d63d3fddcb653bf10bfc1593bdc080f6d0d44be3"},{"nct_id":"NCT05519085","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","readout_date":"2027-01-10","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Celgene","ticker":null,"ticker_confidence":0.0,"conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":810,"url":"https://clinicaltrials.gov/study/NCT05519085","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05519085","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5ef86d535b7f564cb8094d65b83422675d470b07165c70088933c8bc2305f2c8"},{"nct_id":"NCT05615974","title":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","readout_date":"2027-01-11","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"LaNova Medicines Limited","ticker":null,"ticker_confidence":0.0,"conditions":"Malignant Tumors","enrollment":139,"url":"https://clinicaltrials.gov/study/NCT05615974","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05615974","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8aa7be4e65f0605a403888e684f65d120414e178caacb8a275c5802432c08f9b"},{"nct_id":"NCT06177041","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","readout_date":"2027-01-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","ticker":null,"ticker_confidence":0.0,"conditions":"Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":486,"url":"https://clinicaltrials.gov/study/NCT06177041","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06177041","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ebad1573d911337de7434037671cba5e4b6ff4d96547c42b515763f47d591656"},{"nct_id":"NCT06417814","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","readout_date":"2027-01-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":768,"url":"https://clinicaltrials.gov/study/NCT06417814","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06417814","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0e5718e0d03ee5e1168f658423bc8c84b9c61a09f7bbf949a04ed8d1b0f4f380"},{"nct_id":"NCT07000123","title":"A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event","readout_date":"2027-01-11","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Cardiovascular Disease","enrollment":3103,"url":"https://clinicaltrials.gov/study/NCT07000123","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07000123","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cc765b2e792743bcd04e917c79e4cc986983012689b1147a6cc351c74db93ab0"},{"nct_id":"NCT05609968","title":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46)","readout_date":"2027-01-12","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","ticker":"MRK","ticker_confidence":0.6,"conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":614,"url":"https://clinicaltrials.gov/study/NCT05609968","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05609968","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:dd8c59262becae3931bfca3fb2b7d40e11b0f5147375cdd11204ae8ea9597d5b"},{"nct_id":"NCT07092865","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","readout_date":"2027-01-12","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Respiratory Syncytial Virus Infections","enrollment":168,"url":"https://clinicaltrials.gov/study/NCT07092865","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07092865","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:99fb64bbd10fd8aef796696c4b708df768e43df80dc7fc18e1248ed71fd4b597"},{"nct_id":"NCT05952206","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","readout_date":"2027-01-13","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"iVascular S.L.U.","ticker":null,"ticker_confidence":0.0,"conditions":"Coronary Artery Disease","enrollment":2312,"url":"https://clinicaltrials.gov/study/NCT05952206","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05952206","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0cf4bbf70647cd0498264b31fc1129c1d5b67c1654cc357ad8e732b252cde9b4"},{"nct_id":"NCT06550011","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","readout_date":"2027-01-13","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avirmax Biopharma Inc","ticker":null,"ticker_confidence":0.0,"conditions":"Neovascular (Wet) AMD","enrollment":18,"url":"https://clinicaltrials.gov/study/NCT06550011","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06550011","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:991b59a670e1d32c8ba16e9f59567e8d479ef103e6dd2b02c7625480a0684448"},{"nct_id":"NCT06706817","title":"A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab","readout_date":"2027-01-13","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":181,"url":"https://clinicaltrials.gov/study/NCT06706817","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06706817","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9b8b0ca95a9287a847d7362fdcbaab153e73b5fc0b8144518bedca1a9e80bd6e"},{"nct_id":"NCT06951503","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","readout_date":"2027-01-13","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Akeso","ticker":null,"ticker_confidence":0.0,"conditions":"Colorectal Adenocarcinoma","enrollment":560,"url":"https://clinicaltrials.gov/study/NCT06951503","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06951503","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8d594dad7429ef4fb2af126d8de4453cdc962a8044ccb0a12705027ed9e15847"},{"nct_id":"NCT07261644","title":"A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)","readout_date":"2027-01-14","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","ticker":"SBFM","ticker_confidence":0.6,"conditions":"Ankylosing Spondylitis","enrollment":500,"url":"https://clinicaltrials.gov/study/NCT07261644","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07261644","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:75679c4ac7e73a87b063e6c6f0b78860ee3372f391afa05abdfd4bb4a8d506cf"},{"nct_id":"NCT07395687","title":"A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity","readout_date":"2027-01-14","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Novo Nordisk A/S","ticker":"NVO","ticker_confidence":0.95,"conditions":"Overweight; Obesity","enrollment":333,"url":"https://clinicaltrials.gov/study/NCT07395687","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07395687","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:70a86f62d0266f5114b07866cccc4ea65d010ec45c9991873627fd9a131e2225"},{"nct_id":"NCT04199689","title":"Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)","readout_date":"2027-01-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","ticker":"MRK","ticker_confidence":0.6,"conditions":"Papillomavirus Infections","enrollment":6033,"url":"https://clinicaltrials.gov/study/NCT04199689","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04199689","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:49e24b8c01c2217df723ceaf36d2a84341162a9d9b13236b3ecea7f00941260b"},{"nct_id":"NCT04644575","title":"Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A","readout_date":"2027-01-15","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioverativ, a Sanofi company","ticker":null,"ticker_confidence":0.0,"conditions":"Hemophilia A","enrollment":261,"url":"https://clinicaltrials.gov/study/NCT04644575","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04644575","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a3852b92558b4401a7bb0e17ba99636b385bd12b46677ec989dabb0d32016740"},{"nct_id":"NCT05987332","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","readout_date":"2027-01-15","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","ticker":"IDYA","ticker_confidence":0.9,"conditions":"Metastatic Uveal Melanoma","enrollment":420,"url":"https://clinicaltrials.gov/study/NCT05987332","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05987332","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:99256ab240c209b19df109f2c9ca3c41ca8453c18289bd9a0db14f06f9cd3e86"},{"nct_id":"NCT06590090","title":"Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment","readout_date":"2027-01-15","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"XBiotech, Inc.","ticker":"XBIT","ticker_confidence":0.9,"conditions":"Rheumatoid Arthritis","enrollment":108,"url":"https://clinicaltrials.gov/study/NCT06590090","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06590090","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ca38f81cd8af40769db4395cfecfacbb4615b73029f7ed7b2ebd20dcc93c79ea"},{"nct_id":"NCT06764940","title":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","readout_date":"2027-01-15","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Biostar Pharma, Inc.","ticker":null,"ticker_confidence":0.0,"conditions":"HER2-negative Breast Cancer Patients With Brain Metastases","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT06764940","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06764940","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d9d7b8c55ffa1e4e155b76a62cb6271b58d6e425364a0db4d303aad0d863c230"},{"nct_id":"NCT07376629","title":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","readout_date":"2027-01-15","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Huabo Biopharm Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"TNBC","enrollment":60,"url":"https://clinicaltrials.gov/study/NCT07376629","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07376629","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:55f127c2bb6ea16bf3a5f10b69c233125ba53a7edaf0cf60f7c44fa86f9da659"},{"nct_id":"NCT06265727","title":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","readout_date":"2027-01-16","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Corbus Pharmaceuticals Inc.","ticker":"CRBP","ticker_confidence":0.9,"conditions":"Solid Tumor, Adult","enrollment":348,"url":"https://clinicaltrials.gov/study/NCT06265727","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06265727","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:bc955b0c62a335707690eb585321348e4c499eb92fe402f49946ac4cb435776c"},{"nct_id":"NCT05035212","title":"Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.","readout_date":"2027-01-18","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Lower Respiratory Tract Illness","enrollment":38861,"url":"https://clinicaltrials.gov/study/NCT05035212","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05035212","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:b6282b97a01146d0b9babb6cfe609e90df97f27959d1fcb3f6007fc86f0e4ff0"},{"nct_id":"NCT05319353","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)","readout_date":"2027-01-18","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Takeda","ticker":"TAK","ticker_confidence":0.9,"conditions":"Cytomegalovirus (CMV)","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT05319353","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05319353","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:06a59ae6b07cc005b78ee6681d30efe1fe34f034c1cb088fe8fd199436b9acc8"},{"nct_id":"NCT05374603","title":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","readout_date":"2027-01-18","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","ticker":"AZN","ticker_confidence":0.9,"conditions":"Lung Cancer","enrollment":47,"url":"https://clinicaltrials.gov/study/NCT05374603","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05374603","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3b28af932d7e355e957200c78209e526878a3ef87b88d099b7b0482fa5effc46"},{"nct_id":"NCT05786729","title":"Aerobic Exercise After Traumatic Brain Injury","readout_date":"2027-01-18","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ENROLLING_BY_INVITATION","sponsor":"Centre for Neuro Skills","ticker":null,"ticker_confidence":0.0,"conditions":"Traumatic Brain Injury","enrollment":190,"url":"https://clinicaltrials.gov/study/NCT05786729","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05786729","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:ac04bdd9da05f48f4ec32571ef51a231a505f4df306ae5ee8e111c1a0a336f59"},{"nct_id":"NCT06686654","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","readout_date":"2027-01-18","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","ticker":"SNY","ticker_confidence":0.6,"conditions":"Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization","enrollment":1530,"url":"https://clinicaltrials.gov/study/NCT06686654","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06686654","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:9a6064b25c62fc6b3b9ed2cadbbd3a32aa3f3d31b06392a55d775175577fcb64"},{"nct_id":"NCT05584670","title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","readout_date":"2027-01-19","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Sanofi","ticker":"SNY","ticker_confidence":0.9,"conditions":"Solid Tumor","enrollment":542,"url":"https://clinicaltrials.gov/study/NCT05584670","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05584670","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:0adbd8bae0aed034e30d51c3f0c1f234742efb0b38d5cb6b5961b8edb2448cd8"},{"nct_id":"NCT06053242","title":"Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain","readout_date":"2027-01-20","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Creative Medical Technology Holdings Inc","ticker":"CELZ","ticker_confidence":0.9,"conditions":"Chronic Low-back Pain; Degenerative Disc Disease","enrollment":45,"url":"https://clinicaltrials.gov/study/NCT06053242","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06053242","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3c536ff0d0246012fd219d07a195b32012d701dbaa2f0d215dc05c18c81fc8af"},{"nct_id":"NCT07355075","title":"A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)","readout_date":"2027-01-20","readout_date_type":"ESTIMATED","phase":"PHASE2/PHASE3","status":"RECRUITING","sponsor":"Turn Therapeutics","ticker":"TTRX","ticker_confidence":0.9,"conditions":"Eczema Atopic Dermatitis; Eczema; Atopic Dermatitis","enrollment":190,"url":"https://clinicaltrials.gov/study/NCT07355075","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07355075","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:455fc4dc0bde4423977e758bd83aba1cb568873015103b9f4b45c01748483baf"},{"nct_id":"NCT05877963","title":"Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab","readout_date":"2027-01-21","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"TG Therapeutics, Inc.","ticker":"TGTX","ticker_confidence":0.9,"conditions":"Relapsing Multiple Sclerosis","enrollment":800,"url":"https://clinicaltrials.gov/study/NCT05877963","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05877963","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:5b0566494c9408f13ec1c8e50cfe25b7f9be6db46af06d4d18e3e67c3ea9e7ee"},{"nct_id":"NCT06858839","title":"Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight","readout_date":"2027-01-21","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","ticker":"AMGN","ticker_confidence":0.9,"conditions":"Obesity","enrollment":3853,"url":"https://clinicaltrials.gov/study/NCT06858839","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06858839","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d85446feead3e5a5f968ecabf539609392b8702e50039161f7226131bdd2a43b"},{"nct_id":"NCT06858878","title":"Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight","readout_date":"2027-01-21","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","ticker":"AMGN","ticker_confidence":0.9,"conditions":"Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight","enrollment":1105,"url":"https://clinicaltrials.gov/study/NCT06858878","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06858878","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:7c855465d955ee91ffb9f214dd9b50f849e2bf6d60c0ff154a1bb97f342ec415"},{"nct_id":"NCT07169695","title":"A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","readout_date":"2027-01-21","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"RECRUITING","sponsor":"Laboratoires Thea","ticker":null,"ticker_confidence":0.0,"conditions":"Moderate to Severe Vernal Keratoconjunctivitis","enrollment":120,"url":"https://clinicaltrials.gov/study/NCT07169695","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07169695","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:92402ce7c600f89d3dcea79ff88460aad3f68c3133485bc217bb0130dd9fdad9"},{"nct_id":"NCT07097701","title":"An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR","readout_date":"2027-01-22","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Lupin Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Myotonia","enrollment":24,"url":"https://clinicaltrials.gov/study/NCT07097701","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07097701","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:603dff8bf8cce17c4549732ddfa734583fac3d50e2db02236d94ce408673191c"},{"nct_id":"NCT06622486","title":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","readout_date":"2027-01-23","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"RECRUITING","sponsor":"Egle Therapeutics","ticker":null,"ticker_confidence":0.0,"conditions":"Solid Tumor, Adult","enrollment":50,"url":"https://clinicaltrials.gov/study/NCT06622486","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06622486","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:a7fac3bc1484a352f41a990ab590615c0661ffd071466167370e1d41d83fe196"},{"nct_id":"NCT07483671","title":"Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients","readout_date":"2027-01-24","readout_date_type":"ESTIMATED","phase":"PHASE2","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Syncor Pharmaceutical Co., Ltd.","ticker":null,"ticker_confidence":0.0,"conditions":"Bacterial Vaginosis","enrollment":80,"url":"https://clinicaltrials.gov/study/NCT07483671","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07483671","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:e82d8cd7db0b75d8e8a52f8175ce8793b5c881383eda47c6c6df0b885fdbf75d"},{"nct_id":"NCT04699188","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","readout_date":"2027-01-25","readout_date_type":"ESTIMATED","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","ticker":"NVS","ticker_confidence":0.9,"conditions":"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung; Cancer of the Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms","enrollment":344,"url":"https://clinicaltrials.gov/study/NCT04699188","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT04699188","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:8cbd7a356f995df989b53051c20e022bc21ff5e191adf2485c0792a7b8d0b4dd"},{"nct_id":"NCT06696443","title":"Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)","readout_date":"2027-01-25","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","ticker":"VERX","ticker_confidence":0.9,"conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":455,"url":"https://clinicaltrials.gov/study/NCT06696443","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT06696443","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:d0a460ed5ea521b8afa528648878c4427f4d0f77525c889e7e8969e84d698f95"},{"nct_id":"NCT07076199","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","readout_date":"2027-01-25","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","ticker":"NVO","ticker_confidence":0.95,"conditions":"Diabetes Mellitus, Type 1","enrollment":877,"url":"https://clinicaltrials.gov/study/NCT07076199","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07076199","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:cb9ab795f58a0dabc1157cffb5875351ad7d26635f09e85b223fdf06e8cf0cff"},{"nct_id":"NCT07653100","title":"A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF","readout_date":"2027-01-25","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"Pfizer","ticker":"PFE","ticker_confidence":0.9,"conditions":"Respiratory Syncytial Virus (RSV)","enrollment":540,"url":"https://clinicaltrials.gov/study/NCT07653100","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT07653100","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:3b67d274a29686bc8fa319b46a6f4df36c08fc497798d3f7439f7eae68fcd0e1"},{"nct_id":"NCT05757102","title":"A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma","readout_date":"2027-01-26","readout_date_type":"ESTIMATED","phase":"PHASE3","status":"RECRUITING","sponsor":"GlaxoSmithKline","ticker":null,"ticker_confidence":0.0,"conditions":"Asthma","enrollment":138,"url":"https://clinicaltrials.gov/study/NCT05757102","source_url":"https://clinicaltrials.gov/api/v2/studies/NCT05757102","verified_as_of":"2026-10-28T18:41:33Z","verify_hash":"sha256:2152561fdf86d72e89bad775de2e57fca8e4bc32ab0148c356cf2e40849c5411"}],"source":"ClinicalTrials.gov API v2","note":"Readout = primary completion date (sponsor-reported; ESTIMATED dates often slip). Not investment advice."}